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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct BMP-2 delivery 
1.1. Large Animal Models 
Dog 
rhBMP-2 
Mongrel Dog, 
humerus 
segmental defect – 
3 mm 
 4 weeks HA/TCP, implant 100 to 800 µg 
Significant bone ingrowth in lower dose groups with the 
greatest effect at 100 µg showing a 3.5 fold increase 
over controls. Backscatter SEM, histology and 
radiography. 
(Sumner et al., 2004) 
rhBMP-2  
Beagle Dog, 
resection between 
femoral head and 
medial half of the 
femoral end – 
25mm 
 6 months PLA-DX-PEG, implant 100 to 1,000 µg 
New bone formation was observed in a dose dependent 
manner. New bone mass showed evidence of 
remodelling to normal cortical bone at 6 months. 
Histology and radiography. 
(Murakami et al., 2003) 
rhBMP-2 
Mongrel Dog, 
bilateral radial 
segmental defect - 
25mm 
 12 to 48 weeks Collagen sponge, implant 150 to 2,400 µg 
Implants treated with rhBMP-2 achieved union and 
gross stability. Lower rhBMP-2 doses resulted in better 
biomechanical strength. Early signs of bone 
remodelling were observed. Biomechanical testing, 
histology and radiography. 
(Sciadini and Johnson, 2000) 
rhBMP-2 
Foxhound Dog, 
cleft defect – 10 
mm 
 2 and 4 months 
PLGA + autogenous blood, 
implant 200 µg 
Response to the rhBMP-2 may have been suboptimal 
either because the dose was too low or because the 
PLGA-autogenous blood delivery system did not 
temporally maintain and spatially position rhBMP-2 at 
the recipient bed. However, new bone area increased 
2.4 fold with treatment compared to a 1.2 fold increase 
in untreated groups. Histology and radiography. 
(Mayer et al., 1996) 
rhBMP-2 
Hound Labrador 
Mongrel Dog, 
bilateral supra-
alveolar defect – 
5mm 
 3 to 8 weeks 
Titanium porous oxide 
scaffold, implant 
300, 600 and 
1,200 µg 
Lower rhBMP-2 doses promoted local bone formation, 
alveolar ridge augmentation and osseointegration. Bone 
height and area were increased a maximum 5.5 and 10.5 
fold respectively, within treated groups compared to 
controls over all dosages. Histology, fluorescence 
microscopy and radiography. 
(Wikesjo et al., 2008) 
rhBMP-2 
Male Beagle Dog, 
cranial defect – 
2.5 x 4cm 
 16 weeks Collagen and HA/TCP, implant 
310 µg to 2,150 
µg 
Implants induced bone formation within large cranial 
defects. Bone values increased from 25 % to 49 % with 
increasing rhBMP-2. Histology, histomorphometry and 
radiography. 
(He et al., 2009) 
rhBMP-2 
Female Mix-
Breed Dog, femur 
segmental defect – 
60 mm 
 24 weeks  
Absorbable collagen 
sponge wrapped around 
allograft, implant 
460 to 920 µg 
Significantly greater new bone formation leading to 
improved bone union, a 2.5 fold increase in callus area 
and larger osteon radii. Histology and 
histomorphometry. 
(Zabka et al., 2001) 
rhBMP-2 
Dog, tibial 
segmental 
diaphyseal defect 
– 25mm 
 32 to 104 weeks 
PLGA/ gelatin sponge, 
implant 800 µg 
Bone union was observed with restored biomechanical 
strength and significantly increased torsional stiffness 
by 2.6 fold of that of intact tibia. Biomechanical testing, 
histology and radiography. 
(Kokubo et al., 2004) 
rhBMP-2 Dog, mandible defect - 35mm  12 weeks Collagen sponge, implant 1,600 µg 
Enhanced bone regeneration was observed upon 
immediate BMP-2 delivery. Bone morphometry, 
immunofluorescence and qPCR. 
(Hussein et al., 2012) 
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rhBMP-2 
Beagle Dog, 
Postlateral 
interbody lumbar 
fusion 
 3 and 8 months Open cell PLA, implant 2,300 µg 
Osseous bridging of postlateral gutters occurred in the 
rhBMP-2 implanted sites after 2 months. CT and 
radiography. 
(Sandhu et al., 1995) 
BMP-2 (Canine) 
Adult Mongrel 
Dog, radial 
segmental defect – 
3 mm 
 12 weeks 
Demineralised bone or 
PLA enriched with BMP-2, 
implant 
15,000 µg 
A significant increase in new bone formation was 
observed when PLA containing 15 mg of BMP-2 was 
implanted. Histomorphometry and radiography. 
(Heckman et al., 1991) 
BMP-2 (Bovine) 
Adult Mongrel 
Dog, ulna 
segmental defect – 
25 mm 
 1 to 3 months  Gelatin capsules, implant 100,000 µg 
Calcified callus formation was observed early. By 12 
weeks the defect was completely bridged by new bone. 
Bone area increased 4.5 fold compared to controls. 
Histology and radiography. 
(Nilsson et al., 1986) 
rhBMP-2 
Beagle Dog, ulna 
segmental defect – 
20mm 
 16 weeks PLGA/gelatin sponge, implant 1.6 µg/mL 
Addition of rhBMP-2 significantly enhanced bone 
union through new bone formation after only 12 weeks. 
After 16 weeks, bone mineral content at the defect site 
increased approx. 6 fold. Analysis showed the 
appearance of cortical bone and marrow cells. 
Histology and radiography. 
(Itoh et al., 1998) 
rhBMP-2 
Male Beagle Dog, 
calvarial defect – 
5 x 5cm 
 8 to 24 weeks Collagen sponge, implant 200 µg/mL 
Bone healing was observed alongside ectopic bone 
formation. Radiopacity reached 100 % after 8 weeks 
compared to controls reaching 32.7 % after 24 weeks. 
Spatial control of rhBMP-2 release is required for 
further improved healing. Histology and radiography. 
(Kinsella et al., 2011) 
rhBMP-2 
Beagle Dog, 
mandibular supra-
alveolar premolar 
tooth defects - 
5mm 
 8 weeks Bioerodable particles + autologous blood, implant 200 µg /mL 
Cementum regeneration was observed in all defects 
exhibiting 21 fold increase in bone area. Small amount 
of root resorption was seen in rhBMP-2 defects 
compared to controls. Histomorphometry. 
(Sigurdsson et al., 1995) 
rhBMP-2 Beagle Dog, periodontal defect   8 weeks 
DBM, bovine deorganified 
crystalline bone matrix 
(Bio-Oss), absorbable 
collagen sponge,  PLGA or 
PLA granules (Drilac), 
implant 
200 µg/mL 
Substantial bone regeneration was observed in all 
defects implanted with rhBMP-2. DBM and Bio-Oss 
performed well as carriers for rhBMP-2-driven 
periodontal regeneration, although other impediments to 
their clinical use exist. Histology and 
histomorphometry. 
(Sigurdsson et al., 1996) 
rhBMP-2 
Mongrel Dog, 
zygomatic arch 
osteotomy – 8 to 
10 mm 
 4 to 12 weeks 
Absorbable collagen 
sponge, implant 400 µg/mL 
Significant bone formation was observed in all rhBMP-
2 grafted sites as early as 4 weeks and radiopacity of 
bone continued to increase over time. Histology and 
radiography. 
(Yudell and Block, 2000) 
rhBMP-2 
Beagle Dog, 
mandibular 
premolar defect – 
5mm 
 16 weeks Collagen sponge, implant 430 µg/mL 
Bone regeneration (height) and osseointegration within 
the defect were enhanced by 8.4 and 2.3 fold, 
respectively compared to controls. Histomorphometry 
and radiography. 
(Sigurdsson et al., 1997) 
rhBMP-2 
Adult Female 
Dog, bilateral 
tibial osteotomy – 
10 mm  
 4 and 8 weeks 
Rapidly resorbable calcium 
phosphate paste, injection 700 µg/mL 
Treatment with rhBMP-2 significantly increased bone 
union through greater callus formation exhibiting 
elevated bending and torsion stiffness. Biomechanical 
testing and radiography. 
(Edwards et al., 2004) 
Goat 
rhBMP-2 
Ovariectomized 
Goat, osteoporosis 
model, vertebral 
defect, 5mm  x 
10mm 
 0 to 140 d 
Loaded gelatin 
microspheres (GM) in 
CPC, implant 
20 µg 
rhBMP-2/GM/CPC composite provides ideal bone 
substitute capable of inducing accelerated bone healing 
within an osteoporotic model. Mineralisation rate 
increased approx. 2 fold. Biomechanical testing, 
histology, micro CT and radiography. 
(Li et al., 2010b) 
        
Supplementary Table 1. Bone tissue engineering in vivo utilising BMP-2 within animal models and human trials. 
 
3 
 
rhBMP-2 
Adult Goat, 
bilateral closed 
tibial fracture 
 6 weeks Absorbable collagen sponge, implant 860 µg 
Total callus volume was significantly increased up to 2 
fold, exhibiting greater torsional stiffness. 
Biomechanical testing, histology and radiography. 
(Welch et al., 1998) 
Horse 
rhBMP-2 
Horse, metacarpal 
bone drill defect, 
4.5mm x 27mm 
 1 dy to 12 weeks 
Gelatin-β-TCP sponge, 
implant 3 µg 
BMP-2 treatment within the defect site accelerated bone 
regeneration. Histology and radiography. (Tsuzuki et al., 2012) 
Monkey 
rhBMP-2 
Rhesus Monkey,  
mandibular defect 
– 20 x 15 mm 
 6 and 12 weeks 
PLGA coated gelatin 
sponge, implant 280 µg 
Resected bone defects regenerated completely 
exhibiting signs of remodelling. Bone area and mineral 
content increased 3.1 and 3.3 fold respectively, 
compared to controls. CT, histology and radiography. 
(Marukawa et al., 2001) 
rhBMP-2 
Adult Rhesus 
Monkey, 
Percutaneous 
vertebroplasty – 
3mm drill defect 
 2 and 6 months CPC, injection 900 µg 
New bone and vessel formation after 2 months. Fully 
replaced cement with mature bone by 6 months. 
Histology and radiography. 
(Bai et al., 2009) 
rhBMP-2 
Rhesus Monkey, 
lumbar interbody 
fusion 
 24 weeks 
Collagen sponge and 
biphasic ceramic phosphate 
granules, implant 
3,000 µg 
Spine fusion was observed in all rhBMP-2 treated 
groups confined to the area in or adjacent to the carrier 
matrix with no ectopic bone formation. CT, histology 
and radiography. 
(Akamaru et al., 2003) 
rhBMP-2 
Adult Rhesus 
Macaque Monkey, 
posterolateral 
arthrodesis 
 24 weeks 
HA/TCP (15%/85%) with 
collagen, or plain collagen 
sponge wrapped around 
HA/TCP, implant 
6,000 µg (low 
dose) 
10,000 µg (high 
dose) 
High dose rhBMP-2 achieved lumbar fusion where lose 
dose did not. However, combination of low dose 
rhBMP-2 on collagen wrapped around the HA/TCP 
bulking agent did achieve lumbar fusion (3 fold lower 
dose). Histology, micro CT and radiography. 
(Barnes et al., 2005) 
rhBMP-2 
Rhesus Monkey, 
mandibular defect 
– 30 mm 
 15 and 30 weeks 
PLGA coated gelatin 
sponge, implant 9,000 µg 
Resected mandible completely regenerated with the 
addition of rhBMP-2. Excellent remodelling and 
consolidation of new bone was observed after loading. 
Histology and radiography. 
(Marukawa et al., 2002) 
rhBMP-2 
Rhesus Monkey, 
maxillary defect – 
8 mm 
 3 months Collagen sponge, implant 430 µg /mL 
Cancellous bone formation was observed with 
increasing trabecular thickness. Fluorescence 
microscopy, histology and histomorphometry. 
(Boyne et al., 1998) 
rhBMP-2 
Adult Male 
Cynomolgus 
Monkey, fibular 
osteotomy – 1 mm 
blade 
 8 to 14 weeks 
Calcium phosphate paste, 
hyaluronan gel, hyaluronan 
paste, and gelatin foam, 
implant 
1,000 µg/mL 
Complete bone bridging of defect osteotomies was 
observed exhibiting greater torsional stiffness compared 
to controls. Mean callus area, torsional stiffness and 
maximum torque was 1.9, 1.7 and 1.7 fold greater than 
controls. Histology and radiography. 
(Seeherman et al., 2004) 
rhBMP-2 
Female Rhesus 
Monkey, calvarial 
defect – 25 mm, 
craniotomy – 25 x 
40 mm 
 6 months 
Absorbable collagen 
sponge or bone flap, 
implant 
1,500 µg/mL 
Bone flaps treated with rhBMP-2 showed enhanced 
osseointegration through bone bridge formation leading 
to 71 % closure compared with 28 % closure in 
controls. CT, histology and MRI. 
(Sheehan et al., 2003) 
Pig 
rhBMP-2 
Yorkshire Pig, 
anterior lumbar 
interbody fusion 
 9 months PCL/TCP, implant 600 µg 
Implants demonstrated bone ingrowth and solid fusion 
of good mechanical strength. Fusion mass bone volume 
increased approx. 5 fold compared to scaffold alone. 
Histology, micro CT and radiography. 
(Abbah et al., 2011) 
rhBMP-2 
Adolescent 
Yorkshire Pig, 
mandibular defect 
(subperiosteal 
osteotomy) 
 3 months Heliostat absorbable collagen sponge, implant 1,500 µg/mL 
Host cell migration into the defect site and osteogenesis 
was observed alongside extensive vascular invasion. 
Histology and radiography. 
(Carstens et al., 2005) 
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Sheep 
rhBMP-2 
Sheep, lumbar 
interbody defect – 
12mm depth and 
7mm diameter 
 12 months CPC/Silk Fibroin, injection 5 µg 
Composites exhibited enhanced osteo-
conduction/induction/genesis, allowing for less invasive 
spinal fusion surgery. Fusion rates were 3 fold higher 
with rhBMP-2. Biomechanical testing, CT, histology, 
histomorphometry and radiography. 
(Gu et al., 2011) 
rhBMP-2 
Sheep, trepanation 
defect within 
femoral epiphysis 
 3 months TCP, implant 200 µg 
Faster remodelling was observed with bone formation 
comparable to native bone. Bone and total mineral 
content increased approx. 3 and 4 fold respectively. 
Histology, histomorphometry and microradiography. 
(Maus et al., 2008) 
rhBMP-2 Sheep, sinus floor augmentation  12 weeks 
PLGA and gelatin sponge, 
implant 800 µg 
Implants demonstrated higher bone density (44 % vs 
30.9 %) and bone-implant contact (15.4 % vs 7.7 %) 
compared to controls. Histology and histomorphometry. 
(Gutwald et al., 2010) 
rhBMP-2 
Mature Female 
Crossbred Sheep, 
femur diaphyseal 
segmental defect – 
25 mm 
 12 months PLGA with autologous blood, implant 
2,000 to 4,000 
µg 
Recanalization of the medullary cavity approached 
completion at 52 weeks followed by complete woven 
and lamellar bone bridging of the defect site. Histology 
and radiography. 
(Kirker-Head et al., 1998) 
rhBMP-2 
Sheep, femur 
segmental defect – 
25 mm 
 3 months Inactivate bone matrix, implant unknown 
All defects treated with rhBMP-2 exhibited bone 
regeneration with increased mean bending strength; 1.9 
fold of that of contralateral femur, compared with 1.1 
fold in the inactive matrix control group. Radiography. 
(Gerhart et al., 1993) 
1.2. Small Animal Models 
Mouse 
BMP-2 
ICR Mouse, 
cranial defect 
(parietal bone) – 
4.6mm 
 4 weeks CHPA/Hydrogel, implant 0.1 to 2 µg 
Implants revealed novel bone formation through 
stimulation of endogenous osteoblast activity. 
Histology, micro CT and radiographic. 
(Hayashi et al., 2009) 
rhBMP-2 
Male CD-1 Nude 
Mouse, calvarial 
defect – 4mm 
 1 to 8 weeks 
Human adipose stem cells 
on PLGA scaffold, 
intravenously injected 
rhBMP-2 
0.5 µg daily (3 
days post-
operatively) 
BMP-2 signalling beneficially modulates cell-mediated 
bone repair increasing approx. 2.6 fold. Histology, 
histomorphometry, in situ hybridization, micro CT and 
qPCR. 
(Levi et al., 2010) 
rhBMP-2 
Female ddY 
Mouse, 
subcutaneous 
implant 
 7 weeks Gelatin hydrogel 3 µg 
BMP-2 release enhanced cell accumulation for de novo 
generation of bone tissue. Histology, 
immunofluorescence and radiography. 
(Kimura et al., 2010) 
rhBMP-2 Nude Mouse, tibial defect  6 weeks 
Fibrous PLGA/HA 
Scaffold, implant 5 µg 
Implants demonstrated improved bone healing as a 
result of sustained BMP-2 release. Biomechanical 
testing, histology, immunohistochemistry and 
radiography. 
(Fu et al., 2008) 
rhBMP-2 
Male ddy Mouse, 
ectopic 
implantation - left 
dorsal muscle 
pouch 
 3 weeks PLA-PEG , implant 10 µg 
New bone formation with trabeculae structures was 
observed. Bone mineral content and density were 
increased approx. 2 and 1.5 fold compared with 
collagen control. Histology and radiography. 
(Saito et al., 2003) 
rhBMP-2 
Male C57B6 
Mouse, tibial 
fracture defect 
 7 and 14 d Direct injection or collagen sponge implant 10 µg 
BMP-2 treatment increased bone callus (approx. 2.3 
fold) and cartilage formation (approx. 4 fold). 
Specifically, BMP-2 modulated periosteum cell fate and 
differentiation. Histology, histomorphometry and 
immunohistochemistry. 
(Yu et al., 2010b) 
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rhBMP-2 
CB17 SCID 
Mouse, 
subcutaneous 
implant 
 10 weeks PLGA microspheres in coralline HA, implant 20 µg 
Prolonged in vivo bone formation was observed up to 
10 weeks. 17.61 % of the implant surface was covered 
with bone-like tissue. Histology, histomorphometry, 
immunohistochemistry, micro CT and SEM analysis. 
(Fu et al., 2010) 
rhBMP-2 
Male Mouse, 
ectopic 
intramuscular 
implant 
 3 d to 3 weeks 
Type I collagen sponge, 
implant 30 µg 
Induced β-catenin mediated signalling through Wnt 
ligands leading to both osteogenesis and 
chondrogenesis. Histology and immunohistochemistry. 
(Chen et al., 2007) 
rhBMP-2 
Male CD-1 
Mouse, ectopic 
muscle pouch 
implantation 
 28 d 
Infuse (BMP-2) and OP-1 
(BMP-7) in collagen 
sponge within a gelatin 
capsule, implant 
52.5 µg 
Treatment with rhBMP-7 increased bone volume 
approx. 1.9 fold compared to rhBMP-2 treatment. 
Histology and micro CT. 
(Barr et al., 2010) 
rhBMP-2 
Sprague-Dawley 
Mouse, ectopic 
injection – 
quadriceps muscle 
 3 weeks Chitosan and hyaluronan hydrogels, injection 150 µg 
Induced bone formation at ectopic injection sites. 
Mineralised bone formation was 2 to 3 fold higher in 
hyaluronan hydrogels compared to chitosan hydrogels, 
though less mature. Differences between hydrogels 
were down to degradation rates. Histology and micro 
CT. 
(Luca et al., 2010b) 
Rabbit 
rhBMP-2 
Japanese White 
Rabbit, patella 
drill defect – 5mm 
depth, 5mm 
diameter 
 2 to 8 weeks Type I Collagen, implant 1.18 µg 
BMP-2 acts in a spatiotemporally stringent manner 
recruiting endogenous MSCs and driving osteochondral 
differentiation. Histology and immunohistochemistry. 
(Mimura et al., 2011) 
rhBMP-2 
Male New 
Zealand Rabbit, 
posterolateral 
lumbar fusion 
 16 weeks Alginate and MSCs, implant 2.5 µg 
Addition of MSCs allowed for low dose rhBMP-2-
induced bone fusion mass formation. Torsional strength 
was increased approx. 17 % compared to samples 
without rhBMP-2. Histology, micro CT and 
radiography. 
(Fu et al., 2009) 
rhBMP-2 
Adult Male 
Japanese White 
Rabbit, condylar 
defect 
 2 to 24 weeks 
PLGA and gelatin sponge, 
implant 5 µg 
Bone and cartilage-like tissue growth was observed in 
all implants (with and without rhBMP-2) but no growth 
was observed in the control group. Histology. 
(Ueki et al., 2003) 
rhBMP-2 
New Zealand 
White Rabbit, 
calvarial defect – 
6mm 
 12 weeks HA/TCP, implant 5 µg 
Implants revealed enhanced bone formation bridging 
defect sites. Approx. 1.3 fold increase in bone area was 
observed upon treatment with rhBMP-2. Histology. 
(Schopper et al., 2008) 
rhBMP-2 
New Zealand 
White Rabbit, 
cranial defect – 
6mm long x 1mm 
deep 
 12 weeks 
Deproteinized bovine 
bone/porcine collagen, 
(DBBB) or cortico-
cancellous human bone 
block (CHBB), implant 
6 µg (DBBB) 
and 5 µg 
(CHBB) 
rhBMP-2 and DBBB exhibited vertical bone 
augmentation within cranial defects. Percentage area of 
new bone increased approx. 3.4 fold. Histology and 
histomorphometry. 
(Kim et al., 2010c) 
rhBMP-2 
Rabbit, radial 
segmental defect – 
15 mm 
 24 weeks PLGA capsule, implant 12 µg 
Bone union was observed in bone implanted with 
rhBMP-2/PLGA. Bone area and mineral content 
increased approx. 4.25 and 5 fold, respectively. 
Histology and radiography. 
(Mori et al., 2000) 
rhBMP-2 
New Zealand 
White Rabbit, 
radial segmental 
defect – 15 mm 
 4 and 8 weeks 
Interconnected-porous 
calcium hydroxyapatite 
and PLA-PEG co-polymer, 
implant 
5 and 20 µg 
All bone defects treated rhBMP-2 were completely 
repaired. After 8 weeks bone mineral density was 
increased 1.7 fold with rhBMP-2 treatment. 
Biomechanical testing, CT, histology and radiography. 
(Kaito et al., 2005) 
rhBMP-2 
New Zealand 
White Rabbit, 
parietal bone 
elevation 
 8 weeks PEG and HA/TCP. implant 10 and 30µg 
Enhanced bone regeneration and ingrowth within 
titanium cylinders was observed. Newly formed bone 
increased 2 fold compared to controls. Histology and 
histomorphometry. 
(Jung et al., 2008) 
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BMP-2 
New Zealand 
White Rabbit, 
alveolar cleft (drill 
defect – 6mm) 
 4 weeks Gelatin hydrogel, implant 17 µg 
Bone volume but not osteoid matrix was increased 1.5 
fold compared to untreated controls, showing bone 
regeneration. Histology, histomorphometry and 
radiology. 
(Sawada et al., 2009) 
rhBMP-2 
Rabbit, bilateral 
mid-ulnar 
osteotomies - 0.5 
to 1 mm 
 2 to 6 wks  Absorbable collagen sponge, implant 40 µg 
Mineralised callus area was significantly increased 1.2 
to 1.6 fold through addition of rhBMP-2 and exhibited 
enhanced mechanical strength (1.8 fold greater), both 
compared to controls. Biomechanical testing, histology 
and radiography. 
(Bouxsein et al., 2001) 
rhBMP-2 
New Zealand 
White Rabbit, 
distal ulna defect 
– 15mm 
 8 weeks PCL, implant 75 µg 
Osteoinductive rhBMP-2 loaded onto PCL scaffold 
acted in synergy to recruit, differentiate, and guide host 
bone ingrowth. Histology, micro CT and radiography. 
(Bae et al., 2011) 
rhBMP-2 
Rabbit, humerus 
segmental defect – 
15 mm 
 6 weeks 
PLA-PEG co-polymer 
incorporated into titanium 
fiber-mesh cylinders, 
implant 
60 and 120 µg 
New bone formed throughout the implant cylinders 
bridging the defect. All defects treated with the higher 
rhBMP-2 dose were repaired completely. Histology and 
radiography. 
(Murakami et al., 2002) 
rhBMP-2 
New Zealand 
White Rabbit, 
radial defect – 
15mm 
 2 to 8 weeks 
Chitosan hydrogel with 
TCP granules, injection 150 µg 
Evidence of partial defect bridging with new woven and 
lamellar bone was observed. TCP addition increased 
mineralised bone formation 4.7 fold. Histology, micro 
CT and radiography. 
(Luca et al., 2010a) 
rhBMP-2 
Adult New 
Zealand White 
Rabbit, bilateral 
posterolateral 
arthrodesis 
 8 weeks 
Type 1 collagen sponge 
wrapped around HA/TCP 
(15%/85%), implant 
1,075 µg 
100 % of rabbits treated with rhBMP-2 achieved lumbar 
fusion whereas without treatment no rabbits achieved 
lumbar fusion. Biomechanical testing, histology, micro 
CT and radiography 
(Kraiwattanapong et al., 2005) 
rhBMP-2 
New Zealand 
White Rabbit, 
forearm segmental 
defect – 15mm 
 12 weeks Collagen and chitosan microspheres, implant 2500 µg 
The composite scaffold accelerated bone repair in a 
large radial defect. Bone mineral content was 1.3 fold 
greater than in controls. Biomechanical testing, 
histology, micro CT and radiography. 
(Hou et al., 2012) 
rhBMP-2 
New Zealand 
White Rabbit, 
lumbar spinal 
fusion 
 8 weeks Porous β-TCP granules, implant 
5,000 to 
150,000 µg 
Implants revealed enhanced lumbar fusion in a dose-
dependent manner. Biomechanical testing, CT and 
histology. 
(Dohzono et al., 2009) 
rhBMP-2 
New Zealand 
White Rabbit, 
calvarial defect - 
7.9 mm 
 6 weeks 
PLGA microspheres in 
aqueous sodium 
carboxymethylcellulose, 
implant 
2 µg/mL 
Significant bone growth was observed in all rhBMP-2 
treated defects while defects without treatment or with 
rhBMP-2 free implants showed minimal bone healing. 
Prolonged and immediate rhBMP-2 release regenerated 
75-79 % and 45 % of the defect area. Histology and 
histomorphometry. 
(Woo et al., 2001) 
rhBMP-2 
New Zealand 
White Rabbit, 
interfrontal suture 
expansion 
 33 days Absorbable collagen sponge, implant 
10 to 400 
µg/mL 
Stimulation with low dose rhBMP-2 formed new bone 
at suture edges during expansion, whilst higher doses 
stimulated suture fusion. Fluorescence microscopy, 
micro CT and radiography. 
(Liu et al., 2013) 
rhBMP-2 
Rabbit, bilateral 
mid-ulna 
osteotomies - 0.5 
to 1 mm 
 4 weeks Calcium phosphate paste, implant 670 µg/mL 
Complete bone bridging was observed with greater 
mineralised callus formation (1.6 fold) in rhBMP-2 
treated groups. Torsional stiffness and strength were 
also significantly increased by 1.6 and 2 fold 
respectively. Biomechanical testing, CT, histology and 
radiography. 
(Li et al., 2003) 
rhBMP-2 
Male New 
Zealand White 
Rabbit, tibial 
fracture - 0.5 mm 
 4 to 28 d 
PLGA particles in 
dehydrated collagen gel, 
implant 
4,000 µg/mL 
Particles prevented migration of cells hindering rhBMP-
2-induced bone callus formation, however, rhBMP-2 
treatment increased callus formation by approx. 1.35 
fold compared to controls. Histology. 
(Bax et al., 1999) 
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rhBMP-2 
Female 
Ovariectomized 
Wistar Rat, tibial 
segmental defect – 
4mm 
 8 weeks Collagen sponge, implant 1 µM Implants demonstrated increased bone strength, callus formation and calcification. Histology and radiography. (Sarban et al., 2009) 
rhBMP-2 
Rabbit, calvarial 
defect (critical 
size) 
 6 weeks PCL fumarate with PVA and HA scaffolds, implant unknown 
Delivery of biologically active rhBMP-2 promoted bone 
healing within critical size defects (Kim et al., 2012) 
Rat 
rhBMP-2 
Sprague-Dawley 
Rat, cranial defect 
– 5mm 
 8 weeks PCL/PEG scaffold, implant 0.135 µg New bone formation was observed bridging the cranial defect. Micro CT. (Srouji et al., 2011) 
BMP-2-derived 
peptide 
Wistar Rat, 
ectopic 
implantation in 
calf muscle 
 3 to 8 weeks  Alginate hydrogel, implant 0.2 µg 
Ectopic bone formation was observed in alginate 
hydrogel linked with BMP-2-derived peptide. Histology 
and immunohistochemistry. 
(Suzuki et al., 2000) 
rhBMP-2 
Sprague-Dawley 
Rat, femur 
segmental defect – 
5mm 
 9 weeks Demineralised rat bone, implant 1.4 and 11 µg 
rhBMP-2 induced endochondral bone formation within 
defects in a dose-dependent manner. High dose rhBMP-
2 resulted in bone union. Biomechanical testing, 
histology and radiography. 
(Yasko et al., 1992) 
rhBMP-2 
Wistar Rat, 
cranial defect – 
6mm 
 2 weeks Monoolein and Poloxamer 407 1 to 7 µg 
Analysis showed an approx. 1.4 fold increase in 
collagen fiber deposition with 3 µg BMP-2 compared to 
with lower doses. Histology. 
(Issa et al., 2009) 
rhBMP-2  
Sprague-Dawley 
Rat, femur 
segmental defect – 
4 × 5 mm 
 3 to 9 weeks 
β-TCP and monocalcium 
phosphate monohydrate - 
implant 
1.26 and 6.28 
µg 
High dose rhBMP-2 generated a large bone shell around 
the defect, resulting in osseous union within 3 weeks. 
Failure torque and bone stiffness recovered 2 and 2.4 
fold after 9 weeks compared with intact contralateral 
femur. Biomechanical testing, histology and 
radiography. 
(Ohura et al., 1998) 
rhBMP-2 
Male Sprague-
Dawley Rat, 
femur segmental 
defect – 6mm 
 4 and 8 weeks 
Biodegradable PUR, 
implant 2 µg 
PUR scaffolds delivered sustained BMP-2 release 
inducing 1.5 fold more bone formation. Histology and 
micro CT. 
(Brown et al., 2011) 
rhBMP-2 Long-Evans Rat, calvarial defect  7 to 21 d 
Insoluble collagenous bone 
matrix, implant 2.2 and 6.5 µg 
Mineralized bone formation was observed, maturing 
over 21 days. Histology, histomorphometry and 
radiography. 
(Marden et al., 1994) 
rhBMP-2 
Sprague-Dawley 
Rat, calvarial 
defect – 8 mm 
 4 weeks 
Fibrin or heparin-
functionalised 
nanoparticle-fibrin gel, 
implant 
4 µg 
rhBMP-2 induced new bone formation which exhibited 
greater maturity and mineralisation. Defect closure 
increased from 24 % to 70 % with rhBMP-2 addition. 
Histology, immunohistochemistry and radiography. 
(Chung et al., 2007) 
rhBMP-2 
Female Sprague-
Dawley Rat, 
bilateral femur 
defect – 6mm 
 2 to 12 weeks 
Alginate & electrospun 
PCL, implant 5 µg 
Defect sites exhibited effective bone healing with new 
bone formation. Mechanical loading further enhanced 
bone formation. Biomechanical testing, faxitron, 
histology and micro CT. 
(Boerckel et al., 2012) 
rhBMP-2 
Wistar Rat, 
cranial defect – 
5mm 
 2 weeks Monoolein 5 µg 
rhBMP-2 within monoolein exhibited potent 
osteoinductive action generating 2 fold more new bone 
compared to monoolein alone. Histology and 
immunohistochemistry. 
(Iyomasa et al., 2012) 
rhBMP-2 
Male Wistar Rat, 
cranial defect – 
6mm 
 4 weeks Monoolein 5 and 10 µg 
Analysis revealed a max. 3.8 fold increase in novel 
bone formation. Histology, histomorphometry and 
immunohistochemistry. 
(Issa et al., 2012) 
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rhBMP-2 
Female Sasco 
Sprague-Dawley 
Rat, bilateral 
segmental femur 
defects – 8mm 
 2 to 12 weeks 
Alginate hydrogel within 
PCL nanofiber tube, 
implant 
5 µg 
Spatiotemporal protein delivery through alginate and 
PCL constructs showed evidence of enhanced bone 
regeneration with a 2.25 fold increase in total bone 
volume compared to collagen control gels. 
Biomechanical testing, histology, micro CT and 
radiography. 
(Kolambkar et al., 2011) 
rhBMP-2 
Male Wistar Rat, 
cranial defect – 
6mm 
 4 weeks Monoolein 5 µg 
Addition of pure rhBMP-2 increased the bone 
trabeculae volume fraction 1.08 fold without collagen 
and 1.12 fold with collagen, compared to critical defect 
control. Histology and histomorphometry. 
(Issa et al., 2010) 
rhBMP-2 
Sprague-Dawley 
Rat, calvarial 
defect – 8mm 
 8 weeks 
Apatite-coated PLGA/HA 
particulates within fibrin 
gel, implant 
5 µg 
Implants demonstrated virtually complete surface bone 
healing of the critical-sized calvarial defect. Approx. 50 
fold increase in new bone was observed. Histology and 
radiography. 
(Kim et al., 2008) 
rhBMP-2 
Lewis Rat, 
femoral defect – 
5mm 
 12 weeks PLGA microparticles in PPF scaffold, implant 8 µg 
New bone formation was observed but no defect 
bridging due to the barrier action of PPF. Torsional 
stiffness increased a max.3.6 fold compared to controls. 
Biomechanical testing, histology, micro CT and 
radiography. 
(Henslee et al., 2011) 
rhBMP-2 
Long-Evans Rat, 
calvarial defect – 
8 mm 
 21 d PLGA, implant 10 and 30 µg 
Radiopacity and normal calvarial contouring restoration 
of inner and outer bone was observed. Histology, 
histomorphometry and radiography. 
(Kenley et al., 1994) 
rhBMP-2 
Long-Evans Rat, 
femur segmental 
defect – 5 mm 
 6 and 15 weeks 
PPF/TCP and dicalcium 
phosphate dehydrate used 
as a carrier, implant 
10 µg 
Scaffolds with rhBMP maintained bone length and 
allowed for bone bridging exhibiting restored 
mechanical strength. Histology, micro CT and 
radiology. 
(Chu et al., 2007) 
rhBMP-2 
Male Sprague-
Dawley Rat, 
femur segmental 
defect – 8mm 
 6 weeks Collagen sponge, implant 30 µg 
Implants showed significant healing with approx. 15.9 
fold increase in new bone formation exhibiting 6.3 and 
18 fold increase in breaking load and stiffness, 
respectively. Biomechanical testing, histology and qCT.  
(Tolli et al., 2011) 
rhBMP-2 
Sprague-Dawley 
Rat, closed tibial 
fracture 
 28 and 42 d PLA, implant 50 µg 
Callus volume was not affected however callus 
mineralisation was significantly increased approx. 17.1 
and 36.9 fold following 28 and 42 d. Significantly 
elevated maximum load (2.1 fold) and torsional 
stiffness (2.3 fold) were also observed after 42 days. 
Biomechanical testing, histology and radiography. 
(Schmidmaier et al., 2002) 
rhBMP-2 Female Sprague-Dawley Rat,   
2 to 6 
weeks Collagen sponge, implant 50 µg 
Mechanical loading further enhanced BMP-2-induced 
bone regeneration and defect bridging. Histology, 
histomorphometry and micro CT. 
(Schwarz et al., 2012) 
rhBMP-2 
Rat, ectopic 
subcutaneous 
injection and 
carrier implant 
 5 to 21 d  Demineralised matrix carrier, implant 12 to 115 µg 
Ectopic bone formation was observed following 
mineralisation of hypertrophic cartilage. Histology. (Wang et al., 1990) 
rhBMP-2 
Male Wistar Rat, 
cranial defect – 
8mm 
 4 and 12 weeks 
CPC/PLGA microparticle 
injection 55 and 275 µg 
Novel incomplete bone bridging of critical size cranial 
defects was observed at 12 weeks following slow 
sustained BMP-2 release. After 4 weeks, bone volume 
increased approx. 1.5 fold compared to plain controls. 
Histology, histomorphometry and micro CT. 
(Bodde et al., 2008) 
rhBMP-2 
Sprague-Dawley 
Rat, mid-
diaphyseal femur 
defect – 6mm 
 1 to 4 weeks 
Type I bovine collagen 
sponge, implant 200 µg 
Defect sites inoculated with bacteria (S. aureus) and 
BMP-2 upregulated BMP-2 receptor expression; overall 
faster bone healing. qPCR. 
(Brick et al., 2009) 
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rhBMP-2 
Rat, ectopic 
intramuscular 
implant 
 21 d PLG scaffold, implant 500 µg 
BMP-2 treatment increased radiopacity approx. 2.3 
fold, bone volume approx. 17.7 fold, and osteoid 
volume approx. 3.6 fold. Histology, histomorphometry 
and radiography. 
(Whang et al., 1998) 
rhBMP-2 Rat, calvarial defect – 5 mm  unknown PLGA scaffold, implant 
0.03 to 0.24 
µg/mL 
Increased bone regeneration was observed in a dose 
dependant manner in rhBMP-2-treated mice, with 
higher dose of BMP-2 inducing greater bone area, 
volume and density. Micro CT. 
(Cowan et al., 2007) 
rhBMP-2 
Male Sprague-
Dawley Rat, 
calvarial defect – 
8mm 
 2 and 8 weeks 
Absorbable collagen 
sponge, implant 25 µg/mL 
Treatment enhanced local bone formation. Histology, 
histomorphometry and immunohistochemistry. (Hyun et al., 2005) 
rhBMP-2 
Long-Evans Rat, 
mandibular defect 
– 5 mm 
 4 weeks PLGA/gelatin sponge, implant 100 µg/mL 
Bone defects were completely filled with new bone and 
enhanced within rhBMP-2 groups. Histology and 
histomorphometry. 
(Higuchi et al., 1999) 
rhBMP-2 
Male Fisher Rat, 
cranial defect – 
5mm 
 8 weeks CDHA, implant  200 µg/mL 
Sulfated chitosan coating modified BMP-2 release from 
CDHA implants promoting new bone formation. 
Histology, histomorphometry and micro CT. 
(Zhao et al., 2012) 
rhBMP-2 
Fischer Rat, 
subcutaneous 
implant 
 14 and 28 d PLGA/ gelatin sponge, implant 500 µg/mL 
Implanted sponge volume decreased 28 d and became 
filled with induced bone. CT, histology and 
radiography. 
(Yokota et al., 2001) 
rhBMP-2 
Male Long-Evans 
Rat, ectopic 
subcutaneous 
implantation in 
calf muscle 
 9 weeks PLGA mixed with blood clot, implant 1,000 µg/mL 
Bone formation was observed by 4 weeks, maturing by 
9 weeks. Histology and radiography. (Alpaslan et al., 1996) 
 
2. Animal Models for indirect BMP-2 delivery 
2.1. Large Animal Models 
Dog 
hBMP-2 
(adenovirus) 
Beagle Dog, 
orbital defect – 
12mm 
 12 and 24 weeks 
Transduced BMSCs on 
biocoral composite, 
implant 
2 x 107 cells 
Enhanced repair of critical sized defects with almost 
complete bone bridging. Transduced cells generated 
bone covering 27.4 % more defect area compared to 
non-transduced cells (1.8 fold increase). Histology, 
histomorphometry and radiography. 
(Xiao et al., 2010) 
Horse 
BMP-2 
(adenovirus) 
Pony, femoral 
condyle drill 
defect – 13mm 
 12 to 52 weeks Direct injections 
4 x 109 
infectious units 
Both chondrocyte cloning and subchondral bone 
mineral density were significantly enhanced upon 
BMP-2 treatment compared to controls. CT, histology, 
histomorphometry and quantitative MRI. 
(Menendez et al., 2011) 
rhBMP-2 
(adenovirus) 
Horse, metatarsal 
osteotomy (1mm) 
and ostectomy 
(1cm) 
 6 weeks 
E1 defective adenovirus-5 
with cytomegalovirus 
promoter, injection 
5 x 1011 
particles 
Large strong bone callus formation within defect sites 
was observed. Treated osteotomy and ostectomy defects 
showed a 1.8 and 2.8 fold increase in bone volume and 
a 1.8 and 1.3 fold increase in mineral density, 
respectively, compared to controls. Biomechanical 
testing, histology, qCT and radiography. 
(Ishihara et al., 2008) 
BMP-2 
(adenovirus) 
Horse, metacarpal 
and metatarsal 
osteotomies – 
1mm 
 6 weeks Transduced dermal fibroblasts, injection 5 x 10
7 cells 
Bone healing within defect sites through endochondral 
ossification and mineralisation. Bone volume within 
defect sites increased approx. 3.2 fold compared with 
controls. Biomechanical testing, histology, qCT and 
radiography. 
(Ishihara et al., 2010) 
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Pig 
rhBMP-2 
(liposome vector) 
Adult Pig, 
calvarial defect – 
10 mm diameter, 
7 mm depth 
 4 weeks Autologous bone graft with liposome vector, implant 12 µg 
At 4 weeks, BMP-producing cells were present which 
significantly enhanced new bone formation, compared 
with control collagen groups. Immunohistochemistry 
and microradiography. 
(Park et al., 2007) 
Sheep 
BMP-2 
(adenovirus) 
White Mountain 
Sheep, 
Monocortical iliac 
crest defect – 5 
mm diameter and 
20mm depth 
 8 weeks Single local injection 1 x 10
11 
particles 
Callus formations were significantly reduced following 
direct application of adenovirus showing a systemic 
retardation of bone formation contrary to data obtained 
from small animal models. Biomechanical testing, 
histology, micro CT and radiography. 
(Egermann et al., 2006) 
2.2. Small Animal Models 
Minipig 
BMP-2 
(adenovirus)  
Miniature Swine, 
maxillary defect – 
30 x 12 mm 
 3 months Type I collagen gel, implant 5 x 10
7 cells/mL 
Solid bone mass exhibiting good mineralisation and 
woven bone structure was observed (approx. 1.5 fold 
increase). Biomechanical strength was similar to native 
bone. Biomechanical testing, CT and histology. 
(Chang et al., 2003) 
Mouse  
rhBMP-2 
(adenovirus)  
C3H/HeN Mouse, 
radial segmental 
defect – 25 mm 
 4 to 8 weeks  Collagen sponge, implant 3 µg 
Analysis of new bone formation revealed genetically 
engineered cell-mediated segmental defect repair. 
Histology, histomorphometry and in vivo imaging. 
(Gazit et al., 1999) 
hBMP-2 (plasmid 
construct) 
Male ICR Mouse, 
gastrocnemius 
muscle injection 
 7 to 21 d 
Plasmid injection with 
microbubbles and 
sonoporation 
75,000 µg 
(plasmid) 
Non-surgical method for BMP-2 induced bone 
formation heterotopically. Histology, 
immunohistochemistry and radiography. 
(Osawa et al., 2009) 
rhBMP-2 
(adenovirus) 
SCID Mouse, 
ectopic 
intramuscular 
injection 
 2 to 5 weeks Bilateral injection 
1.5 x 107 
particles 
Radiodense bone containing mature bone marrow 
elements was observed. Histology and radiography. (Musgrave et al., 1999) 
rhBMP-2 
(retroviral vector) 
Female Athymic 
Nude Mouse, 
bilateral 
segmental defect – 
8mm 
 12 weeks 
Transfected hMSCs on 
type I collagen coated PCL 
scaffold, implant 
5 x 108 to 5 x 
109 particles 
Bone bridge formation was enhanced showing an 
approx. 1.3 and 1.5 fold increase in bone mineral 
volume after 6 and 12 weeks respectively, compared to 
control groups. Biomechanical testing, micro CT and 
radiography. 
(Dupont et al., 2012) 
BMP-2 (retroviral 
vector) 
Female C57BL/6 
Mouse, femoral 
segmental defect – 
4mm 
 6 weeks Viral coated femoral allograft, implant 
1 x 107 to 1 x 
1010 particles 
Callus formation was observed exhibiting a 3.8, 10.9 
and 2.7 fold increase in bone volume, torsional rigidity 
and max. torque compared to plain allograft when 
treated with 1010 particles. Biomechanical testing, 
histology, histomorphometry and  micro CT. 
(Yazici et al., 2011) 
rhBMP-2 
(adenovirus) 
SCID Mouse, 
calvarial defect – 
5 mm 
 4 weeks 
Transduced primary 
muscle-derived cells on 
collagen sponge, implant 
5 x 105 cells 
Bone healing was observed within mice transplanted 
with genetically engineered muscle cells. Treated 
groups showed 95 % to 100 % defect closure after 4 
weeks compared to 30 % to 40 % closure observed in 
controls. Histology and immunohistochemistry. 
(Lee et al., 2001a) 
BMP-2 
(lentivirus) 
Balb/c/nu Mouse, 
femur fracture 
defect 
 4 weeks 
Lentiviral transduced 
human MSCs in Matrigel, 
injection 
5 x 105 cells 
BMP-2-MSCs generated mature chondrocytes 
following injection, and correlate with extensive bone 
marrow formation. Histology and qPCR. 
(Choi et al., 2011) 
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rhBMP-2 
(retroviral vector) 
Female C3H/HeN 
Mouse, radial 
bone segmental 
defect – 2.5mm, 
posterior spinal 
fusion  
 
2 weeks 
(radial) 
3 and 6 
weeks 
(spine) 
Transfected hMSCs within 
PFTBA enriched fibrin 
hydrogel, implant 
1 x 106 cells 
(radial), 3 x 106 
cells (spine) 
Both defect sites displayed increased bone regeneration, 
and exhibited enhanced bone volume and quality (1.4 
fold increase). New bone (2.5 fold increase) was also 
observed within ectopic implant sites subcutaneously 
and intramuscularly. Histology and micro CT. 
(Kimelman-Bleich et al., 2009) 
BMP-2 (plasmid 
vector) 
Female C3H/HeN 
Mouse – spinal 
fusion model 
 4 weeks Genetically engineered MSCs, implant 2 x 10
6 cells Newly formed bone fused the spine through active osteogenesis. Histology and micro CT. (Hasharoni et al., 2005) 
rhBMP-2 
(plasmid vector) 
Female C3H/HeN 
Mouse – radial 
segmental defect – 
2.5 mm 
 10 and 35 weeks 
Genetically engineered 
MSCs on a collagen 
sponge, implant 
2 x 106 cells 
Graft sites showed significantly increased bone 
formation (approx. 4 fold) exhibiting enhanced 
biomechanical strength (approx. 2 fold) after 10 weeks. 
Biomechanical testing, histology and micro CT. 
(Kallai et al., 2010) 
BMP-2 
(adenovirus) 
NOD/SCID 
Mouse, 
heterotopic 
quadriceps 
injection 
 2 weeks 
Transduced ovine cells – 
PEG diacrylate micro-
encapsulated, injection 
3 x 106 cells Heterotopic bone formation was observed within muscle tissue. Micro CT and radiography.  (Mumaw et al., 2012) 
rhBMP-2 
(adenovirus) 
SCID Mouse, 
ectopic implant in 
hindlimb muscle 
pouch 
 2 weeks Transduced cells on collagen sponge, implant 5 x 10
6 cells 
Orthotropic bone formation was shown 2 weeks 
following transplantation of transfected rat bone 
marrow MSCs. Histology and radiography. 
(Abe et al., 2002) 
BMP-2 
(adenovirus) 
NOD/SCID 
Mouse, 
mandibular defect 
– 1mm 
 8 weeks Collagen sponge, implant 5 x 106 cells Significant enhancement of bone regeneration was observed within defects. Histology and micro CT. (Steinhardt et al., 2008) 
BMP-2 
(adenovirus) 
NOD/SCID 
Mouse, 
heterotopic 
quadriceps 
injection 
 2 weeks 
Transduced human MRC5 
cells – PEG diacrylate 
micro-encapsulated, 
injection 
5 x 106 cells 
Microencapsulation aided prolonged cell function and 
BMP-2 induced bone formation heterotopically 
(approx. 1.8 fold increase in bone volume).  Micro CT 
and radiography. 
(Olabisi et al., 2010) 
BMP-2 and 
hMSCs 
Mouse, critical 
sized cranial 
defect – 4 mm 
 5 weeks Cells on silk fibroin, implant 50 µg/mL 
Scaffolds loaded with BMP-2 and seeded with hMSCs 
resulted in significant bone ingrowth and formation 
(approx. 5.6 fold increase compared to scaffold alone). 
Histology and histomorphometry. 
(Karageorgiou et al., 2006) 
rhBMP-2 
(adenovirus) 
Female CD Nude 
Mouse, radial 
segmental defect – 
25 mm 
 45 d 
Transduced human MSCs 
on collagen sponge, 
implant 
unknown 
Transduced human MSCs regenerated and bridged the 
defect site with both new cartilage and 
trabecular/cortical bone. Histology, histomorphometry 
and micro CT. 
(Turgeman et al., 2001) 
Rabbit 
BMP-2 
(adenovirus)  
New Zealand 
White Rabbit, 
femur segmental 
defect – 13 mm 
 8 to 12 weeks 
Injection into the defect 
site 
2 x 1010 
particles 
Ossification across the defect site was observed within 
all treated groups, exhibiting enhanced biomechanical 
strength and bending stiffness (2.4 and 1.7 fold 
increase, respectively). Biomechanical testing, 
histology and radiography. 
(Baltzer et al., 2000) 
BMP-2 
(adenovirus) 
Female New 
Zealand White 
Rabbit, femur 
defect – 10 mm 
 2 to 4 weeks 
Injection into the defect 
site 
7 x 1010 
particles 
Bridging-callus formation resulted in higher ossification 
within BMP-treated groups. Histology and radiography. (Southwood et al., 2004) 
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BMP-2 (retroviral 
vector) 
Female New 
Zealand White 
Rabbit, patella 
osteochondral 
defect – 3.6mm 
diameter x 3mm 
depth 
 4 and 12 weeks 
Transfected chondrocytes 
within fibrinogen clot, 
implant 
1 x 105 cells 
BMP-2 increased bone tissue repair 2 fold, but failed to 
induce complete defect healing despite efficient 
transduction and stable expression. Histology, 
histomorphometry, immunohistochemistry and qPCR. 
(Vogt et al., 2009) 
Rat 
BMP-2 
(adenovirus) 
Male Sprague-
Dawley Rat, 
femur segmental 
defect – 5 mm 
 8 weeks Percutaneous injection 4 x 108 particles 
Osseous union was observed with increased defect 
bridging by lamellar and trabecular bone exhibiting 
high mineral density similar to intact bone. Mean bone 
volume was increased 5 fold compared to control 
groups. Histology, histomorphometry and radiography. 
(Betz et al., 2006) 
BMP-2 
(adenovirus) 
Sprague-Dawley 
Rat, femur defect  8 weeks  Single injection 4 × 10
8 particles 
Union incidence was markedly increased when 
administration of adenovirus was delayed. Greater bone 
mineral content within the defect site and improved 
average mechanical strength of the healed bone was 
observed. Biomechanical testing, DXA, micro CT and 
radiography. 
(Betz et al., 2007a) 
BMP-2 
(adenovirus) 
Sprague-Dawley 
Rat, femur defect  8 weeks Percutaneous injection 
2.7 x 107 to 2.7 
x 109 particles 
Bone mineral content and bone volume of the defect 
receiving high dose adenovirus were significantly 
higher than those receiving lower dose, exhibiting 
trabecular bone and small amounts of cartilage. DXA, 
histology, micro CT and radiography. 
(Betz et al., 2007b) 
hBMP-2 
(adenovirus) 
Fischer F344 
Male Rat, 
calvarial defect – 
8mm 
 8 weeks Transduced autograft muscle 
1 x 1010 viral 
particles (8mm 
x 2mm graft) 
Transduced muscle underwent osteogenic 
differentiation forming new bone (approx. 2 fold 
increase in mineralised tissue). Rapid cartilage 
formation was observed which may have undergone 
endochondral ossification. DXA, histology and micro 
CT. 
(Liu et al., 2012) 
rhBMP-2 
(adenovirus) 
Athymic RNU 
Nude Rat, fibula 
segmental defect – 
2/4mm 
 1 to 12 weeks 
Transduced human 
fibroblasts (MRC5), 
injected 
5 x 104 to 5 x 
107 cells 
The system delivers 130x less BMP-2 and shows 
equivalent bone formation and regeneration to other 
studies. Bone volume increased 10 fold between high 
and low cell numbers. Histology, micro CT and 
radiography. 
(Lazard et al., 2011) 
hBMP-2 
(adenovirus, 
retrovirus and 
cationic lipid 
vectors) 
Male Fischer Rat, 
calvarial defect – 
8 mm 
 30 d 
Transduced/transfected 
cells seeded on titanium 
mesh, implant 
4 x 105 cells 
Enhanced osteogenic capacity of transduced cells 
mediated bone healing. Immunohistochemistry, 
histology and histomorphometry. 
(Blum et al., 2003) 
rhBMP-2 
(adenovirus)  
Wistar Rat, 
mandibular defect 
– 6 mm 
 1 to 8 weeks 
Transduced cells on 
collagen sponge, implant 1 x 10
6 cells Critical size defects were completely healed. Histology, in situ hybridisation and radiography. (Park et al., 2003) 
hBMP-2 
(adenovirus) 
 
Rat, femur defect 
– 8 mm  2 months 
Transduced cells on DBM, 
implant 5 x 10
6 cells 
Bone healing with coarse trabecular structure was 
observed. Bone area increased approx. 7.5 fold 
compared to scaffold alone. Biomechanical testing, 
histology, histomorphometry and radiography. 
(Lieberman et al., 1999) 
BMP-2 
(adenovirus) 
Female NIH rnu 
Athymic Nude 
Rat,  
Distal femoral 
osteotomy 
 2 weeks 
Injection of transduced 
cells within alginate beads, 
or direct  injection 
5 x 106 cells 
Direct injection showed completely healed defects. 
Bone density was 2 fold higher in treated groups 
compared to saline controls. However, bone healing 
within alginate groups was impeded by development of 
a chondroid mass. Histology and micro CT. 
(Zachos et al., 2007) 
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BMP-2 
(lentivirus) 
Lewis Rat, 
vertebral lumbar 
fusion 
 4 to 8 weeks 
Transduced rat bone 
marrow cells 5 x 10
6 cells 
Sustained BMP-2 delivery induced increased bone 
formation and spinal fusion. Histochemistry, histology, 
micro CT and radiography. 
(Miyazaki et al., 2008) 
BMP-2 (plasmid 
construct) 
Sprague-Dawley 
Rat, calvarial 
defect – 8mm 
 4 to 16 weeks 
Transfected rat cells in 
alginate gel, implant 1 x 10
7 cells Complete repair of cranial defects was observed through new bone formation. Histology and RT-PCR. (Lin et al., 2008) 
rhBMP-2 
(retroviral vector) 
Fischer and 
Sprague-Dawley 
Rat, calvarial 
defect – 5mm  
 4 to 10 weeks 
Transfected dermal 
fibroblasts on collagen 
sponge, implant 
2 x 107 cells 
Treatment promoted bone formation in defect sites, 
increasing calcified tissue area approx. 9 fold compared 
to control groups. Histology, immunohistochemistry 
and radiography. 
(Wang et al., 2009) 
 
3. Animal Models for combinational direct and indirect BMP-2 delivery 
3.1. Large Animal Models 
Dog 
BMP-2 and 
VEGF  
Beagle Dog, 
ectopic paraspinal 
muscle implant 
and 
ulna critical size 
defect 
 9 weeks 
Gelatin (fast release) or 
PLGA microparticle 
(sustained release) loaded 
biphasic calcium phosphate 
scaffold, implant 
12 µg BMP-2 
0.4 µg VEGF 
(ectopic site) 
 
120 µg BMP-2 
4 µg VEGF 
(ulnar defect) 
Ectopic BMP-2 fast release showed significantly more 
bone compared to sustained release, independent of the 
VEGF profile. Significant enhancement of bone 
formation was observed within all orthotopic groups 
compared to controls independent of growth factor 
release profile or combination. Histology, 
histomorphometry and immunohistochemistry. 
(Geuze et al., 2012) 
BMP-2, bFGF, 
PDGF and TGF-β  
Adult Hound, 
mandibular 
premolar implant 
osteotomies 
 12 weeks 
Titanium implants with 
non-HA calcium phosphate 
cement 
unknown Growth factor combination increased bone formation compared to controls. Histology and histomorphometry. (Meraw et al., 2000) 
Horse 
BMP-2 and 
BMP-7 
(adenovirus) 
Horse, metacarpal 
IV ostectomy – 
15mm 
 2 to 16 weeks Direct injection 
2 x 1011 virus 
particles 
Bone defect regeneration was not enhanced further than 
controls when treated with BMP-2 and BMP-7 viral 
particles, possibly due to incorrect dosing. DXA, 
histology and radiography. 
(Southwood et al., 2012) 
Pig 
rhBMP-2 and 
VEGF 
Female Domestic 
Pig, cranial drill 
defect – 4.2mm 
 1 to 4 weeks 
Titanium plugs with 
adsorbed octacalcium 
phosphate, implant 
5.26 µg BMP-2, 
1.32 µg VEGF 
Implants revealed enhanced bone volume density 
(approx. 1.6 fold increase), but not osseointegration. 
Histology, histomorphometry and micro-radiography. 
(Ramazanoglu et al., 2011) 
3.2. Small Animal Models 
Minipig 
BMP-2 and 
BMP-7 
Minipig, calvarial 
defect – 8mm  
2 to 6 
weeks Collagen sponge, implant 5 µg 
Combination treatment increased bone formation 2.1, 
1.4 and 1.6 fold compared to controls, BMP-2 alone, 
and BMP7 alone. Histology, histomorphometry, 
immunohistochemistry,  
(Sun et al., 2012b) 
BMP-2 and 
BMP-7 
Guangxi Bama 
Minipig, calvarial 
defect – 8mm 
diameter x 4mm 
depth 
 2 to 6 weeks Collagen sponge, implant 
5 µg (30 
ng/mm3) 
Low dose BMP-2/7 heterodimer facilitated more rapid 
bone regeneration (approx. 1.5 fold increase in bone 
volume compared to either factor alone) of improved 
quality. Micro CT. 
(Wang et al., 2012) 
Mouse 
rhBMP-2, VEGF-
A and FGF-2  
CD-1 Mouse, 
calvarial defect – 
2 mm 
 12 weeks Collagen sponge, implant 0.2 µg 
BMP-2 and VEGF-A showed enhanced healing 
capacities compared to FGF-2, however no significant 
differences between VEGF-A and BMP-2 were 
observed. Immunohistochemistry and micro CT. 
(Behr et al., 2012) 
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rhBMP-2 and 
hMSCs 
BALB/c Mouse, 
subcutaneous 
injection 
 2 to 7 weeks 
pH/thermosensitive 
polymer hydrogel, 
injection 
0.5 µg rhBMP-2 
and 1 x 105 cells 
Ectopic mineralisation and calcium deposition was 
observed. Histology and immunohistochemistry. (Kim et al., 2009) 
rhBMP-2 and 
Epo 
C57BL/6 Mouse, 
cranial defect – 
5mm 
 5 to 42 d Collagen sponge, implant 
1 µg rhBMP-2 
and 1,000 U/mL 
Epo  
Epo enhanced BMP-2-induced bone formation. 
Histology, histomorphometry and micro CT. (Sun et al., 2012a) 
rhBMP-2 and 
Bisphosphonate 
(zoledronic acid) 
NF1deficient 
Mouse, 
neurofibromatosis 
model – fracture 
 3 weeks CMC carrier, implant 10 µg 
BMP-2 and bisphosphonate administration 
demonstrated enhanced bone union, decreasing non-
unions by 50% and increased bone volume by 31%. 
Histology and radiography. 
(Schindeler et al., 2011) 
rhBMP-2 and 
VEGF 
Male MF1 nu/nu 
Mouse, femur 
segmental defect – 
5mm 
 4 weeks Alginate and PLA, implant 20 µg 
Enhanced bone repair (approx. 3.2 fold increase) was 
observed within the defect environment. Histology, 
immunohistochemistry and micro CT. 
(Kanczler et al., 2010) 
rhBMP-2 and 
BMP binding 
protein (BBP) 
Male Lewis Rat, 
ectopic 
subcutaneous and 
intramuscular 
implantation 
 2, 4 and 7 d Collagen sponge, implant 20 μg rhBMP-2 
500 μg BBP 
Addition of BBP reduced rhBMP-2 related 
inflammation area a max. 1.4 and 1.3 fold 
subcutaneously and intramuscularly, respectively. 
Histology, histomorphometry and MRI. 
(Lee et al., 2011) 
BMP-2/VEGF 
(recombinant 
adeno-associated 
virus 6) 
Athymic Nude 
Mouse, tibiae 
segmental defect – 
2/3mm 
 5 weeks 
Transduced male mouse 
MSCs, intravenous 
injection 
1 x 106 cells: 
5 x (2 x 105 
cells per d) 
Enhanced bone formation was observed within defect 
sites compared to control groups. Bone volume, peak 
load and stiffness increased approx. 6, 4.5 and 4 fold 
respectively, compared to control groups. DXA, 
histology, immunohistochemistry and micro CT. 
(Kumar et al., 2010b) 
BMP-2 and 
Runx2 (plasmid 
vector) 
Female Athymic 
Mouse (BALB/c-
nu), subcutaneous 
implantation 
 6 weeks 
Transfected adipose 
derived stem cells on 
PLGA scaffold, implant 
1 x 106 cells 
Histological analysis revealed enhanced bone formation 
(approx. 4 fold increase in bone area) through promoted 
osteogenic activity. Biochemistry, histology, RT-PCR 
and western blot. 
(Lee et al., 2010) 
rhBMP-2 and 
Mouse α4 
integrin 
(recombinant 
adeno-associated 
virus 2) 
Female OVX 
C57BL/6 Mouse 
(osteopenia 
model) 
 1 to 15 weeks 
Transduced male mouse 
MSCs, intravenous 
injection  
2 x 106 cells: 
5 x (4 x 105 
cells) – 1 per 
day 
Transduced MSCs were found to restore bone growth 
by both direct incorporation and indirect pro-
osteoblastic activity. Bone mineral density increased 
1.26 fold compared to non-transduced controls at 5 
weeks. DXA, histology, immunohistochemistry and 
micro CT. 
(Kumar et al., 2010a) 
BMP-2 and 
VEGF (plasmid 
vector) 
BALB/c nu/ nu 
Nude Mouse, 
ectopic 
intramuscular 
implant 
 4 and 8 weeks 
Transfected cells on β-TCP 
scaffold, implant 
2.5 x 106 
cells/mL 
Co-expression showed significant bone formation 
compared to BMP-2 alone at 4 weeks. Bone area 
increased 10 fold by 8 weeks. VEGF may enhance 
BMP-2 induced bone formation through angiogenesis 
modulation. Histology, histomorphometry, 
immunohistochemistry and in situ hybridization.  
(Samee et al., 2008) 
BMP-2 and 
BMP7 
(adenovirus) 
C57BL6 Mouse, 
critical sized 
calvarial defect – 
7mm 
 4 weeks 
Transduced mouse BLK 
cells in gelatin sponge, 
implant 
4 x 106 cells 
Implants revealed robust osteogenic activity with 
complete bone coverage of defects. Bone volume 
increased 2 and 1.7 fold compared to BMP-2 and BMP-
7 alone, respectively. Histology, micro CT and 
radiography. 
(Koh et al., 2008) 
Rabbit 
BMP-2 and 
VEGF  
Male New 
Zealand Rabbit, 
intramedullary 
femur defect. 
 2 to 12 weeks 
Growth factor loaded-
PLGA microspheres within 
porous PLGA scaffolds, 
implant 
3.5 or 17.5 µg 
BMP-2 
0.35 or 1.75 µg 
VEGF 
Co-expression exhibited a temporal dose-dependent 
positive synergistic effect on bone formation, with new 
bone after 2 weeks and neovascularisation after 4 
weeks. Histology, histomorphometry and 
immunohistochemistry. 
(Hernandez et al., 2012) 
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BMP-2 and TGF-
β2 
New Zealand 
White Rabbit, 
femoral condyle 
defect – 3mm 
 28 d Copolymer coated titanium cylinders, implant 
12.5 µg BMP-2 
0.625 µg TGF-
β2 
Dual growth factor delivery induced 13.5% more bone 
formation compared to controls. Interestingly, delivery 
of BMP-2 alone increased bone formation by 15.4%. 
Biomechanical testing and micro CT. 
(Thorey et al., 2011) 
BMP-2 and 
rhVEGF165 
New Zealand 
Rabbit, sinus floor 
elevation 
 4 and 12 weeks 
Sonication-induced silk 
hydrogel, implant 
30 µg BMP-2 
20 µg VEGF165 
VEGF promoted higher tissue infiltration and 
accelerated gel degradation. Co-expression induced 
significantly larger bone area than single factor groups 
and the silk control (1.4 to 4.9 fold more bone). 
Histology, histomorphometry, micro CT and 
radiography. 
(Zhang et al., 2011a) 
rhBMP-2 and 
MSCs (rabbit) 
New Zealand 
White Rabbit, 
cranial defect – 15 
mm 
 8 and 16 weeks Coral scaffold, implant 
200 µg 
rhBMP-2 
1 x 107 MSCs 
Generated new bone comparable to auto-bone-graft 
repair. Regenerated bone defect area was increased 
approx. 3.9 fold compared to scaffold alone. Histology, 
immunohistochemistry and radiography. 
(Hou et al., 2007) 
BMP-2 and 
VEGF 
(baculovirus) 
New Zealand 
White Rabbit, 
femoral segmental 
defect – 10mm 
 8 weeks Transduced rabbit MSCs in PLGA scaffold, implant 3 x 10
6 cells 
Increased bone formation of improved quality was 
observed. Torsional stiffness and maximum torque were 
increased 208 and 26.5 fold respectively, compared to 
scaffold alone. Biomechanical testing, histology, 
immunohistochemistry, micro CT, micro PET and 
radiography. 
(Lin et al., 2010) 
BMP-2, VEGF 
and FLP 
(baculovirus) 
Female New 
Zealand White 
Rabbit, calvarial 
defect – 8mm 
 4 and 12 weeks 
Transduced rabbit MSCs in 
PLGA scaffold, implant 3 x 10
6 cells 
FLP episome formation prolonged BMP-2/VEGF 
expression and augmented bone repair from rabbit 
MSCs. Bone regeneration area increased 3.4 fold 
compared to scaffold alone. Histology, micro CT, 
micro-PET and radiography 
(Lin et al., 2012a) 
BMP-2 and 
VEGF 
Female New 
Zealand White 
Rabbit, bilateral 
orbital defect – 
12mm 
 4 to 16 weeks 
Transduced BMSCs on 
biocoral composite, 
implant 
4.8 x 106 cells 
BMP-2 
1.2 x 106 cells 
VEGF 
New bone deposition and formation was observed, 
indicating mimicking of natural bone development. 
Bone volume increased approx. 20 fold after 4 weeks, 3 
fold after 8 weeks and 2 fold after 16 weeks, compared 
to controls. Histology, histomorphometry, 
immunocytochemistry, micro CT and radiology. 
(Xiao et al., 2011) 
Rat 
BMP-2 and 
rMSCs 
Male Sprague-
Dawley Rat, 
calvarial defect – 
8mm 
 1 to 9 weeks 
PEG-DA and PEG-MMP 
degradable, implant 
0.0025 µg 
(PEG-DA), 
0.0075 µg 
(PEG-MMP) 
and 1 x 107 cells 
PEG-MMP alone improved bone regrowth. Addition of 
BMP-2 and MSCs did not show further enhancement of 
bone regeneration. Histology and micro CT. 
(Terella et al., 2010) 
BMP-2 and 
PDGF-BB 
Male Sprague-
Dawley Albino 
Rat, calvarial 
defect - 6 mm 
 4 weeks Fibrinogen scaffold, implant 0.05 µg 
Fibronectin and GFs improved bone healing compared 
to growth factors alone. Flow cytometry and micro CT. (Martino et al., 2011) 
BMP-2 and 
VEGF 
Male Fischer Rat, 
cranial defect – 
8mm 
 12 weeks 
Loaded PPF/gelatin 
microparticle composite, 
implant 
0.5 to 2µg 
BMP-2 
6 to 12µg 
VEGF 
Dose-dependent increase in bone formation was 
observed with increased BMP-2 (approx. 5.3 fold). 
VEGF showed no further augmentation, however 
increased defect bridging was observed. Histology and 
micro CT. 
(Young et al., 2009) 
rhBMP-2 and 
Zoledronic acid 
Rat, femoral 
fracture model  6 weeks Collagen sponge, implant 1 µg rhBMP-2 
Effective fracture repair was observed with significantly 
enhanced bone fusion. Bone volume and stiffness 
increased approx. 1.5 and 8.3 fold respectively, 
compared to scaffold alone. Biomechanical testing, 
histology, micro CT and radiography. 
(Doi et al., 2011) 
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BMP-2 and 
VEGF 
Syngeneic 
Fischer-344 Rat, 
calvarial defect – 
8 mm 
 4 and 12 weeks 
Gelatin microparticles 
entrapped within 
PPFscaffolds, implant 
2 µg BMP-2 
12 µg VEGF 
VEGF increased blood vessel formation and acted 
synergistically with BMP-2 to enhance bone formation. 
Bone volume was increased approx. 5 fold. Histology 
and micro CT. 
(Patel et al., 2008) 
BMP-2 and 
rMSCs 
Male Sprague-
Dawley Rat, 
calvarial defect – 
8mm 
 4 and 8 weeks Chitosan gel, injection 
2 µg BMP-2 
3 x 105 cells 
Significant bone regeneration was observed within 
defect sites showing increased bone volume (approx. 
3.4 fold) and osseointegration. Histology, 
immunohistochemistry and micro CT. 
(Stephan et al., 2010) 
BMP-2 and FGF-
2 Rat, femur defect  
4, 8 and 12 
weeks 
Nanostructured colloidal 
gelatin within porous 
titanium scaffold, implant 
3 μg BMP-2 
0.6 μg FGF-2 
Bone formation was accelerated; observed earlier than 
controls. Increased bone volume was also observed 
exhibiting superior bone-implant integrity. 
Biomechanical testing, histology and micro CT. 
(van der Stok et al., 2013) 
BMP-2 and FGF-
2  
Wistar Rat, 
ectopic 
intramuscular 
implantation 
 3 weeks Type I collagen carrier, implant 
5 μg BMP-2 
0.0016 to 50 μg 
FGF-2 
Combination treatment with 0.08 μg FGF-2 exhibited 
the greatest increase in bone area compared to controls 
(3.3 and 2.1 fold, assessed by radiopacity and histology, 
respectively), and BMP-2 alone (1.7 and 1.07 fold). 
Biochemistry, histology, histomorphometry and 
radiography. 
(Fujimura et al., 2002) 
BMP-2 and FGF-
2 
Male ddY Mouse, 
subfascial 
implantation 
 1, 2 and 3 weeks 
Porous collagen disc, 
implant 
5 μg BMP-2 
0.001 to 5 μg 
FGF-2 
Combination treatment with lose dose FGF-2 (0.001 
μg) increased mineral density, radiopacity and bone 
formation approx. 1.2, 2 and 1.5 fold, respectively after 
3 weeks. DXA, histology, histomorphometry and 
radiography 
(Nakamura et al., 2005) 
BMP-2 and PTH 
(1-34) 
Harlan Sprague-
Dawley Rat, mid-
diaphyseal 
femoral defect – 
5mm 
 8 weeks 
PLGA microspheres in 
gelatin hydrogel, implant 
Subcutaneous injection 
(PTH (1-34)) 
6.5 μg BMP-2 
10 μg/kg PTH 
PTH did not induce bone formation in empty control 
defects. BMP-2 scaffolds with PTH treatment increased 
bone volume by approx. 4.1 and 1.7 fold compared to 
control defects and BMP-2 scaffold only, respectively. 
DXA, histology and micro CT. 
(Kempen et al., 2010) 
rhBMP-2 and 
VEGF 
Harlan Sprague-
Dawley Rat, 
ectopic 
subcutaneous 
implant and 
femoral defect – 
5mm 
 4 and 6 weeks 
PLGA in poly-PPF 
(rhBMP-2) within gelatin 
hydrogel (VEGF), implant 
6.5 µg rhBMP-2 
and 2 µg VEGF 
Microangiography showed an approx. 2 fold increase in 
vascularization within subcutaneous implants. Bone 
formation within orthotopic defects also demonstrated 
an approx. 2 fold increase compared to controls. 
Histology, histomorphometry and micro CT. 
(Kempen et al., 2009) 
rhBMP-2 and 
Tobramycin 
Sprague-Dawley 
Rat, femur 
segmental defect – 
5mm 
 8 weeks Collagen sponge, implant 11 μg rhBMP-2 and tobramycin 
Enhanced bone formation was observed upon dual 
application of rhBMP-2 and tobramycin. Bone area was 
increased approx. 1.2 fold compared to controls. 
Biomechanical testing, DXA, histology, micro CT and 
radiography. 
(Glatt et al., 2009) 
rhBMP-2 and 
rhBMP-7 
(plasmids) 
Male Wistar Rat, 
ectopic 
intramuscular 
injection 
 1 to 10 d Direct injection and in vivo electroporation 12.5 μg 
Enhanced bone formation and calcification was 
observed compared to single modalities, with 
upregulation of BMP-4. Histology, 
immunohistochemistry, radiography and rtPCR. 
(Kawai et al., 2006) 
rhBMP-2 and 
rhBMP-7 
(plasmid) 
Male Wistar Rat, 
ectopic 
intramuscular 
injection 
 10 d 
Direct injection of double 
cassette plasmid and in 
vivo electroporation 
50 μg 
Enhanced bone formation and calcification was 
observed compared to single modalities. Histology and 
radiography. 
(Kawai et al., 2009) 
rhBMP-2 and 
bFGF 
Rat (WKY, 
Lewis, Fisher), 
irradiated 
mandible 
 7 weeks Liquid injection 100 µg 
Irradiation reduced bone apposition, BMP-2 or bFGF 
alone generated new bone, but together they did not 
show bone maintenance. Fluorescence microscopy, 
histology and micro CT. 
(Springer et al., 2008) 
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BMP-2 and 
BMP7 
(adenovirus) 
Sprague-Dawley 
Rat, bilateral 
single level 
posterolateral 
spine fusion 
 8 weeks 
Allograft bone and CMC 
hematostatic foam soaked 
with adenovirus, implant 
0.75 x 108 to 
0.75 x 1011 
particles 
Co-administration of Ad.BMP-2 and Ad.BMP7 resulted 
in significantly greater numbers of mechanically stable 
fusions and also 2 fold higher mineralisation rate of 
bone volume in the fusion mass. Histology and 
radiography. 
(Zhu et al., 2004) 
BMP-2 and 
rhPDGF-BB 
(adenovirus) 
Male Sprague-
Dawley Rat, 
calvarial defect – 
8mm 
 2 to 4 weeks 
rhPDGF protein and 
BMSCs expressing BMP-
2, implant 
1 x 106 cells 
Increased bone regeneration by delivery of autologous 
AdBMP2-transfected BMSCs and rhPDGF-BB in both 
the amount of new bone formed and bone mineral 
density. The bone growth was greater than those 
observed in the group treated with AdBMP2-transfected 
BMSCs alone.  
(Park et al., 2013) 
BMP-2 and 
BMP-7 
(lentivirus) 
Sprague-Dawley 
Rat, calvarial 
defect – 2mm 
 2 to 6 weeks 
Transduced cells in β-TCP 
scaffold, implant 1 x 10
6 cells 
New bone formation was observed after 4 weeks in all 
treated defects. Only dual factor treated defects 
exhibited complete defect regeneration after 6 weeks. 
Biochemistry, cytochemistry, histology, qPCR and 
radiography. 
(Qing et al., 2012) 
 
4. Human Trials 
Facial Reconstruction and Bone Augmentation 
rhBMP-2  
Human, maxillary 
sinus floor 
augmentation 
16 weeks Absorbable collagen sponge, implant 1.77 to 3.4 mg 
Significant bone growth was observed increasing 
maxillary sinus floor height. Biochemistry, CT and 
histology. 
(Boyne et al., 1997) 
rhBMP-2  Human, mandible lesion 
3 to 18 
months Collagen sponge, implant 4 to 8 mg 
Osseous restoration of the edentulous area was 
observed with new bone formation. Radiography. (Herford and Boyne, 2008) 
rhBMP-2  
Human, maxillary 
sinus floor 
augmentation 
4 and 6 
months 
Absorbable collagen 
sponge, implant 
0.75 to 1.5 
mg/mL 
Induced adequate bone for the placement and functional 
loading of endosseous dental implants. 76 % of patients 
with treated dental implants remained functional after 
36 months compared to 62 % of patients who received 
bone graft alone. CT. 
(Boyne et al., 2005) 
rhBMP-2  
Human, alveolar 
ridge 
augmentation 
unknown Absorbable collagen sponge, implant 
0.75 to 1.5 
mg/mL 
New bone formation was observed similar to native 
bone. Bone adequacy for dental implant was approx. 2 
fold greater than no treatment or placebo. CT and 
histology. 
(Fiorellini et al., 2005) 
rhBMP-2  Human, mandible defect 22 months Collagen sponge, implant 1.5 mg/mL 
Mandibular defects can be successfully reconstructed 
with BMP-2 soaked collagen scaffolds. Radiography. (Carter et al., 2008) 
rhBMP-2  Human, cleft alveolar defect 1 year 
Collagen sponge within 
gelatin sponge, implant 1.5 mg/mL 
Improved bone healing and reduced morbidity, 
exhibiting higher bone volume and mineralisation. 
Treated bone defects exhibited 95 % bone filling 
compared to 63 % within control iliac graft defects. CT 
and radiography. 
(Dickinson et al., 2008) 
rhBMP-2  
Human, maxillary 
sinus floor 
augmentation 
6 to 24 
months Collagen sponge, implant 1.5 mg/mL 
Significant bone formation comparable to native bone 
in structure and density was observed. Approx. 83 % of 
treated patients retained their implants, fully integrated 
and functional at 6 months. CT and radiography. 
(Triplett et al., 2009) 
rhBMP-2  Human, mandible resection 9 months 
Collagen sponge within 
titanium mesh, implant unknown 
Appreciable bone regeneration was observed bridging 
the maxillofacial defect. Radiography. (Cicciu et al., 2012) 
Long Bone Fracture and Non-Union 
rhBMP-2  Human, long bone non-union 20 months 
Collagen gel and 
cancellous allograft bone 
chips, implant 
12 mg 
Implant analysis demonstrated reduced operative time 
(approx. 35 %) and intraoperative blood loss (approx. 
40 %), suggesting rhBMP-2 be used as an alternative to 
iliac crest autograft. Radiography. 
(Tressler et al., 2011) 
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hBMP-2 and 
iNCP  
Human, long bone 
non-union 
9.3 to 48.9 
months 
Ultra-thin gelatin capsules 
or PLA/PGA, implant 50 to 100 mg 
Bone union was observed in most patients, with new 
bone formation. Radiography. (Johnson et al., 1988a) 
hBMP-2 and 
iNCP  
Human, tibial 
segmental defect – 
3 to 17 cm 
18 months PLA/PGA, implant 50 to 100 mg Tibial defects within five of six patients healed without further surgical treatment. Radiography. (Johnson et al., 1988b) 
rhBMP-2  Human, open tibial fracture 12 months 
Absorbable collagen 
sponge, implant 
0.75 to 1.5 
mg/mL 
High dose rhBMP-2 resulted in reduced risk of failure 
(approx. 44 %), significantly fewer invasive 
interventions and faster wound-healing (83 % compared 
to 65 % in control patients). Radiography. 
(Govender et al., 2002) 
rhBMP-2  Human, open tibial fracture 12 months 
Absorbable collagen 
sponge, implant 1.5 mg/mL 
Implants were well tolerated and yielded a healing rate 
equivalent to that of autogenous bone-grafting. 
Radiography. 
(Jones et al., 2006) 
rhBMP-2  Human, open tibial fracture 12 months 
Absorbable collagen 
sponge, implant 1.5 mg/mL 
Bone healing was observed, reducing the frequency of 
autogenous bone grafts, secondary interventions and 
lowering the rate of infection. Radiography. 
(Swiontkowski et al., 2006) 
rhBMP-2  Human, open tibial fracture unknown Collagen sponge, implant unknown 
Implantation of rhBMP-2, combined with an absorbable 
collagen sponge, was found to be feasible and safe. 
Radiography. 
(Riedel and Valentin-Opran, 
1999) 
Lumbar Fusion 
rhBMP-2  
Human, anterior 
cervical 
discectomy and 
fusion (ACDF)  
6 to 52 
weeks PEEK, implant 
1.1 mg to 2.1 
mg 
Bone fusion was observed between vertebrae where 
PEEK spacers had been implanted. Bone formation was 
also observed beyond the PEEK spacer confines. 
Radiography. 
(Klimo and Peelle, 2009) 
BMP  
Human, anterior 
cervical 
disectomy 
2 to 3 years Fibular allograft, implant 0.9 to 2.7 mg 
Patients demonstrated spinal fusion with new bone 
formation comparable to traditional iliac crest bone 
graft. Radiography. 
(Buttermann, 2008) 
rhBMP-2  Human, lumbar disc disease 6 years 
Collagen sponge within 
lumbar tapered fusion 
cage, implant 
4.2 to 8 mg 
Implants showed anterior intervertebral spinal fusion 
with new bone formation in 98 % of patients. Disability 
index scores were reduced for back and leg pain 
showing an increase in patients returning to work (63 
%) at 6 months than were in work pre-operatively (52 
%), and this was sustained at 6 years (68 %). 
Radiography. 
(Burkus et al., 2009) 
rhBMP-2  Human, paediatric spinal fusion 
11 to 18 
months 
Autologous iliac crest bone 
graft 12 mg 
Spinal fusion was achieved in children with 
compromised bone healing due to congenital, local and 
systemic conditions. Radiography. 
(Mladenov et al., 2010) 
rhBMP-2  Human, postero-lateral arthrodesis 2 years 
Collagen sponge/HA-TCP 
ceramic bulking agent, 
implant 
12 mg 
Implants demonstrated trabecular bone bridging and 
intervertebral fusion within 95 % of treated patients 
compared to 70 % of control patients at 24 months. CT 
and radiography. 
(Dawson et al., 2009) 
rhBMP-2  Human, spinal lumbar fusion 
0.5, 1 and 6 
years PLGA, implant 15 mg 
Bone fusion progressed for 2 years without further 
improvement up to 6 years. Bone union rate within 
treated patients was not statistically different to that in 
control patients, 82 % and 91 %, respectively. 
Radiography. 
(Katayama et al., 2009) 
rhBMP-2  Human, postero-lateral arthrodesis 2 years 
Type I Bovine Collagen 
sponge/HA-TCP particles, 
implant 
20 mg 
Significant enhanced bilateral bridging bone formation 
and intervertebral disc fusion was observed in 96 % of 
treated patients compared with 89 % of control patients. 
CT and radiography. 
(Dimar et al., 2009) 
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rhBMP-2  
Human, anterior 
lumbar interbody 
fusion 
6 to 24 
weeks 
Bovine absorbable 
collagen sponge, implant 1.5 mg/mL 
All patients who received rhBMP-2 showed 
radiographic evidence of osteoinduction and interbody 
fusion. New bone formation was observed outside cage 
implants in 82 % of treated patients after 6 months, 
compared with 50 % of control patients after 24 
months. CT and radiography. 
(Burkus et al., 2003a) 
rhBMP-2  
Human, cervical 
discectomy and 
interbody fusion 
3 to 24 
months 
Absorbable collagen 
sponge, implant 1.5 mg/mL 
Interbody fusion was observed through formation of 
new bone bridging. Treated patients exhibited improved 
neck and arm pain scores. CT and radiography. 
(Baskin et al., 2003) 
rhBMP-2  
Human, posterior 
lumbar interbody 
fusion 
2 years Absorbable collagen sponge, implant 1.5 mg/mL 
Fusion rate was higher within treated groups (92.3 %) 
compared with autograft control groups (77.8 %) at 24 
months. Post-surgery pain scores were also improved. 
CT and radiography. 
(Haid et al., 2004) 
rhBMP-2  
Human, postero-
lateral lumbar 
fusion 
2 years Absorbable collagen sponge, implant 1.5 mg/mL 
rhBMP-2 treated patients exhibited significantly 
increased lumbar fusion. Treated patients exhibited a 97 
% fusion rate compared to 77 % in control patients. CT. 
(Singh et al., 2006) 
rhBMP-2  
Human, postero-
lateral spine 
fusion 
2 years Absorbable collagen sponge, implant 1.5 mg/mL 
Enhanced spinal fusion was observed within rhBMP-2 
treated patients. Non-union rate within treated patients 
was only 4.2 % compared to 11.4 % in control patients. 
CT. 
(Glassman et al., 2007) 
rhBMP-2  Human, vertebral osteomyelitis  40 months Collagen sponge, implant 1.5mg/mL 
Spinal fusion was observed in all patients receiving 
rhBMP-2. Infection rate was significantly reduced. CT 
and radiography. 
(O'Shaughnessy et al., 2008) 
rhBMP-2  Human, anterior lumbar fusion 
6 to 24 
months 
Absorbable collagen 
sponge, implant unknown 
Spinal fusion was successful in most patients with 
rhBMP-2 treatment. Operative time, blood loss and 
hospital stay were all benefited by rhBMP-2 addition on 
collagen sponge. Radiography. 
(Burkus et al., 2003b) 
rhBMP-2  
Human, postero-
lateral lumbar 
fusion 
0.5, 1 and 2 
years 
Bone autograft, allograft 
and collagen sponge, 
implant 
unknown rhBMP-2 delivery exhibited bone healing and fusion comparable to autograft controls. CT and radiography. (Taghavi et al., 2010) 
 
Abbreviations: BMP-2 (bone morphogenetic protein 2), BMSC (bone marrow stromal cell), CDHA (calcium deficient hydroxyapatite), CHBB (cortico-cancellous human bone block), CHPA (cholesterol-bearing pullulan 
nanogel with acrylol residue), CMC (calcium phosphate cement), CPC (calcium phosphate cement), CT (computer tomography), DBBB (deproteinized bovine bone/porcine collagen), DBM (demineralised bone matrix), 
DX (para-dioxanone), DXA (dual energy X-ray absorptiometry), Epo (erythropoietin), FGF (fibroblast growth factor), GM (gelatin microspheres), HA (hydroxyapatite), hASC (human adult stem cell), iNCP (bone matrix 
water insoluble non-collagenous proteins), MMP (metalloprotease), MRI (magnetic resonance imaging), MSC (mesenchymal stem cell), PCL (poly-caprolactone), PEEK (polyetheretherketone), PEG (poly-ethylene 
glycol), PEG-DA (poly-ethylene glycol-diacrylate), PET (positron emission tomography), PLA (poly-lactic acid), PFTBA (perfluorotributylamine), PLG (poly(D,L-lactide-co-glycolide)), PLGA (poly-lactic co-glycolic 
acid), PPF (poly-propylene fumarate), PUR (polyurethane), PVA (poly(vinyl alcohol)), qCT (quantitative computer tomography), qPCR (quantitative polymerase chain reaction), rhBMP-2 (recombinant human BMP-2), 
rtPCR (reverse transcription PCR), RT-PCR (real time PCR), TCP (tricalcium phosphate), SEM (scanning electron microscopy) and VEGF (vascular endothelial growth factor). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct BMP-7/OP-1 delivery 
1.1. Large Animal Models 
Baboon 
OP-1 (BMP-7) 
Adult Male 
Chacma Baboon, 
calvarial defect 
 30 to 365 d Porous HA, implant 100 and 500 μg Treatment repaired calvarial defects. Histology and histomorphometry. (Ripamonti et al., 2001a) 
rhOP-1 
Adult Male 
Chacma Baboon, 
calvarial defect – 
25mm 
 90 to 365 d Irradiated bovine collagen matrix, implant 
100, 500 and 
2,500 μg 
High dose treatment increased bone and osteoid 
volumes 2.3 and 1.6 fold after just 90 d. Low and 
medium dose also exhibited bone augmentation. 
Histology and histomorphometry. 
(Ripamonti et al., 2000) 
rhOP-1 
Adult Male 
Chacma Baboon, 
calvarial defect – 
25mm 
 15 to 365 d  Collagen matrix, implant 100, 500 and 
2,500 μg 
Lower doses OP-1 induced complete regeneration of 
calvarial bone defect. Histology and histomorphometry. (Ripamonti et al., 1996) 
Dog 
OP-1 
Labrador Dog, 
femoral condyle 
defect, implant 
fixation 
 3 weeks Bovine type I collagen carrier, implant 300 μg 
Treatment increased the volume fraction of woven bone 
close to the implant 1.7 fold. Histology and 
histomorphometry. 
(Jensen et al., 2002) 
OP-1 
Dog, femoral 
condyle defect - 
6mm (titanium 
implant with 
0.75mm gap) 
 4 weeks Allograft, implant 400 and 800 μg 
Generation of mineralised tissue which improved 
implant fixation was increased 1.8 and 1.5 fold 
following revision surgery with low and high dose 
treatment, respectively. Biomechanical testing, 
histology and histomorphometry. 
(Soballe et al., 2004) 
rhOP-1 
Adult Male Dog, 
ulna segmental 
defect – 25mm 
 8 to16 weeks 
Collagen carrier in 
demineralized, guanidine-
extracted, insoluble bovine 
bone matrix, implant 
1,200 μg 
Treatment resulted in formation of new cortical and 
cancellous bone exhibiting mechanical strength 
between 1.7 and 1.9 fold that of controls. 
Biomechanical testing, histology and radiography. 
(Cook et al., 1994a) 
rhOP-1 
Adult Male 
Mongrel Dog, 
bilateral femur 
segmental defect – 
60mm 
 2 to 12 weeks 
Bovine type I collagen 
putty and allogenic cortical 
graft, implant 
3,500 μg 
Treatment increased mineralised area 1.9, 2.7 and 2.4 
fold at 2, 4 and 6 weeks. Torsional stiffness and 
strength were increased 2.3 and 2.2 fold. Biomechanical 
testing, histology and microradiography. 
(Fukuroku et al., 2007) 
OP-1 
Mature Dog, 
humerus condyle 
defect – 4mm 
(HA coated 
titanium implant 
with 3mm gap) 
 6 weeks Bovine type I collagen carrier, implant 
0.65 and 3.25 x 
105 μg 
High dose had no effect on bone formation. Low dose 
had a moderate effect on bone healing but no effect on 
implant fixation. Biomechanical testing, histology and 
histomorphometry. 
(Lind et al., 2001) 
OP-1 
Adult Male 
Mongrel Dog, 
bilateral ulna 
segmental defect – 
25mm 
 2 to 12 weeks 
Bovine type-1 collagen 
carrier in autograft or 
allograft, implant 
2.5, 5 and 7.5 x 
105 μg 
Histological and radiological analysis revealed a max. 
1.6 and 1.9 fold increase (autografts) and 8.3 and 2.9 
fold increase (allografts) in bone-graft incorporation 
and bone formation, respectively. Biomechanical 
testing histology and radiography. 
(Salkeld et al., 2001) 
rhOP-1 
Adult Hound-type 
Dog, femur 
segmental defect - 
40 mm 
 2 to 12 weeks 
Canine bone allograft, 
implant 1,000 μg/mL 
Periosteal callus area was increased 1.7 and 1.3 fold 
after 2 and 12 weeks compared to controls. Bone 
porosity was increased 2.7 fold compared to controls. 
Biomechanical testing, histology, histomorphometry 
and radiography. 
(Cullinane et al., 2002) 
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rhBMP-7 
Hound Labrador 
Mongrel Dog, 
alveolar ridge 
defect – 5mm 
 4 and 8 weeks 
Titanium porous-oxide, 
implant 
1,500 and 3,000 
μg/mL 
Implants exhibited robust bone formation with no 
differences between doses. Histology and radiography. (Leknes et al., 2008) 
OP-1 
Mature Mongrel 
Dog, femur 
condyle defect – 
20mm 
 4 months Bone graft, implant 250 μg per μg bone 
Defect healing was observed following allograft 
treatment with and without OP-1. Biomechanical 
testing, histology and radiography. 
(Mont et al., 2001) 
rhOP-1 
Adult Male Dog, 
ulna segmental 
defect – 25mm 
 12 weeks Particulate collagen carrier and CMC, implant 
1,750 and 3,500 
μg per g carrier 
Radiographic analysis revealed a 1.06 and 1.2 fold 
increase in defect regeneration score after 12 weeks 
with full and half dose OP-1. Biomechanical testing, 
histology and radiography. 
(Cook et al., 2005) 
OP-1 
Dog, ulna 
segmental defect – 
25mm 
 12 weeks Collagen, implant unknown 
Treatment with OP-1 resulted in 89 % of defects 
exhibited complete healing with mechanical strength 
1.65 fold that of intact ulna. Biomechanical testing, 
histology and radiography.  
(Cook et al., 1998) 
Goat 
rhOP-1 
Adult Female 
Goat, closed tibial 
fracture 
 2 and 4 weeks Collagen matrix, injection 1,000 μg 
Local delivery of OP-1 increased callus volume 2.3 fold 
compared to untreated controls. OP-1 treatment with 
collagen matrix increased callus volume 2.5 and 1.4 
fold compared to collagen matrix alone and untreated 
controls, respectively. Biomechanical testing, CT, DXA 
and histology. 
(den Boer et al., 2002) 
rhOP-1 
Adult Female 
Goat, closed tibial 
fracture 
 2 and 4 weeks 
Bovine type I collagen 
matrix, injection 1,000 μg 
Treatment with OP-1 increased histological scoring of 
woven bone volume 1.8 fold compared to untreated 
controls. Addition of collagen increased woven bone 
volume 1.4 and 1.25 fold compared untreated controls 
and collagen alone, respectively. Biomechanical testing 
and histology. 
(Blokhuis et al., 2001) 
Monkey 
rhOP-1 
African Green 
Monkey, 
tibia/ulna 
segmental defect – 
20mm 
 20 weeks  Bovine type I collagen carrier, implant 
250 to 2,000 μg 
(tibia) 
1,000 μg (ulna) 
Complete healing was observed within both treated 
defects at 6 to 8 weeks with defect bridging as early as 
4 weeks. New cortices with areas of woven and lamellar 
bone were observed at 20 weeks. Histology and 
radiography. 
(Cook et al., 1995) 
OP-1 
African Green 
Monkey, ulna 
segmental defect – 
20mm 
 1 to 20 weeks 
Bovine type I collagen 
carrier, implant 1,000 μg 
Lamellar and woven bone found at 12 weeks, with 
remodelling and revascularization found at 20 weeks. 
CT, histology, MRI and radiography. 
(Cook et al., 2002) 
Sheep 
OP-1 
OVX Female 
Sheep, mid-
vertebral defect – 
8mm 
 6 months PLGA microspheres with CMC carrier, implant 370 μg 
Treatment with OP-1 increased bone volume 1.4 fold, 
and torsional stiffness 3.3 fold, both compared to carrier 
alone. Biomechanical testing, DXA, histology and 
histomorphometry. 
(Phillips et al., 2006) 
OP-1 
Female Merino 
Sheep, lumbar 
interbody fusion 
 8 weeks PLGA microbeads with HA, injection 1,600 μg 
Radiographic scoring of defect bridging was increased 
3.1 and 3.9 fold compared to HA alone and autograft 
control. Histology and radiography. 
(Blattert et al., 2002) 
rhBMP-7 
Merino Sheep, 
tibia segmental 
defect – 30mm 
 3 months PCL with TCP scaffold, implant 
1,750 and 3,500 
μg 
Treatment with rhBMP-7 enhanced bone formation 
approx. 8 and 4 fold compared to control scaffolds 
when given a 1.75 and 3.5 mg dose respectively. 
Biomechanical testing, histology, micro CT and 
radiography. 
(Cipitria et al., 2013) 
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rhOP-1 
Sheep, tibia 
segmental defect – 
30mm 
 12 weeks Granular porous HA, implant 2,500 μg  
Treatment with OP-1 on HA increased torsional 
strength and stiffness approx. 3 fold compared to HA 
alone. Biomechanical testing, histology and 
radiography. 
(den Boer et al., 2003) 
hOP-1 
Female Merino 
Crossbreed Sheep, 
lumbar interbody 
fusion 
 1 to 6 months 
Bovine hydroxylapatite 
(Bio-Oss), 2,500 μg 
After 6 months bone formation was increased 2.1 and 
1.3 fold (CT), and 2 and 1.3 fold (MRI) compared to 
HA alone and autograft alone. Biomechanical testing, 
CT, histology and MRI. 
(Magin and Delling, 2001) 
rhBMP-7 
Merino Sheep, 
tibia segmental 
defect – 30mm 
 3 to 12 months 
PCL with TCP scaffold, 
implant 3,500 μg 
Bone volume was increased 3.3 and 1.9 fold after 3 and 
12 months compared to scaffold alone. Biomechanical 
testing, histology, histomorphometry, micro CT and 
radiography. 
(Reichert et al., 2012) 
rhOP-1 Sheep, mandible defect – 60mm  
1 to 8 
weeks 
Bovine type I collagen 
matrix or allograft, implant 3,500 μg 
Treatment with OP-1 increased bone formation approx. 
1.5 fold, and addition of allograft further enhanced bone 
formation approx. 1.8 fold, both compared to control 
defects. Histology, immunohistochemistry and 
radiography. 
(Forriol et al., 2009) 
rhBMP-7 
Alpine Sheep, 
metatarsal defect 
– 30mm  
 4, 8 and 16 weeks 
Bovine type I collagen, 
implant 3,500 μg 
Increased callus formation and bone remodelling were 
observed at 8 and 16 weeks, respectively. 
Biomechanical testing, histology, histomorphometry 
and radiography. 
(Donati et al., 2008) 
OP-1 
Mature Merino 
Sheep, cemented 
hemiarthroplasty 
 6, 18 and 26 weeks 
Type I collagen in 
allograft, implant 
60 to 89 μg per 
g allograft 
Extensive periosteal bone formation and remodelling of 
cortical and trabecular bone was observed. Histology, 
histomorphometry and radiography. 
(McGee et al., 2004) 
BMP-7 
Adult Sheep, 
mandible defect - 
35mm 
 3 months Type I collagen carrier, implant 1,000 μg/cm
3 
Bone appositional rate was close to that of humans 
(1.98 μm/d), but bone volume was lower than native 
bone with an approx. 1.3 fold increase in trabecular 
spacing. Histology and histomorphometry 
(Abu-Serriah et al., 2004) 
1.2. Small Animal Models 
Minipig 
rhOP-1 
Adult Female 
Minipig, mandible 
defect – 45mm 
 12 weeks Xenogenic bone mineral, implant 600 μg 
Quantification by CT revealed a 2 fold increase in 
defect reconstruction. CT and histology. (Terheyden et al., 2001) 
rhBMP-7 
Infant Female 
Minipig, mandible 
replacement 
implantation – 
180mm 
 6 weeks Polylactide or titanium mesh, implant 3,500 μg 
Compression resistance was statistically equivalent to 
natural porcine mandibular bone. Biomechanical 
testing, CT and histology. 
(Warnke et al., 2006) 
Mouse 
BMP-7 
C57BL/6 Mouse, 
ectopic 
intramuscular 
implantation 
 5 to 20 d Collagen fleece, implant 5 μg 
Ectopic bone nodule was observed at the implant site. 
Diclofenac treatment reduced trabecular number and 
increased spacing. Histology, histomorphometry, micro 
CT and radiography. 
(Spiro et al., 2010) 
Bone-forming 
peptide 1 (BMP-7 
derivative) 
ICR Mouse, 
calvarial defect – 
4mm 
 8 weeks 
Immobilised on 
electrospun PLGA fibers, 
implant 
200 μg/mL 
Bone formation was increased 2.9 and 2.5 fold 
compared to control defects and PLGA fibers alone, 
respectively. Biochemistry, histology, micro CT, 
radiography and SEM. 
(Lee et al., 2013) 
Rabbit 
OP-1 
New Zealand 
White Rabbit, 
distraction 
osteotomy 
 5 weeks 
Nanoparticle injection 
(Liposome core with 
alginate and chitosan 
layered shell) 
0.5, 1 and 5 μg 
Relative bone volume was increased 1.5, 1.7 and 1.8 
fold following treatment with 0.5, 1 and 5 μg OP-1. 
Histology, histomorphometry, immunohistochemistry, 
micro CT and radiography. 
(Haidar et al., 2010b) 
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rhOP-1 Rabbit, ulna non-union  
8 or 12 
weeks 
Demineralised, guanidine-
extracted, insoluble rabbit 
bone matrix, implant 
3.13 to 400 μg 
OP-1 treatment induced complete radiographic osseous 
union within 8 weeks, except for defects which received 
3.13 μg. Defects were primarily regenerated with 
lamellar bone. Torsional strength was comparable to 
intact bone. Histology and radiography. 
(Cook et al., 1994b) 
rhOP-1 Rabbit, knee prosthesis  
3 and 6 
weeks Bone allograft, implant 26.5 μg 
Fusion rate was 82 % in treated defects compared to 
10% in non-treated controls, and 42% in autograft 
controls. Histology and histomorphometry. 
(Tagil et al., 2003) 
OP-1 
New Zealand 
White Rabbit, 
femur condyle 
defect – 5mm(Lee 
et al., 2013) 
 6 weeks 
Periapatite-coated titanium 
implants (5mm x 9mm), 
implant 
60 μg 
Bone ingrowth and implant bone coverage were 
increased 2.9 and 2.6 fold respective, compared to 
controls. Biomechanical testing, histology, 
histomorphometry and radiography. 
(Zhang et al., 2004) 
OP-1 
Male New 
Zealand White 
Rabbit, tibia 
osteotomy and 
distraction 
osteogenesis – 
0.25mm per 12 
hours 
 3 weeks Acetate buffer, injection 80, 800 and 2,000 μg 
Low dose OP-1 increased bone regeneration volume 1.2 
and 1.1 fold respective, compared to sham and carrier 
alone defects. High dose OP-1 increased both bone 
mineral content and density approx. 1.2 fold compared 
to controls. Biomechanical testing, DXA, histology, 
histomorphometry and immunohistochemistry. 
(Hamdy et al., 2003) 
rhOP-1 
Female New 
Zealand White 
Rabbit, distal tibia 
wedge osteotomy 
– 4mm 
 1 to 4 weeks 
β-TCP particles and CMC, 
implant 200 μg 
Bone mineral content was increased 1.2 fold compared 
to normal healing following OP-1 treatment. Maximum 
torque and torsional stiffness were increased 1.4 and 1.3 
fold respective, compared to normal healing. 
Biomechanical testing, CT and histology. 
(Tsiridis et al., 2007b) 
rhBMP-7 
New Zealand 
White Rabbit, 
mandible 
osteotomy and 
distraction 
 7 weeks Lactate buffer, injection 200 μg Bone density was increased, but not significantly. Radiography. (Zakhary et al., 2005) 
BMP-7 
New Zealand 
White Rabbit, 
ulna defect – 
15mm 
 2 to 10 weeks 
Homologous compressed  
cancellous bone , implant 300 μg 
Osteoid thickness within the regenerated defect area 
was increased approx. 1.4 fold compared to control 
defects. Histology, histomorphometry and radiography. 
(Djapic et al., 2003) 
        
OP-1 
New Zealand 
White Rabbit, 
tibial osteotomy 
distraction – 
15mm 
 10 weeks Bone filler, implant 800 μg 
Bone density and length were not increased with 
treatment. Computerized axial tomography, histology 
and radiography. 
(Lammens et al., 2009) 
OP-1 
New Zealand 
White Rabbit, 
posterolateral 
lumbar fusion in a 
pseudarthrosis 
model 
 5 and 10 weeks 
Bovine type I collagen 
matrix and CMC, implant 1,200 μg 
After 5 weeks OP-1 induced solid intertransverse 
process fusion in a rabbit model. CT, histology, 
histomorphometry and radiography. 
(Grauer et al., 2004) 
Rat 
rhOP-1 
Rat, ectopic 
subcutaneous 
implantation 
 5 to 21 d Rat collagen matrix, implant 0.025 to 50 µg 
Cartilage calcification was observed after 9 d. Higher 
doses resulted in remodelling at day 9. At day 21 the 
carrier was almost completely replaced with new 
ossicle formation. Biochemistry, histology, 
immunohistochemistry and radioimmunoassay. 
(Sampath et al., 1992) 
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OP-1 
Wistar Rat, 
ectopic 
intramuscular 
injection 
 28 and 70 d 
Nanoparticle injection 
(Liposome core with 
alginate and chitosan 
layered shell) 
0.5 and 1 μg 
Nanoparticles enabled localised delivery without health 
complications, and enhanced de novo bone formation. 
Biochemistry, histology and immunohistochemistry. 
(Haidar et al., 2010a) 
rhBMP-7 
Male Sprague-
Dawley Rat, 
ectopic 
subcutaneous 
implantation 
 3 and 6 weeks 
Encapsulated within PLGA 
nanospheres on PLLA 
scaffold, implant 
5 μg 
Radiopacity was increased approx. 2 and 1.9 fold 
compared to controls after 3 and 6 weeks respective. 
Histology and radiography. 
(Wei et al., 2007) 
rhOP-1 
Sprague-Dawley 
Rat, 6 mm 
segmental femur 
defect 
 2, 4 and 9 weeks 
Lyophilized bovine type I 
collagen (carrier for the 
OP-1) 
11 or 50 µg 
OP-1 maintains its osteoinductive capability in a 
contaminated segmental bone defects Histology and 
quantitative radiography. 
(Chen et al., 2002) 
rhOP-1 
Sprague-Dawley 
Rat, Staph. 
aureus-infected 
femur segmental 
defect – 6mm 
 2 to 12 weeks 
Lyophilised collagen 
carrier. Groups with and 
without antibiotic 
(ceftriaxone), implant 
20 and 200 µg 
Low dose: Mineralised callus formation was increased, 
1.1 (4 weeks) to 4.4 (2 weeks) fold, and 1.4 (12 weeks) 
to 7.8 (2 weeks) fold with and without antibiotics 
respectively, compared to untreated controls. High 
dose: Mineralised callus formation was increased 6.1 (8 
weeks) to 96 (2 weeks) fold, and 4.5 (8 weeks) to 21 (2 
weeks) fold with and without antibiotics respectively, 
compared to untreated controls. Biomechanical testing, 
histology, micro CT and quantitative radiography. 
(Chen et al., 2006) 
rhBMP-7 
Long-Evans Rat, 
femur osteotomy 
and distraction 
0.25mm every 12 
hours - 10mm 
 2 and 4 weeks Aqueous solvent, injection 20 µg 
BMD was increased 4 fold compared to controls. 
Maximum torque and stiffness were increased 3.9 and 
11.6 fold compared to controls. Biomechanical testing 
and radiography. 
(Mizumoto et al., 2003) 
rhOP-1 
Male Sprague-
Dawley Diabetic 
Rat, femoral 
closed fracture 
 2 and 4 weeks 
Bovine type I collagen 
carrier, implant 25 μg 
Fracture callus area was increased 17, 29.5 and 9.8 fold 
(2 weeks), and 5.2, 4.3 and 2.6 fold (4 weeks) compared 
to carrier alone, sham surgery and sham surgery in non-
diabetic mice respective. Biomechanical testing, 
histology and radiography. 
(Kidder et al., 2009) 
rhBMP-7 
Fisher 344 Rat, 
femoral non-union 
- atrophic 
 2 to 8 weeks 
Rat tail tendon collagen 
buffer, implant 50 μg 
63 % of treated defects had healed by 4 weeks, and 100 
% by 8 weeks, compared to no healing in control 
defects. Maximum torque to failure and stiffness had 
increased 6.1 and 6.8 fold after 4 weeks and 5.9 and 
11.7 fold after 8 weeks, respective. Biomechanical 
testing, histology and radiography. 
(Makino et al., 2005) 
rhBMP-7 
Fisher 344 Rat (3 
and18 month old), 
femoral closed 
fracture 
 3 and 6 weeks 
Rat tail tendon collagen, 
implant 100 µg 
Defect regeneration was more rapid within younger 
rats: 100 % healed at 3 weeks, compared to 56 % healed 
in older rats.  Maximum torque and stiffness were 
increased 15.9 and 31 fold, and 8.6 and 29.8 fold 
compared to controls, in young and old rats, 
respectively after 3 weeks. Maximum torque and 
stiffness were increased 14.9 and 26.1 fold, and 6.8 and 
7.5 fold compared to controls, in young and old rats, 
respectively after 6 weeks.  Biomechanical testing, 
histology and radiography. 
(Hak et al., 2006) 
rhBMP-7 
Male Sprague-
Dawley Rat, 
calvarial defect – 
8mm 
 2 and 8 weeks 
Absorbable collagen 
sponge, implant 25 µg/mL 
Treatment enhanced local bone formation. Histology, 
histomorphometry and immunohistochemistry. (Hyun et al., 2005) 
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rhBMP-7 
Wistar Rat, 
mandible 
augmentation, and 
ectopic 
intramuscular 
implantation 
 50 d 
Acetate buffer carrier on 
either anorganic bovine 
bone or autograft, implant 
20 µL 
(mandible) 
10 µL (ectopic) 
Area of ‘bone tissue of total core’ increased 10.3 and 
1.3 fold compared to controls with bovine bone and 
autograft respective. Area of newly mineralised bone 
increased 3.6 fold compared to control, but only with 
bovine bone. Ectopic implantation also demonstrated 
new bone formation. Histology, histomorphometry and 
microradiography. 
(Roldan et al., 2004) 
 
2. Animal Models for indirect BMP-7/OP-1 delivery 
2.1. Large Animal Models 
Dog 
rhBMP-7 
(adenovirus) 
Adult Hybrid 
Dog, mandible 
defect – 5mm 
 4 to 12 weeks 
Chitosan- collagen 
scaffold, implant 
2 x 1010 
particles 
Bone formation within the defect site increased approx. 
2 fold compared to carrier alone. Histology and 
histomorphometry.  
(Zhang et al., 2007) 
rhBMP-7 
(adenovirus) 
Beagle Dog, 
intervertebral disc 
transplantation 
 12 and 24 weeks 
Transduced nucleus 
pulposus cells within 
allogenic intervertebral 
discs, implants 
1 x 105 cells 
Treatment with rhBMP-7 maintained allograft integrity, 
compared to controls which exhibited a 2.1 and 1.5 fold 
increase in disc degeneration at 12 and 24 weeks 
respectively. Biomechanical testing, histology, MRI and 
radiography. 
(Chaofeng et al., 2013) 
rhBMP-7 and 
rhPDGF-B 
(adenovirus) 
Adult Hybrid 
Dog, mandible 
defect – 6mm  
4, 8 and 12 
weeks 
Chitosan/collagen 
scaffolds, implant 
2 × 1010 
particles/mL 
New bone formation was increased approx. 2.3 and 1.6 
fold following combination treatment after 4 and 8 
weeks. Percentage defect fill and new bone implant 
contact were increased approx. 1.5 and 1.4 fold 
compared to controls after 12 weeks. Histology and 
histomorphometry. 
(Zhang et al., 2009b) 
Goat 
BMP-7 
(adenovirus) 
Adult Goat, 
segmental femur 
defect – 25mm 
 
Nude Mouse, 
ectopic 
intramuscular 
injection 
 
3 to 8 
months 
(goat) 
 
3 weeks 
(mouse) 
 
Transduced cell/coral 
constructs, implant (goat) 
 
 
Direct injection (mouse) 
 
5 x 107 cells 
(goat) 
 
 
4 x 106 cells 
(mouse) 
 
New bone formation was radiographically visible after 
3 weeks within nude mice. Bone mass increased 
approx. 2.5 fold maximum after 3 months compared to 
an approx. 1.5 fold increase with non-transfected 
BMSCs. Histology, histomorphometry and radiography. 
(Zhu et al., 2010) 
2.2. Small Animal Models 
Mouse 
BMP-7 
(adenovirus) 
BALB/c Mouse, 
calvarial defect – 
3mm 
 1, 2 and 4 weeks Silk fibroin, implant 
1.8 x 1011 
PFU/mL 
An approx. 5 fold increase in bone volume within the 
defect site was observed compared to blank control, and 
2 fold compared to scaffold alone. Biochemistry, 
cytochemistry, histology, micro CT, RT-PCR and SEM. 
(Zhang et al., 2012b) 
BMP-7 
(adenovirus) 
SCID Mouse, 
calvarial defect – 
3mm 
 4 weeks Silk fibroin, implant 1 x 105 cells 
No histological evidence of inflammation. New bone 
formation compared to little or no bone in negative 
controls. histology, immunocytochemistry, RT-PCR 
and SEM. 
(Zhang et al., 2010c) 
BMP-7 and 
adLMP3 
(adenovirus) 
NIH-III Nude 
Mouse, ectopic 
subcutaneous 
implantation 
 3 weeks 
Transduced periodontal 
ligament cells in type I 
collagen scaffold, implant 
1 x 106 cells 
BMP-7 alone induced radiographically visible bone 
formation after 3 weeks. Combination treatment 
induced approx. 4 fold increased bone formation after 4 
weeks. Histology, micro CT and RT-PCR. 
(Lin et al., 2012c) 
 
       
Supplementary Table 2. Bone tissue engineering in vivo utilising BMP-7/OP-1 within animal models and human trials. 
7 
 
BMP-7 
(adenovirus) 
N:NIH-bg-nu-xid 
Mouse, ectopic 
subcutaneous 
implantation 
 4 and 8 weeks 
Transduced human 
gingival fibroblasts on 
PCL scaffold, implant 
1.5 x 106 cells 
New bone formation was observed in all groups after 8 
weeks. Larger scaffold pore size resulted in early bone 
formation at 4 weeks (approx. 2 fold more bone with 
high pore size compared to low pore size). 
Biomechanical testing, histology and micro CT. 
(Roosa et al., 2009) 
BMP-7 (plasmid 
vector) 
BALB/c Nude 
Mouse, ectopic 
subcutaneous 
implantation 
 4 weeks 
Transfected human dental 
pulp cells in 
chitosan/collagen 
composite, implant 
1 x 106 cells/mL 
(1mL per 6 
scaffolds) 
No hard tissue was observed within treated groups 
compared to controls. Histology and 
immunohistochemistry. 
(Yang et al., 2012) 
Rabbit 
BMP-7 
(adenovirus) 
New Zealand 
White Rabbit, 
bilateral 
mandibular defect 
- 12 x 8mm 
 4, 8 and 16 weeks 
Transduced rabbit MSCs 
on nano-HA/PA scaffold, 
implant 
2 x 106 cells 
New bone volume within BMP-7 treated groups was 
increased 1.6, 1.3 and 1.03 fold compared to scaffold 
alone groups, at 4, 8 and 16 weeks, respectively. 
Biomechanical testing, histology, histomorphometry 
and radiography. 
(Li et al., 2010a) 
Rat 
OP-1 
(recombinant 
protein or 
plasmid vectors) 
Adult Sprague-
Dawley Rat, 
single-level 
posterior lumbar 
arthrodesis 
 2 and 4 weeks 
With and without rat tail 
type I collagen carrier, 
injection 
30 to 40 µg 
25 and 250 µg 
(plasmid) 
Bone formation was observed after delivery of 25 µg 
plasmid (75 %). Single-level spine fusion was only 
achieved with 30 µg recombinant protein in collagen 
carrier or 40 µg alone. Histology and radiography. 
(Bright et al., 2006) 
rhBMP-7 
(adenovirus) 
Sprague-Dawley 
Rat, alveolar ridge 
osteotomy – 2mm 
 3 to 28 d Collagen matrix, implant 2.5 × 10
11 
particles 
Treatment enhanced alveolar bone defect fill, coronal 
new bone formation, and new bone-to-implant contact 
1.5, 2 and 1.5 fold respective, compared to controls. 
Histology, histomorphometry and SEM.   
(Dunn et al., 2005) 
BMP-7 
(adenovirus) Rat, spinal fusion  8 weeks 
Transduced cells on 
allograft, implant 1.5x10
6 cells 
New bone formation was increased 21 and 14 fold 
compared to saline and adenovirus controls. 
Biomechanical testing, histology and radiography. 
(Hidaka et al., 2003) 
rhBMP-7 
(adenovirus) 
Lewis Rat, ectopic 
subcutaneous 
implantation 
 1, 2 and 4 weeks 
Type I collagen matrix, 
implant 1 x 10
6 cells 
Transduced cells initiated endochondral ossification 
with new trabeculae by 4 weeks. No new bone was 
observed in implants treated with non-transduced cells. 
Histology. 
(Yang et al., 2005) 
BMP-7 
(adenovirus) 
Fisher Rat, 
calvarial defect – 
9mm 
 4 weeks 
Transduced cells in 
collagen carrier on gelatin 
sponge, implnat 
2 x 106 cells 
BMP-7 ex vivo gene therapy increased bone 
regeneration in rat calvarial defects even after a 
therapeutic dose of radiation. Histology, 
histomorphometry and radiography. 
(Nussenbaum et al., 2003) 
 
3. Animal Models for combinational direct and indirect BMP-7/OP-1 delivery 
3.1. Large Animal Models 
Baboon 
OP-1 and TGF-β1 
Adult Male 
Chacma Baboon, 
ectopic 
intramuscular 
implantation 
 
Adult Male 
Chacma Baboon, 
bilateral calvarial 
defect – 25mm 
 
30 to 90 d 
 
 
 
1 to 12 
months 
Collagen matrix or HA 
discs, implant 
Collagen: 
5 to 125 μg  
OP-1 
0.5 to 5 μg 
TGF-β1 
 
HA: 
20 to 2,500 μg 
OP-1 
5 to 15 μg  
TGF-β1 
OP-1within collagen matrix induced ectopic 
endochondral bone formation, and extensive defect 
regeneration. Combination treatment within collagen 
matrix induced large ossicles. Implantation of HA with 
OP-1 induced extensive bone formation by 30 days and 
bone remodelling by days 90 to 365. Histology. 
(Ripamonti et al., 2001b) 
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rhOP-1 and TGF-
β1 
Chacma Baboon, 
ectopic 
intramuscular 
implantation and 
calvarial defect 
 14 to 90 d Collagenous bone matrix, implant 
25 to 100 µg 
OP-1 
5 and 15 µg 
TGF-β1 
OP-1 induced ectopic ossicle formation by day 30, 
where TGF-β1 did not. Combination treatment induced 
endochondral bone formation within the defect site with 
exuberant tissue formation and osteoid production 
compared to either factor individually. Histology and 
RT-PCR. 
(Duneas et al., 1998) 
rhOP-1 and TGF-
β3 
Adult Chacma 
Baboon, ectopic 
intramuscular 
implantation  
 90 d 
HA/calcium carbonate 
macroporous scaffold, 
implant 
125 μg 
Bone volume within implants was increased 4.2 fold 
after OP-1 treatment, compared to control implants. 
Combination with TGF-β3 further enhanced bone 
volume compared to controls (5.3 fold increase). 
Histology, histomorphometry, RT-PCR and 
radiography. 
(Ripamonti et al., 2010) 
rhOP-1 and TGF-
β1 
Adult Male 
Chacma Baboon, 
ectopic 
intramuscular 
implantation 
 15 and 30 d Insoluble collagen matrix, implant 
5,000, 25,000 
and 125,000 µg 
OP-1  
0.5, 1.5, and 5 
µg TGF-β1 
(both per 
100,000 µg 
matrix) 
Combination treatment resulted in a 2 to 3 fold increase 
in mineralised bone and osteoid formation compared to 
OP-1 alone after 15 days. High dose OP-1 and TGF-β1 
increased mineralised bone and osteoid formation 
approx. 2 fold. Biochemistry, histology and 
histomorphometry. 
(Ripamonti et al., 1997) 
Dog 
hOP-1 and bone 
marrow or blood 
Male Mongrel 
Dog, proximal 
and distal femur 
defect – 10mm 
 4 weeks Bovine type I collagen and CMC, implant 
3,500 μg OP-1 
3.5 mL bone 
marrow or 
blood 
Defects which received OP-1 and bone marrow 
exhibited an increase of 1.5 fold and decrease of 1.4 
fold in bone volume, compared to those receiving OP-1 
and blood for proximal and distal defects respectively. 
Histology and micro CT.  
(Takigami et al., 2007) 
rhBMP-7 and 
rhPDGF-B 
(adenovirus) 
Adult Hybrid 
Dog, mandible 
defect – 6mm 
 4, 8 and 12 weeks 
Chitosan-collagen scaffold, 
implants 
2 x 1010 
particles/mL 
New bone formation was increased approx. 2.3 and 1.6 
fold following combination treatment after 4 and 8 
weeks. Percentage defect fill and new bone implant 
contact were increased approx. 1.5 and 1.4 fold 
compared to controls after 12 weeks. Histology and 
histomorphometry.  
(Zhang et al., 2009b) 
Horse 
BMP-7 and 
BMP-2 
(adenovirus) 
Horse, metacarpal 
IV ostectomy – 
15mm 
 2 to 16 weeks Direct injection 
2 x 1011 virus 
particles 
Bone defect regeneration was not enhanced further than 
controls when treated with BMP-2 and BMP-7 viral 
particles, possibly due to incorrect dosing. DXA, 
histology and radiography. 
(Southwood et al., 2012) 
3.2. Small Animal Models 
Minipig 
BMP-7 and 
BMP-2 
Minipig, calvarial 
defect – 8mm  
2 to 6 
weeks Collagen sponge, implant 5 µg 
Combination treatment increased bone formation 2.1, 
1.4 and 1.6 fold compared to controls, BMP-2 alone, 
and BMP7 alone. Histology, histomorphometry, 
immunohistochemistry,  
(Sun et al., 2012b) 
BMP-7 and 
BMP-2 
Guangxi Bama 
Minipig, calvarial 
defect – 8mm 
diameter x 4mm 
depth 
 2 to 6 weeks Collagen sponge, implant 
5 µg (30 
ng/mm3) 
Low dose BMP-2/7 heterodimer facilitated more rapid 
bone regeneration (approx. 1.5 fold increase in bone 
volume compared to either factor alone) of improved 
quality. Micro CT. 
(Wang et al., 2012) 
OP-1 and rhTSP-
1 
Female Adult 
Minipig, femoral 
trochlea defect – 
5mm, with 1mm x 
3mm 
microfracture 
 6 and 26 weeks Type I collagen, implant 
35 μg OP-1 
5 μg rhTSP-1 
Combination treatment enhanced cartilage 
mineralisation approx. 1.3 and 1.75 fold compared to 
control defects. Histology, histomorphometry and 
immunohistochemistry. 
(Gelse et al., 2011) 
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Mouse 
rhBMP-7 and 
MSCs or 
osteoblasts 
NOD/SCID 
Mouse, ectopic 
subcutaneous 
implantation 
 8 weeks PCL-TCP scaffold, implant 5 μg 2.5 x 105 cells 
Bone volume fraction was significantly increased 
approx. 8.8 fold following treatment with BMP-7 and 
osteoblasts compared to scaffold controls. 
Biomechanical testing, biochemistry, histology, 
histomorphometry, micro CT and SEM 
(Reichert et al., 2011) 
BMP-7 and 
VEGF 
Black C57/B16 
Mouse, ectopic 
subcutaneous 
implant 
 12 weeks 
Injection within biphasic 
calcium phosphate 
ceramics, implant 
5 µg BMP-7 
2 µg VEGF 
Woven bone formation was observed on scaffold 
surface and within pores. However, combination of 
VEGF and BMP-7 did not enhance bone formation 
significantly. Histology and SEM. 
(Roldan et al., 2010) 
rhBMP-7 and 
BBP 
Male Lewis Rat, 
ectopic 
subcutaneous and 
intramuscular 
implantation 
 2, 4 and 7 d Collagen sponge, implant 20 μg rhBMP-7 
500 μg BBP 
Addition of BBP reduced rhBMP-7 related 
inflammation a max. 1.5 fold when administered 
subcutaneously and intramuscularly. Histology, 
histomorphometry and MRI. 
(Lee et al., 2011) 
rhBMP-7 and 
pamidronate 
(bisphosphonate) 
Female C57BL6/J 
Mouse, ectopic 
implantation in 
hind limbs 
 3 to 8 weeks PDLLA scaffold, implant 
25µg rhBMP-7 
0.02 to 2 mg 
pamidronate 
Localised delivery of rhBMP-7 and low dose 
pamidronate (0.02 mg) resulted in approx. 2 fold 
increased bone volume, whereas delivery with high 
dose pamidronate (2 mg) resulted in approx. 2 fold 
decreased bone volume. Histology, micro CT and 
radiography. 
(Yu et al., 2010a) 
BMP-7 
(adenovirus) and 
BMSCs 
SCID Mouse, 
calvarial defect – 
3mm 
 4 weeks Silk fibroin porous scaffold implant 
1.8 x 1011 
PFU/mL 
1 x 105 cells 
Combination treatment increased bone volume approx. 
5.5 fold compared to scaffold only control. Histology, 
immunohistochemistry and micro CT. 
(Zhang et al., 2011b) 
rhBMP-7 and 
IGF-1 
(adenovirus) 
BALB/c-nu 
Mouse, ectopic 
subcutaneous 
implantation 
 8 weeks Porous chitosan/collagen scaffold, implant 1 x 10
6 cells 
Bone formation was 1.17 fold higher than controls, and 
1.22 fold higher upon combination with IGF-1. 
Histology, histomorphometry and 
immunohistochemistry. 
(Yang et al., 2010) 
BMP-7 and 
BMP2 
(adenovirus) 
C57BL6 Mouse, 
critical sized 
calvarial defect – 
7mm 
 4 weeks 
Transduced mouse BLK 
cells in gelatin sponge, 
implant 
4 x 106 cells 
Implants revealed robust osteogenic activity with 
complete bone coverage of defects. Bone volume 
increased 2 and 1.7 fold compared to BMP-2 and BMP-
7 alone, respectively. Histology, micro CT and 
radiography. 
(Koh et al., 2008) 
Rabbit 
rhBMP-7 and 
PTH (1-34) 
Female New 
Zealand White 
Rabbit, tibial 
wedge osteotomy 
- 4 x 10mm 
 4 weeks 
β-TCP particles and CMC, 
implant (rhBMP-7) 
Subcutaneous injection 
(PTH (1-34)) 
200 μg rhBMP-
7 
10 μg/kg/d PTH 
(1-34) 
Micro CT analysis revealed approx. 1.6 and 1.4 fold 
increased bone volume and BMC compared to controls. 
Histological analysis revealed approx. 1.3 fold 
increased bone area compared to controls. Torsional 
rigidity and compressive strength increased approx. 1.4 
and 1.2 fold compared to controls. Biomechanical 
testing, histology, immunohistochemistry and micro 
CT. 
(Morgan et al., 2008) 
rhOP-1 and 
rhFGF-2 
New Zealand 
White Rabbit, 
tibial bone harvest 
and drug test 
chamber 
 48 weeks 
Acetate buffer (rhOP-1) or 
distilled water (rhFGF-2), 
infusion 
0.1 µg/d rhOP-1 
0.05 µg/d 
rhFGF-2 
OP-1 and FGF-2 infusion increased percentage de novo 
bone formation approx. 1.3 and 1.2 fold respective. 
Combination treatment did not further enhance bone 
formation. Histology, histomorphometry and 
immunohistochemistry. 
(Ma et al., 2007) 
BMP-7 and 
VEGF165 
(recombinant 
adeno-associated 
virus) 
Male New 
Zealand Rabbit, 
ectopic 
intramuscular 
injection 
(hindlimb 
ischemia model) 
 2 to 8 weeks 
Direct intramuscular 
injection 
5.5 x 1011 
particles 
Co-expression stimulated angiogenesis and bone 
regeneration. Capillary density and mean blood flow 
were both increased approx. 2 fold. Biochemical 
testing, histology and radiography. 
(Zhang et al., 2010a) 
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Rat 
rhOP-1 and 
MSCs 
Male Wistar Rat, 
ectopic 
intramuscular 
implant 
 28 d 
Insoluble collagen matrix 
on demineralised bone or 
allograft, implant  
2 μg OP-1 improved cell proliferation/differentiation and bone formation. Biochemistry, histology and SEM. (Tsiridis et al., 2007a) 
rhBMP-7 and 
rhBMP-2 
(plasmids) 
Male Wistar Rat, 
ectopic 
intramuscular 
injection 
 1 to 10 d Direct injection and in vivo electroporation 12.5 μg 
Enhanced bone formation and calcification was 
observed compared to single modalities, with 
upregulation of BMP-4. Histology, 
immunohistochemistry, radiography and rtPCR. 
(Kawai et al., 2006) 
rhBMP-7 and 
rhBMP-2 
(plasmid) 
Male Wistar Rat, 
ectopic 
intramuscular 
injection 
 10 d 
Direct injection of double 
cassette plasmid and in 
vivo electroporation 
50 μg 
Enhanced bone formation and calcification was 
observed compared to single modalities. Histology and 
radiography. 
(Kawai et al., 2009) 
BMP-7 and 
BMP2 
(adenovirus) 
Sprague-Dawley 
Rat, bilateral 
single level 
posterolateral 
spine fusion 
 8 weeks 
Allograft bone and CMC 
hematostatic foam soaked 
with adenovirus, implant 
0.75 x 108 to 
0.75 x 1011 
particles 
Co-administration of Ad.BMP-2 and Ad.BMP7 resulted 
in significantly greater numbers of mechanically stable 
fusions and also 2 fold higher mineralisation rate of 
bone volume in the fusion mass. Histology and 
radiography. 
(Zhu et al., 2004) 
BMP-7 and 
BMP-2 
(lentivirus) 
Sprague-Dawley 
Rat, calvarial 
defect – 2mm 
 2 to 6 weeks 
Transduced cells in β-TCP 
scaffold, implant 1 x 10
6 cells 
New bone formation was observed after 4 weeks in all 
treated defects. Only dual factor treated defects 
exhibited complete defect regeneration after 6 weeks. 
Biochemistry, cytochemistry, histology, qPCR and 
radiography. 
(Qing et al., 2012) 
adBMP-7 and 
adPDGF-b 
(adenovirus) 
OVX Female 
Wistar Rat, femur 
defect, drill 2mm 
diameter 
 2 and 4 weeks 
Mesoporous bioglass/silk 
fibroin, implant unknown 
Dual combination resulted in approx. 12 fold increased 
bone volume compared to blank defect, 2 fold 
compared to blank scaffold, and 1.5 fold compared 
BMP-7 alone at 2 weeks. 15 fold compared to blank 
defect, approx. 1.9 fold compared to blank scaffold, 1.2 
fold compared to BMP7 alone at 4 weeks. Histology, 
immunohistochemistry, micro CT and SEM. 
(Zhang et al., 2012a) 
 
4. Human Trials for BMP-7/OP-1 delivery 
Lumbar Fusion 
rhBMP-7  Human, lumbar spinal fusion 
6 weeks to 
36 months 
Bovine bone collagen and 
CMC, implant 
7 mg (3.5 mg 
either side of 
posterolateral 
fusion) 
Treatment induced an immune response in 25.6 % of 
patients, peaking between 6 weeks and 3 months, and 
tailed off after 24 months. Immune response did not 
correlate with fusion efficacy. Biochemistry and 
radiography. 
(Hwang et al., 2010) 
rhOP-1  
Human, 
posterolateral 
lumbar fusion 
1 year Collagen matrix, implant 7 mg (3.5 mg per side) 
rhOP-1 reliably induced new bone formation even 
without autograft. CT, histology and radiography. (Kanayama et al., 2006) 
rhOP-1  
Human, 
intertransverse 
lumbar fusion 
6 weeks 
and 3 to 24 
months 
Bone type I collagen and 
CMC within iliac crest 
autograft, implant 
7 mg (3.5 mg 
per side) 
Treated patients exhibited 20 % improvement in 
Oswestry score. Radiographic fusion was observed 
within 50 % of treated patients. 70 % exhibited bone 
bridging between the transverse processes. Clinical 
assessment and radiography. 
(Vaccaro et al., 2005) 
rhOP-1  
Human, 
posterolateral 
lumbar arthrodesis  
1 year Collagen matrix, implant 7 mg (3.5 mg per side) 
Successful radiographic fusion was obtained using OP-
1 Putty at a rate that was similar to autograft. 
Importantly, no adverse effects were observed. Clinical 
assessment and radiography. 
(Vaccaro et al., 2004) 
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rhOP-1  
Human, 
intertransverse 
process fusion 
6 weeks 
and 3 to 12 
months 
Bone type I collagen and 
CMC within iliac crest 
autograft, implant 
7 mg (3.5 mg 
per side) 
75 % of patients exhibited improved Oswestry scores, 
whilst 55 % exhibited radiographic fusion and 91 % had 
bone bridging. Minimal adverse effects were observed 
indicating that OP-1 is safe to use for spinal fusions. 
Physical examination and radiography. 
(Vaccaro et al., 2003) 
rhOP-1  Human, lumbar fusion 1 year 
Bone type 1 collagen and 
saline putty, implant 
7 mg (3.5 mg 
per side) 
Treatment demonstrated equivalent lumbar fusion to 
that of autograft from the iliac crest. Radiography and 
radiostereometric analysis. 
(Johnsson et al., 2002) 
OP-1  
Human, anterior 
and posterior 
lumbar interbody 
fusion 
3 and 10 
months 
Bovine bone collagen and 
CMC mixed with 
autograft, implant 
17.5 mg (5 
vials, 3.5 mg 
each) 
OP-1 treatment demonstrated equivalent bone fusion 
compared to autograft alone providing a viable 
alternative. However, excessive dosage resulted in 
ectopic bone formation along the surgical track. CT, 
histology and radiography. 
(Kim et al., 2010b) 
rhBMP-7   
Human, 
posterolateral 
fusion and 
posterior fixation 
3 to 18 
months Collagen carrier, implant unknown 
OP-1 treatment did not stimulate sufficient early 
structural bone support, and indications of enhanced 
bone resorption were observed. Clinical assessment, CT 
and radiography. 
(Laursen et al., 1999) 
rhOP-1  
Human, atlanto-
axial posterior 
fusion 
2 to 10 
months Collagen carrier, implant unknown 
Bridging of the bone only occurred in 1out 4 
rheumatoid patients at 6 months. Radiography. (Jeppsson et al., 1999) 
Mandible Reconstruction 
rBMP-7 and 
MSCs  
Human, mandible 
reconstruction, 
tumor resection – 
60mm 
9 to 12 
months 
Demineralised bovine 
xenograft on titanium 
mesh, implant 
2000 mg 
(rBMP-7) 
5mL conc. 
(human bone 
marrow 
aspirate) 
New bone formation was observed around the xenograft 
particles within the defect site after 9 months, and 
osseous implants remained stable after 1 year. 
Histology, histomorphometry and radiography. 
(Hernandez-Alfaro et al., 2012) 
Maxillary Sinus Augmentation 
rhBMP-7  
Human, maxillary 
sinus floor 
elevation 
6 months Collagen carrier, implant 2.5 mg 
Three patient study. OP-1 initiated bone formation but 
remains insufficiently predictable for clinical translation 
as an alternative to bone graft. Averaged patient data 
revealed approx. 1.2 fold increased osteoid formation 
compared to autograft controls. Histology and 
radiography. 
(van den Bergh et al., 2000) 
rhOP-1  
Human, maxillary 
sinus floor 
elevation 
6 months Collagen carrier, implant 2.5 mg 
Three patient study. Treatment induced bone formation 
inconsistently. Averaged patient data revealed approx. 
2.2, 1.2 and 9.7 fold increased osteoid formation within 
OP-1 treated patients compared to DBM, autograft and 
no graft controls, respectively. Histology, 
histomorphometry and radiography. 
(Groeneveld et al., 1999) 
Non-Union Fracture 
rhBMP-7  
Human, upper and 
lower limb 
resistant  non-
union 
5.6 months TCP crystals and bovine bone collagen, implant 3.5 mg 
21.5 months following initial injury, 52 patients with 
non-union fractures received rhBMP-7 treatment. 
Radiological union was achieved in 94 % after 5.6 
months. Clinical assessment and radiography. 
(Papanna et al., 2012) 
rhBMP-7  Human, tibial non-union 1 year 
Bovine type I collagen 
mixed with saline or blood, 
implant 
3.5 mg 
BMP-7 groups showed significantly higher success 
rates. 78 % of patients who received autologous bone 
graft only exhibited successful union after 4 months. 
Comparatively, 92 % of patients with rhBMP-7 
implantation displayed bony consolidation after 4 
months. Clinical assessment and radiography. 
(Zimmermann et al., 2009) 
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rhBMP-7  
Human, aseptic 
atrophic femur 
non-union 
12 to 68 
months 
Bovine type I collagen, 
implant 3.5 mg 
86.7 % of non-union patients (26 cases) exhibited 
successful healing following BMP-7 treatment, in a 
median time of 6 months (range 4 to 10 months). 
Clinical assessment and radiography. 
(Kanakaris et al., 2009) 
rhBMP-7  
Human, atrophic 
upper or lower 
long bone fracture 
non-union 
1 to 18 
months 
Bovine type I collagen 
mixed with autograft, 
implant 
3.5 mg 
100 % of treated patients (45 cases) displayed fracture 
union within 3 to16 months. Clinical assessment and 
radiography.  
(Giannoudis et al., 2009) 
rhOP-1  
Human (children), 
persistent non-
union 
4 to 56 
months 
Bovine type I collagen, 
implant 3.5 mg 
Successful healing occurred in 17 out of 23 sites (74 
%). Clinical assessment and radiography. (Dohin et al., 2009) 
rhBMP-7  Human, aseptic tibia non-union 
12 to 30 
months 
Bovine type I collagen, 
implant 3.5 mg 
Non-union healing was achieved in 89.7 % of BMP-7 
treated patients in a median period of 6.5 months (range 
3 to 15 months). Clinical assessment and radiography. 
(Kanakaris et al., 2008) 
rhBMP-7  
Human, long bone 
non-union (femur, 
humerus, tibia, 
radius, ulna) 
1 to 12 
months 
Bovine type I collagen, 
implant 3.5 mg 
rhBMP-7 treatment resulted in successful fracture 
healing within 86.7 % of patients compared to 68.3 % 
of patients treated with platelet rich plasma. Healing 
time was also reduced following rhBMP-7 treatment. 
Clinical assessment and radiography.   
(Calori et al., 2008) 
rhBMP-7  Human, distal tibia fracture 
1 to 54 
months 
Bovine type I collagen, 
implant 3.5 mg 
Healed fractures were significantly increased 3 and 3.2 
fold compared to controls after 16 and 20 weeks. Mean 
time to union, duration of absence from work, and time 
for which external fixation was required were each 
significantly reduced 1.5, 1.4 and 1.4 fold respectively, 
following BMP-7 treatment. Clinical assessment and 
radiography.   
(Ristiniemi et al., 2007) 
rhBMP-7  Human, pelvic girdle non-union 
12 to 27 
months 
Bovine type I collagen, 
implant 3.5 mg 
Fusion was achieved in 89 % of patients. 78 % of 
patients reported excellent or good subjective functional 
results after a mean 12 months. Clinical assessment and 
radiography.  
(Giannoudis et al., 2007) 
rhBMP-7  
Human, persistent 
fracture non-union 
(clavicle, femur, 
humerus, patella, 
tibia, ulna) 
12 to 27 
months 
Bovine type I collagen 
with and without iliac crest 
autograft, implant 
3.5 mg 
Mean number of procedures per fracture was reduced 
3.5 fold following BMP-7 treatment. Mean hospital stay 
and cost of treatment per fracture were reduced 3.4 and 
1.9 fold respective following BMP-7 treatment. Clinical 
assessment and radiography. 
(Dahabreh et al., 2007) 
rhBMP-7  Human, long bone non-union 
3 to 29.2 
months 
Osigraft®; alone, with 
autograft, or with an 
osteoconductive agent. 
3.5 mg 
83.8 % of non-unions healed treated groups, with an 
average healing time of 7.9 months. Clinical assessment 
and radiography. 
(Ronga et al., 2006) 
rhOP-1  
Human, 
symptomatic 
proximal pole 
scaphoid non-
union 
1 to 24 
months 
Collagen carrier combined 
with autograft or allograft, 
implant 
3.5 mg 
Treatment with OP-1 and allograft increased sclerotic 
bone formation 1.4 and 1.7 fold compared to OP-1 with 
autograft after 3 and 9 months respective. Significant 
sclerotic bone resorption was observed after 24 months. 
Improved functional measurements were recorded at 4 
months and implants exhibited accelerated vascular 
ingrowth. CT, radiography and scintigraphy. 
(Bilic et al., 2006) 
rhBMP-7  
Human, upper and 
lower limb non-
union (clavicle, 
femur, humerus, 
patella, tibia, ulna) 
6 to 27 
months 
Collagen carrier and bone 
autograft, implant  3.5 mg 
Clinical and radiological union occurred in 92.3 % of 
cases. Clinical assessment and radiography. (Dimitriou et al., 2005) 
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rhOP-1  Human, tibial non-union 2 years 
Type I collagen carrier , 
implant 3.5 mg 
OP-1 was safe and effective treatment for tibial non-
unions. Clinically and radiographically assessed 
fracture healing success was observed in 81 % and 75 
% of patients, respectively. This was comparable to 
autograft controls where 85 % and 84 % of patients 
exhibited successful fracture healing. Clinical 
assessment and radiography. 
(Friedlaender et al., 2001) 
Osteotomy 
rhOP-1  
Human, high 
tibial osteotomy 
(24 patients) 
1 year  Type I collagen carrier, implant 2.5 mg 
Following OP-1 treatment all patients except one 
showed new bone formation as early as 6 weeks. 
Clinical assessment, DXA and radiography. 
(Geesink et al., 1999) 
rhBMP-7  
Human, corrective 
radius osteotomy 
with internal 
fixation 
2 to 52 
weeks Collagen paste, implant 3.5 mg 
Patients treated with rhBMP-7 healed at a slower rate 
than patients treated with autograft. rhBMP-7 did not 
confer the same stability as autograft, reducing healing 
capacity and potentially causing osteolysis. Clinical 
assessment and radiography. 
(Ekrol et al., 2008) 
BMP-7  
Human, tibia 
osteotomy and 
distraction – 
70mm 
0.5 to 2.5 
years 
Collagen carrier mixed 
with autograft, implant unknown 
The defect was successfully filled and exhibited 
radiological evidence of remodeling. Tibia length was 
10 mm short of target. BMP-7 treatment enhanced bone 
formation leading to successful bone union. Clinical 
assessment and radiography. 
(Burkhart and Rommens, 2008) 
Pseudarthrosis 
OP-1  
Human, tibia and 
fibula 
pseudarthrosis 
with associated 
neurofibromatosis 
and bone resection 
28 months Collagen matrix, implant 3.5 mg 
Complete healing of the resected defects was observed 
at 28 months with a 50 mm difference in length 
between limbs. The limb was load bearing and pain 
free. Clinical assessment and radiography. 
(Fabeck et al., 2006) 
OP-1  
Human, 
congenital tibia 
pseudarthrosis 
1 to 12 
months 
Collagen matrix mixed 
with autograft, implant 
3.5 mg (7 mg 
following 
revision surgery 
in 1 case) 
New bone formation around the pseudarthrosis site 
within all 5 patients was not observed. However, no 
side effects were observed either. Clinical assessment, 
radiography and scintigraphy. 
(Lee et al., 2006) 
BMP-7  
Human (11 year 
old), congenital 
tibia 
pseudarthrosis and 
sclerotic tibia 
segment resection 
0.5 to 45 
months Collagen carrier, implant unknown 
Tibia was load bearing after 2 weeks, and exhibited new 
bone formation after 4 weeks. 5 months later, non-union 
healing was observed, leading to equal limb length 
between legs at 8 months. At 45 months thicker cortical 
bone was observed and the limb was fully weight 
bearing. Clinical assessment, histology and 
radiography. 
(Anticevic et al., 2006) 
 
Abbreviations: BBP (BMP binding protein), BMC (bone mineral content), BMD (bone mineral density), BMP-7 (bone morphogenetic protein 7), BMSC (bone marrow stromal cell), CMC (carboxymethylcellulose), CT 
(computerised tomography), DBM (demineralised bone matrix), DXA (dual energy x-ray absorbiometry), FGF-2 (fibroblast growth factor 2), HA (hydroxyapatite), IGF-1 (insulin-like growth factor 1), LMP3 (LIM domain 
protein-3), MRI (magnetic resonance imaging), MSC (mesenchymal stem cell), OP-1 (osteogenic protein 1), OVX (ovariectomised), PA (polyamide), PCL (poly(caprolactone)), PDGF-b (platelet derived growth factor b), 
PDLLA (poly (D,L-lactic acid)), PFU (plaque forming units), PLGA (poly(lactic-co-glycolic acid)), PLLA (poly(L-lactic acid)), rhBMP-7/OP-1 (recombinant human BMP-7/OP-1), RT-PCR (real time polymerase chain 
reaction), SCID (severe combined immuno-deficient), SEM (scanning electron microscopy), TCP (tricalcium phosphate), TGF-β1/3 (transforming growth factor beta 1/3), TSP-1 (thrombospondin 1). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct FGF delivery 
1.1. Large Animal Models 
Dog 
FGF-2 
Adult Male 
Beagle Dog, 
alveolar bone 
defect – 5mm 
 8 weeks Collagen minipellets, implant 0.15 μg 
Bone area was significantly increased approx. 2.7 fold 
compared to controls. Histology, histomorphometry and 
radiography. 
(Hosokawa et al., 2000) 
bFGF 
Beagle Dog, 
furcation class II 
defect – 3mm x 
4mm 
 6 weeks Gelatin carrier, implant 30 μg 
New bone, trabecular and cementum formation rates 
were increased 2.4, 2.7 and 2.6 fold compared to 
controls. Histology and histomorphometry. 
(Murakami et al., 2003) 
bFGF Beagle Dog, tibial fracture  
2 to 32 
weeks Direct injection 200 μg 
Callus area increased 3 and 2 fold after 4 and 8 weeks 
respective, compared with controls. BMC was also 
increased 2 fold after 8 weeks. Histology, (Hirata et al., 
2013)histomorphometry and radiography. 
(Nakamura et al., 1998) 
bFGF 
Male Beagle Dog, 
mandible defect – 
5mm 
 2 to 8 weeks 
Hydroxypropyl cellulose 
gel, implant 300 μg/mL 
Treatment significantly increased bone formation 1.3 
fold compared to control defects. Histology, 
histomorphometry and radiography. 
(Shirakata et al., 2010) 
Primate 
FGF-2 
Non-Human 
Primate, inflamed 
furcation defect 
 8 weeks Gelatinous carrier, topical application 
100 to 400 
μg/mL 
Significant periodontal regeneration was observed with 
treatment. No instances of epithelial down-growth, 
ankylosis or root resorption were observed. Unknown. 
(Takayama et al., 2001) 
1.2. Small Animal Models 
Mouse 
 
FGF-1 or FGF-2 
 
 
 
 
 
FGF-1 
 
Male Swiss ICR 
White Mouse, 
subcutaneous 
injection over 
calvaria 
 
OVX Female 
Sprague Dawley 
Rat, osteoporosis 
model 
 
 
3 to 35 d 
 
 
 
 
28 to 56 
days 
(6months 
after OVX) 
Direct injection  
 
 
 
 
Intravenous injection 
0.002 to 2 μg/d 
(4 doses/d over 
3 d) 
 
 
200 μg/kg/d 
 
High dose treatment (2 μg/d) increased bone width 
approx. 7 and 3 fold compared to low dose treatment 
(0.002 μg/d) with FGF-2 and FGF-1, respectively. 
Addition of heparin resulted in a respective approx. 5 
and 3.5 fold increase in bone width between high and 
low dose treatment. Histology and histomorphometry.  
 
Bone area was increased approx. 10 fold following 
continuous treatment for 28 d, and approx. 8 fold after 
56 days, both compared to non-treated OVX controls. 
Histology and histomorphometry. 
(Dunstan et al., 1999) 
FGF-18 
FGFR3-/- Mouse 
(impaired bone 
formation model), 
femur segmental 
defect – 5mm, 
intramedullary 
injection 
 6 weeks Titanium coated nylon rods, implant 0.5 μg 
FGF-18 stimulation resulted in an approx. 5 fold 
increase in percentage bone volume compared to PBS 
treated controls. Histology and micro CT. 
(Carli et al., 2012) 
rhFGF-2 Diabetic Mouse, calvarial defect  14 d 
Polyglycolate/polylactide 
membrane, implant 5 μg 
Treatment reversed bone healing inhibition observed 
within diabetic mice. Histology and histomorphometry (Santana and Trackman, 2006) 
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rhFGF-2 
Female ddY 
Mouse, 
implantation 
beneath maxillary 
periosteum 
 7, 14 and 28 d Gelatin hydrogel, implant 20 μg 
Bony maxilla was augmented 1.6 fold compared to 
original volume. Histology, histomorphometry and 
immunohistochemistry. 
(Kodama et al., 2009) 
Rabbit 
FGF-2 
Male Japanese 
White Rabbit, 
femur full 
thickness circular 
osteochondral 
defect – 5mm 
 3 to 24 weeks 
HA/Collagen 
nanocomposite fibers, 
implant 
0.5 and 5 μg 
Low/high dose FGF-2 increased subchondral bone 
score a max. 4.8 fold and 2.4 fold (6 weeks) compared 
to control defects. Histology, histomorphometry, 
immunohistochemistry and micro CT. 
(Maehara et al., 2009) 
bFGF 
Rabbit, femur 
segmental defect – 
10mm 
 6 weeks Collagen minipellet, implant 1.4 to 2 μg 
Treatment increased callus filling of the defect 6 fold 
reaching 90 % bridging. However, the callus did not 
change into mature bone. Histology, histomorphometry 
and radiography. 
(Inui et al., 1998) 
FGF-1 
or 
FGF-2 
Rabbit, tibial 
fracture  10 d Direct injection 3 μg 
Neither FGF treatment accelerated fracture healing. 
However, calluses were more mature when treated with 
FGF-2. Histology and histomorphometry. 
(Bland et al., 1995) 
FGF-2 
Japanese White 
Rabbit, femoral 
condyle full 
thickness defect – 
5mm 
 2 and 4 weeks 
Interconnected porous 
calcium HA scaffold, 
implant 
100 μg 
After 4 weeks, control scaffolds exhibited 1.5 fold 
increased lamellar bone formation compared to FGF-2 
scaffolds. However, treated scaffolds exhibited 
significantly greater vascularisation and rapid 
osseointegration. Histology and histomorphometry. 
(Nakasa et al., 2008) 
FGF-2 
Japanese White 
Rabbit, ectopic 
subcutaneous 
implantation 
 4 weeks 
Interconnected porous 
calcium HA scaffold, 
implant 
100 μg 
Extensive new osteoid deposition was observed within 
FGF-2 implanted scaffolds, where only fibrous tissue 
was observed within control scaffolds. Histology and 
histomorphometry. 
(Nakasa et al., 2005) 
FGF-2 
Female New 
Zealand Rabbit, 
tibia segmental 
defect – 5mm 
 2 to 12 weeks 
Collagen and β-TCP, 
implant 200 μg 
Treated defects were completely filled with new bone 
tissue where implant alone and no implant controls 
exhibited 32 % and 14 % defect filling. Maximum load 
increased 2.1 fold compared to non-treated controls. 
Biomechanical testing, micro CT and radiography. 
(Komaki et al., 2006) 
FGF-2 
New Zealand 
White Rabbit, 
tibial metaphysis 
implant 
 3 weeks 
Titanium drug test 
chamber, phagocytosable 
polyethylene particles, 
continuous infusion 
0.0005 to 0.5 
μg/day 
Treatment with FGF-2 at 0.05 μg/d increased bone 
formation 1.3 fold. Addition of low dose particles and 
FGF-2 at 0.05 μg/d only increased bone formation 1.14 
fold. Histology, histomorphometry and 
immunohistochemistry. 
(Goodman et al., 2003) 
Rat 
rhFGF-2 
Adult Male 
Sprague Dawley 
Rat, mandibular 
defect – 5mm 
 12 and 24 d Type I collagen sponge, implant 
0.01, 0.1 and 1 
μg 
Medium and high dose treatment increased bone defect 
bridging 2.3 and 1.9 fold respectively after 12 d, and 1.3 
fold after 24 d, compared to carrier alone. Histology, 
histomorphometry and radiography. 
(Zellin and Linde, 2000) 
bFGF 
OVX Sprague 
Dawley Rat, tibia 
condyle defect 
 3 months 
Matrigel within titanium 
cylinder (1mm x 10mm), 
implant 
5 μg 
Treatment increased bone formation and mechanical 
stability 2 and 4 fold respective. Biomechanical testing, 
histology and micro CT. 
(Gao et al., 2009) 
FGF-1 
Male Sprague 
Dawley Rat, 
ectopic 
intramuscular 
implantation 
 2 and 4 weeks 
Fibrinogen-deproteinated 
bovine HA, implant 7 μg 
Treatment increased blood vessel formation approx. 2.6 
and 2 fold compared to untreated controls after 2 and 4 
weeks. Treatment also stimulated osteogenesis. FTIR, 
histology, histomorphometry and SEM. 
(Kelpke et al., 2004) 
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FGF-2 
Male Wistar Rat, 
calvarial defect – 
5mm 
 2, 4 and 8 weeks 
HA ceramic button, 
implant 
0.5 (direct 
application), 8 
and 20 μg 
(precipitated) 
Low dose (8 μg) precipitated HA ceramic button 
implants exhibited the greatest increase in bone 
extension into the defect site and cranial thickness, 
approx. 5 and 1.7 fold respectively. Biochemistry, 
histology and RT-PCR 
(Tsurushima et al., 2010) 
bFGF 
OVX Female 
Sprague Dawley 
Rat, severe 
osteopenia model 
 120 d Subcutaneous injection 
1,000 μg/kg 
(5days per 
week) 
Treatment with bFGF increased trabecular bone volume 
2.7 (micro CT) and 2 fold (histology) compared to 
OVX controls. Biomechanical testing, biochemistry, 
histology, histomorphometry and micro CT. 
(Lane et al., 2003b) 
bFGF 
Rat, skeletal 
growth and 
development 
 7 to 21 d Intravenous injection 
100 to 300 
μg/kg/d (first 7 
days) 
Growth plate width of the proximal tibia was increased 
3 and 1.6 fold after 7 and 21 d compared to controls 
when treated with high dose bFGF. Histology, 
histomorphometry and radiography. 
(Nagai et al., 1995) 
FGF-2 
Rat, skeletal 
growth and 
development 
 2 weeks Intravenous injection 100 μg/kg/d 
Treatment increased osteoblast proliferation and new 
bone formation. Calcified bone area of the tibia 
increased approx. 1.2 fold. Histology, 
histomorphometry and radiography. 
(Mayahara et al., 1993) 
FGF-2 
Male Sprague 
Dawley Rat, 
calvarial defect – 
5mm 
 3 weeks 
Electrospun bioactive glass 
nanofibers and collagen 
fibrils, implant 
10, 50 and 100 
μg/mL 
Bone formation was increased approx. 1.3, 1.9 and 16.4 
fold compared to composite alone, collagen alone, and 
blank control, resulting in an approx. 1.3, 1.9 and 4.2 
fold increase in defect closure, respectively. Histology 
and histomorphometry. 
(Hong et al., 2010) 
FGF-2 
Wistar Rat, 
implantation 
within the parietal 
bone/periosteum 
pocket 
 2 weeks 
Covalent conjugate with 
carbon nanotubes in 
collagen sponge, implant 
10 μg/mL 
Delivery system exhibited favourable biocompatibility 
and FGF-2 addition accelerated new bone formation. 
Histology and SEM. 
(Hirata et al., 2013) 
 
2. Animal Models for indirect FGF delivery 
2.1. Large Animal Models 
Dog 
bFGF (plasmid) Beagle Dog, root furcation  6 weeks 
Transfected cell 
implantation unknown 
Accelerated regeneration of periodontal bone tissue was 
observed following implantation of transfected cell 
compared to non-transfected controls. Clinical 
examination, histology, micro CT and radiography. 
(Tan et al., 2009) 
2.2. Small Animal Models 
Mouse 
modified FGF-2, 
β-globulin 
promoter 
(plasmid vector) 
Irradiated 
C57BL/6 Mouse, 
intravenous 
injection 
 6 to 11 weeks 
Transfected cells 
intravenously injected 
6.25 x 104 to 5 x 
105 cells 
FGF-2 expression was restricted to the bone marrow 
cavity where a 5 fold increase was observed compared 
to controls. Trabecular density increased approx. 2.7 
fold. Osteogenic markers increased a max. 7 fold 
(Runx2).  Biochemistry, pQCT, histology, RT-PCR 
(Meng et al., 2012) 
FGF-2 (plasmid 
vector) 
Adult Nude CD-1 
Mouse, calvarial 
defect – 4mm 
 1 to 20 weeks 
Transfected cells on 
HA/PLGA scaffold, 
implant 
5 x 104 cells 
Chemically controlled FGF-2 release with Shield-1 
induced an approx. 2 fold increase in bone volume 
compared to controls. CT, radiography, histology 
(Kwan et al., 2011) 
modified FGF-2 
(plasmid vector) 
W41/W41 Mouse, 
hematopoietic 
deficient model, 
intravenous 
injection 
 10 to 14 weeks 
Transfected cells 
intravenously injected 
Average 
peripheral blood 
serum conc. 
2.5μg/mL 
(0.077 to 6.4 
μg/mL) 
Histomorphometry analysis revealed a 53.5 fold 
increase in percentage cancellous bone, whilst CT 
analysis revealed a 2.5 fold increase in trabecular BMD 
both within the femur. Biochemistry, histology, 
histomorphometry and pQCT. 
(Hall et al., 2007) 
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Rabbit 
bFGF (plasmid 
vector) 
New Zealand 
White Rabbit, 
radius segmental 
defect – 15mm 
 2 to 12 weeks 
Transfected cells on porous 
β-TCP scaffold, implant 5 x 10
6 cells 
Examination revealed capillary vasculature at 2 weeks, 
vascularised bone at 4 weeks, and large regenerated 
defect areas with new bone formation. Histology, 
immunohistochemistry, radiography, SEM. 
(Guo et al., 2006) 
Rat 
bFGF (plasmid 
vector) 
Sprague Dawley 
Rat, calvarial 
defect – 8mm 
 4, 8 and 12 weeks 
Transfected cells on 
HA/PA66 scaffold, implant 2 x 10
5 cells 
Addition of transfected cells increased new bone 
volume approx. 2 fold compared to controls with non-
transfected cells. Histology, immunohistochemistry, 
histomorphometry, DXA, radiography, micro CT, PCR. 
(Qu et al., 2011) 
 
3. Animal Models for combinational direct and indirect FGF delivery 
3.1. Small Animal Models 
Dog 
bFGF, BMP-2,  
PDGF and TGF-β  
Adult Hound, 
mandibular 
premolar implant 
osteotomies 
 12 weeks 
Titanium implants with 
non-HA calcium phosphate 
cement 
unknown Growth factor combination increased bone formation compared to controls. Histology and histomorphometry. (Meraw et al., 2000) 
3.2. Small Animal Models 
Mouse 
FGF-2, rhBMP-2 
and VEGF-A  
CD-1 Mouse, 
calvarial defect – 
2 mm 
 12 weeks Collagen sponge, implant 0.2 µg 
BMP-2 and VEGF-A showed enhanced healing 
capacities compared to FGF-2, however no significant 
differences between VEGF-A and BMP-2 were 
observed. Immunohistochemistry and micro CT. 
(Behr et al., 2012) 
Rabbit 
rhFGF-2 and 
rhOP-1 
New Zealand 
White Rabbit, 
tibial bone harvest 
and drug test 
chamber 
 48 weeks 
Distilled water (rhFGF-2) 
or acetate buffer (rhOP-1), 
infusion 
0.05 µg/d 
rhFGF-2 
0.1 µg/d rhOP-1 
OP-1 and FGF-2 infusion increased percentage de novo 
bone formation approx. 1.3 and 1.2 fold respective. 
Combination treatment did not further enhance bone 
formation. Histology, histomorphometry and 
immunohistochemistry. 
(Ma et al., 2007) 
FGF-2 and IGF-1 
(plasmid vector) 
Female Rabbit, 
full thickness 
femoral condyle 
osteochondral 
defect – 3.2 x 
4mm 
 3 weeks 
Transfected cells 
encapsulated within 
gelatin, implant 
4 x 106 cells/mL 
(FGF-2 conc. 
0.0061 μg/mL 
IGF-1 conc. 
0.2548 μg/mL) 
Combination treatment increased subchondral bone 
score approx. 2.6 fold compared to control implants. 
Biochemistry, histology and immunohistochemistry 
(Madry et al., 2010) 
Rat 
FGF-2 and BMP-
2 
Wistar Rat, 
ectopic 
intramuscular 
implantation 
 3 weeks Type I collagen carrier, implant 
0.0016 to 50 μg 
FGF-2 
5 μg BMP-2 
Treatment with 0.08 μg FGF-2 exhibited the greatest 
increase in bone area compared to controls (3.3 and 2.1 
fold, assessed by radiopacity and histology, 
respectively), and BMP-2 alone (1.7 and 1.07 fold). 
Biochemistry, histology, histomorphometry and 
radiography. 
(Fujimura et al., 2002) 
FGF-2 and BMP-
2 
Male ddY Mouse, 
subfascial 
implantation 
 1, 2 and 3 weeks 
Porous collagen disc, 
implant 
0.001 to 5 μg 
FGF-2 
5 μg BMP-2 
Combination treatment with lose dose FGF-2 (0.001 
μg) increased mineral density, radiopacity and bone 
formation approx. 1.2, 2 and 1.5 fold, respectively after 
3 weeks. DXA, histology, histomorphometry and 
radiography 
(Nakamura et al., 2005) 
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FGF-2 and BMP-
2 Rat, femur defect  
4, 8 and 12 
weeks 
Nanostructured colloidal 
gelatin within porous 
titanium scaffold, implant 
0.6 μg FGF-2 
3 μg BMP-2 
Bone formation was accelerated; observed earlier than 
controls. Increased bone volume was also observed 
exhibiting superior bone-implant integrity. 
Biomechanical testing, histology and micro CT. 
(van der Stok et al., 2013) 
bFGF and 
rhBMP-2 
Rat (WKY, 
Lewis, Fisher), 
irradiated 
mandible 
 7 weeks Liquid injection 100 µg 
Irradiation reduced bone apposition, BMP-2 or bFGF 
alone generated new bone, but together they did not 
show bone maintenance. Histology, 
immunohistochemistry and micro CT. 
(Springer et al., 2008) 
FGF-2 and 
melatonin 
Female Wistar 
Rat, tibia condyle 
defect – 2mm 
 4 weeks 
Titanium implant (2mm x 
4mm) 
Intraperitoneal injection 
10 μg FGF-2 
100 mg/kg 
melatonin (4 
weeks) 
Bone–implant contact and bone density were increased 
1.7, 1.5 and 2.8 fold, and 1.2, 1.1 and 1.8 fold compared 
to FGF-2 alone, Matrigel alone and control defects, 
respectively. Histology and histomorphometry. 
(Takechi et al., 2008) 
bFGF and 
estrogen 
OVX Female 
Sprague Dawley 
Rat, severe 
osteopenia model 
 3 weeks Subcutaneous injection 
1,000 μg/kg/d 
bFGF 
10 μg/kg 
estrogen (4 d 
per week) 
Bone formation rate, osteoblast surface and osteoid 
surface were increased 1.8, 4 and 8 fold respectively, 
following combination treatment compared to OVX 
controls. Biochemistry, histology and 
histomorphometry. 
(Iwaniec et al., 2003) 
bFGF and 17β-
estradiol or PTH 
(1-34) 
OVX Female 
Sprague Dawley 
Rat, severe 
osteopenia model 
 60 to110 d 
Intravenous injection 
 
 
 
 
 
Subcutaneous injection 
 
 
 
200 μg/kg/d for 
15 d bFGF 
(starting on day 
60) 
 
10 μg/kg/3x per 
week 17β-
estradiol 
80 μg/kg/5x per 
week PTH (1-
34) 
(both starting on 
day 82) 
Percentage bone volume and connectivity were 
increased 1.6 and 2.5 fold when treated with bFGF and 
PTH, and 1.1 and 1.9 fold when treated with bFGF and 
17β-estradiol, both compared to OVX controls after 110 
days. Biochemistry and XTM. 
(Lane et al., 2003a) 
 
Abbreviations: BMC (bone mineral content), BMD (bone mineral density), CT (computerised tomography), DXA (dual energy X-ray absorpiometry), FGF (fibroblast growth factor), FTIR (fourier transform infrared 
spectroscopy), HA (hydroxyapatite), IGF-1 (insulin-like growth factor 1), OVX (ovariectomised), PA66 (polyamide 66), PCR (polymerase chain reaction), PLGA (poly(lactic-co-glycolic acid)), pQCT (peripheral 
quantitative CT), PTH (parathyroid hormone), RT-PCR (real time PCR), SEM (scanning electron microscopy), TCP (tri-calcium phosphate) and XTM (X-ray tomographic microscopy). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct PDGF delivery 
Small Animal Models 
Minipig 
PDGF 
Minipig, bilateral 
mandibular 
alveolar defect 
 3 months Collagen (Mucograft) on titanium mesh, implant 750 µg 
PDGF and collagen matrix appeared to accelerate soft 
tissue healing and promote bone formation (1.5 fold). 
Histology and histomorphometry. 
(Herford et al., 2012) 
PDGF 
Minipig, bilateral 
mandibular defect 
- 30 mm x 20 mm 
 3 months Collagen (Mucograft) on titanium mesh, implant 750 µg 
New bone formation within the defect site was 
increased approx. 1.45 fold compared to controls. 
Titanium mesh exposure was reduced 50% following 
PDGF treatment. Histology, histomorphometry and 
radiography. 
(Herford and Cicciu, 2012) 
Mouse 
PDGF-BB 
(nu/nu) Mouse, 
ectopic 
intramuscular 
implantation 
 8 weeks DBM, implant 0.01, 0.1, and 1 µg/mg 
PDGF inhibits intramuscular osteoinduction by 
demineralized bone matrix in immuno-compromised 
mice. High dose PDGF reduced the area of new bone 
and bone marrow at 28 and 56 d. Histology and 
histomorphometry 
(Ranly et al., 2005) 
Rabbit 
PDGF-BB 
New Zealand 
White Mature 
Male Rabbit, 
calvarial defect - 
8 mm 
 4 weeks Porous PLLA/TCP membranes, implant 0.5 µg 
PDGF-BB releasing molded PLLA-TCP membrane 
improved bone defect regeneration. Histology and 
histomorphometry. 
(Lee et al., 2001b) 
PDGF 
Male New 
Zealand Rabbit, 
femoral condyle 
defect - 15 mm 
 4 weeks HA, PLGA microspheres and Pluronic®, implant 0.6 and 1.2 µg 
PDGF enhanced bone formation compared to the non-
treated bone defect. Histology and histomorphometry. (Delgado et al., 2012) 
PDGF BB Rabbit, unilateral tibial osteotomy  4 weeks Collagen, implant 80 µg 
PDGF stimulated bone fracture healing however 
mechanical strength was not affected compared to non-
operated contralateral bones. Biomechanical testing, 
histology, histomorphometry and radiography. 
(Nash et al., 1994) 
Rat 
PDGF-BB 
Sprague Dawley 
Rat, craniotomy - 
8 mm 
 4 weeks Chitosan sponge, implant 0.1, 0.2 and 0.4 µg 
PDGF treatment increased bone volume approx. 10 fold 
and 1.5 fold compared to untreated and chitosan only 
treated defects, respectively. Histomorphometry and 
histological analysis. 
(Park et al., 2000) 
PDGF-BB 
Sprague Dawley 
Rat, craniotomy - 
8 mm 
 4 weeks PLLA/chitosan emulsion, implant 0.2 µg 
Controlled release of PDGF-BB from chitosan-based 
scaffolds significantly promoted bone growth compared 
to controls. Biochemistry, histology and SEM. 
(Lee et al., 2002) 
rhPDGF-BB 
Diabetic Wistar 
Rat, femur 
fracture 
 6, 8, and 12 weeks 
β-TCP/type I bovine 
collagen matrix, implant 22 and 75 µg 
High dose treatment increased percentage bone area 
within the callus approx. 1.5 fold compared to control. 
Conversely, low dose treatment increased maximum 
torque to failure approx. 1.5 fold. Biomechanical 
testing, histology and histomorphometry. 
(Al-Zube et al., 2009) 
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PDGF 
Male Sprague-
Dawley Rat, 
closed tibial 
fracture 
 10 d PDLLA-coated titanium, implant 50 µg 
Local application of PDGF from biodegradable 
PDLLA-coated implants significantly accelerated 
fracture healing compared to control groups. 
Histology, immunohistochemsitry and radiography. 
(Bordei, 2011) 
PDGF-BB, VEGF 
or BMP-2 
Rat, femoral 
segmental defect - 
3.8 mm 
 8 weeks Fibrin matrix, implant 1 µg/mL 
PDGF-BB and VEGF failed to increase bone healing in 
the atrophic non-union model. BMP-2 was the only 
growth factor to enhance bone formation (2 fold). 
Histology and radiography. 
(Kaipel et al., 2012) 
rhPDGF-BB 
Male Sprague-
Dawley Rat, 
distraction model 
and osteogenesis, 
unilateral mid-
diaphyseal 
lengthening - 7 
mm 
 35 to 63 d 
Bovine collagen dissolved 
in sodium acetate buffer, 
injection 
100, 300 and 
1,000 
µg/mL/week (4 
weeks) 
Union rate was increased 9 fold following PDGF 
treatment. Medium dose injections increased bone 
volume approx. 1.9 fold (histology) and approx. 2.4 
fold (radiography). Histology, micro CT and 
radiography. 
(Moore et al., 2009) 
PDGF-BB Rat, calvarial defect  2 weeks 
PLLA-coated PGA mesh, 
implant unknown 
After 2 weeks complete reunion of the bone defect was 
achieved. Biochemistry, histology, histomorphometry 
and SEM. 
(Park et al., 1998) 
PDGF-BB Rat, craniotomy - 8 mm  
2 and 4 
weeks 
TCP/chitosan sponge, 
implant unknown 
PDGF-BB increased bone formation in the cranial 
defect above control groups. Histology and 
histomorphometry. 
(Lee et al., 2000) 
2. Animal Models for indirect PDGF delivery 
Small Animal Models 
Mouse 
PDGF-A 
(adenovirus) 
SCID Mouse, 
ectopic 
subcutaneous 
implantation 
 3 and 6 weeks 
Transduced cells on PLGA 
scaffold, implant 1 × 10
6 cells  
PDGF-A treatment exhibited reduced implant size and 
mineralisation at 3 weeks, but increased mineral 
formation at 6 weeks. Histology, histomorphometry and 
northern blot. 
(Anusaksathien et al., 2004) 
Rat 
PDGF-B (plasmid 
vector) 
Male Sprague 
Dawley Rat, 
alveolar ridge 
defect - 1 mm 
 10 to 21 d Type 1 collagen matrix, implant 
5.5 × 108 to 5 × 
109 PFU/mL 
300 µg/mL 
PDGF treatment increased defect site fill approx. 1.8 
fold (histology) and bone area fraction within the defect 
site approx. 1.7 fold (backscatter SEM) after 10 d. 
Biochemistry, biomechanical testing, histology, micro 
CT and backscatter SEM. 
(Chang et al., 2010) 
PDGF-B 
(adenovirus) 
Sprague-Dawley 
Rat, alveolar bone 
defect - 3 mm 
 5 weeks Collagen matrix, implant 5.5 x 10
8 to 5.5 
x 109 PFU/mL 
At 35 d, bridging of the defect was complete. Animals 
receiving high-dose PDGF-B demonstrated greater 
evidence of cementogenesis along the tooth root. 
Biochemistry, histology and RT-PCR. 
(Chang et al., 2009) 
PDGF-B and BMP-
7 (adenovirus) 
OVX Rat, femoral 
defect - 2 mm  
2 and 4 
weeks 
Mesoporous-glass/silk 
scaffold, implant unknown 
Combination treatment increased new bone volume 
approx. 2 fold compared to scaffold alone after 4 weeks. 
Histology, immunohistochemistry and micro CT. 
(Zhang et al., 2012a) 
3. Animal Models for combinational direct and indirect PDGF delivery 
3.1 Large Animal Models 
Dog 
PDGF and IGF-1 
Dog, mandibular 
premolar implant 
osteotomies - 8.5 
mm x 3.75 mm 
 8 weeks Implants with methylcellulose gel 5 μg/mL 
Combination treatment increased bone formation 
compared to controls. Histology and histomorphometry. (Nociti Junior et al., 2000) 
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rhPDGF-B and 
rhBMP-7 
(adenovirus) 
Adult Hybrid 
Dog, mandible 
defect - 6mm 
 4, 8 and 12 weeks 
Chitosan/collagen 
scaffolds, implant 
2 × 1010 
particles/mL 
New bone formation was increased approx. 2.3 and 1.6 
fold following combination treatment after 4 and 8 
weeks. Percentage defect fill and new bone implant 
contact were increased approx. 1.5 and 1.4 fold 
compared to controls after 12 weeks. Histology and 
histomorphometry. 
(Zhang et al., 2009b) 
PDGF, bFGF, 
BMP-2 and TGF-β  
Adult Hound, 
mandibular 
premolar implant 
osteotomies 
 12 weeks 
Titanium implants with 
non-HA calcium phosphate 
cement 
unknown Growth factor combination increased bone formation compared to controls. Histology and histomorphometry. (Meraw et al., 2000) 
PDGF and IGF-1 
Dog, extraction 
sockets with large 
buccal 
dehiscences 
 18 weeks ePTFE membranes, implant unkown 
Implant to bone contact, area of bone adjacent to 
implant and total length of the implant surface were 
increase approx. 2 fold compared to controls. Histology 
and histomorphometry. 
(Becker et al., 1992) 
3.2 Small Animal Models 
Rabbit 
PDGF, TGF-β1and 
VEGF 
Male New 
Zealand Rabbit, 
intramedullary 
femur defect - 6 
mm (1.5 to 2 cm 
depth) 
 4 weeks Brushite cement, implant 
0.25 µg PDGF 
0.1 µg TGF-β1 
(liquid phase) 
0.35 µg VEGF 
(PLGA 
encapsulated 
microspheres) 
Triple combination increased new bone formation 
approx. 10 fold compared to controls where individual 
factor treatment increased new bone formation 
maximum 5 fold. Histology and histomorphometry. 
(Reyes et al., 2012) 
PDGF-BB, VEGF 
and MSCs 
Mouse, ectopic 
implantation 
 
Rabbit, segmental 
bone defect 
 unknown PRP membrane, implant unknown 
In an ectopic mouse model as well a rabbit segmental 
bone defect model the platelet-rich plasma-based 
membrane & PDGF was able to biomimic a periosteal 
response in vivo enhancing bone regeneration. 
(El Backly et al., 2013) 
Rat 
PDGF-BB and 
BMP-2 
Male Sprague-
Dawley Albino 
Rat, calvarial 
defect - 6 mm 
 4 weeks Fibrinogen scaffold, implant 0.05 µg 
Fibronectin and growth factors improved bone healing 
compared to growth factors alone. Flow cytometry and 
micro CT. 
(Martino et al., 2011) 
PDGF-BB and 
BMSCs 
Fisher Rat, 
calvarial defect - 
5 mm  
 8 weeks  β-TCP scaffold, implant 
0.001 and 0.05 
µg/mL 
2 x 107 cells 
Combination treatment increased percentage new bone 
area approx. 2.5 fold compared to controls. Histology, 
histomorphometry and micro CT. 
(Xu et al., 2012) 
rhPDGF-BB and 
osteogenin 
Rat, craniotomy  
(8 mm)  4 weeks Rat collagen, matrix 
20, 60 and 200 
µg PDGF-BB 
30 and 150 µg 
osteogenin 
Osteogenin alone increased radiopacity dose 
dependently; maximum 5 fold increase at high dose 
compared to controls. Combination with PDGF did not 
further enhance new bone tissue formation (approx. 5.5 
fold with osteogenin alone and approx. 4.5 fold with 
combination treatment). Histology and 
histomorphometry. 
(Marden et al., 1993) 
rhPDGF-BB and 
BMP-2 
(adenovirus) 
Male Sprague-
Dawley Rat, 
calvarial defect – 
8mm 
 2 to 4 weeks 
rhPDGF protein and 
BMSCs expressing BMP-
2, implant 
1 x 106 cells 
Increased bone regeneration by delivery of autologous 
AdBMP2-transfected BMSCs and rhPDGF-BB in both 
the amount of new bone formed and bone mineral 
density. The bone growth was greater than those 
observed in the group treated with AdBMP2-transfected 
BMSCs alone.  
(Park et al., 2013) 
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4. Human Trials for PDGF delivery 
Periodontitis 
rhPDGF-BB  
Human, advanced 
periodontitis and 
interproximal 
intrabony and/or 
molar Class II 
furcation defects 
9 months Bone allograft, implant 0.5, 1 and 5 mg/mL 
Vertical probing depth was reduced 1.12 fold and 
clinical attachment level was increased 1.17 fold, both 
following treatment compared to control anorganic 
bovine bone in collagen. Clinical assessment, histology 
and radiography. 
(Nevins et al., 2003) 
 
Abbreviations: bFGF (basic fibroblast growth factor), BMSC (bone marrow stromal cell),  BMP-2 (bone morphogenetic protein 2), BMP-7 (bone morphogenetic protein 7), CT (computer tomography), DBM 
(demineralised bone matrix), HA (hydroxyapatite), IGF-1, (insulin growth  factor-1), OVX (ovariectomised), PCL (poly(epsilon-caprolactone), PDGF (platelet-derived growth factor), PDLLA (poly (D, L lactic acid)), PFU  
(plaque forming units), PGA (polyglycolic acid), PLGA (poly(lactic-co-glycolic) acid), PLLA (poly(l-lactide), PRP (platelet-rich plasma), PTFE (polytetrafluoroethylene), RT-PCR (real time polymerase chain reaction), 
SEM (scanning electron microscopy), TCP (tricalcium phosphate), TGF- β1 (transforming growth factor-beta 1) and VEGF (vascular endothelial growth factor). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct PTH delivery 
1.1. Large Animal Models 
Dog 
PTH (1-34) 
American Hound 
Dog, proximal 
tibial defect 
 4 weeks 
Plasma-sprayed titanium, 
implant 
Subcutaneous injection 
5 μg/kg/d 
Surface fraction of woven bone (but not lamellar bone) 
at the implant interface was increased by 1.4 fold in the 
PTH group. No significant difference in bone or fibrous 
tissue was observed in the circumferential regions 
around the implant and there were no differences in 
mechanical parameters. Biomechanical testing and 
histomorphometry.  
(Daugaard et al., 2012) 
PTH (1-34) 
American Hound 
Dog, proximal 
tibial defect - 
1mm 
 4 weeks 
Plasma-sprayed titanium, 
implant 
Subcutaneous injection 
5 μg/kg/d 
PTH increased bone formation in the outer gap (2.7 
fold) and inner gap (2.5 fold), implant interface (1.6 
fold), shear stiffness (2 fold) and energy absorption (1.7 
fold). Biomechanical testing and histomorphometry. 
(Daugaard et al., 2011) 
PTH (1-34) 
American 
Foxhound Dog, 
mandibular defect 
- 1.5 x 4mm 
 4 and 12 weeks 
RGD-modified PEG 
hydrogel, implant 
20 μg/mL 
hydrogel 
All implants osseointegrated. PTH increased the area of 
newly formed bone 1.4 and 1.3 fold, at 4 and 12 weeks 
respectively, and was comparable to the autologous 
bone graft gold standard. Histology and 
histomorphometry. 
(Jung et al., 2007a) 
Monkey 
PTH (1-34) 
Cynomolgus 
Monkey, femoral 
transverse 
osteotomy 
fracture 
 26 weeks Subcutaneous injection 0.75 or 7.5 μg/kg/d  
Complete union occurred in all groups, although callus 
was largest in control groups, and smallest in 7.5 μg 
PTH-treated groups (1.4 fold less). PTH (7.5 μg) 
increased ultimate stress 1.6 fold and elastic modulus 
1.5 fold. Percentage bone area and osteoclast number 
were reduced with both 0.75 and 7.5 μg PTH. 
Biomechanical testing, histology, micro CT and 
radiography. 
(Manabe et al., 2007) 
Teriparatide 
(PTH (1-34)) 
OVX 
Cynomolgus 
Monkey 
 1.5 to 4.5 years Subcutaneous injection 5 μg/kg/d 
Teriparatide increased vertebral and femoral BMD (1.3 
and 1.1 fold), BMC (1.4 and 1.3 fold), ultimate load 
(1.5 and 1.3 fold) and stiffness (1.5 and 1.4 fold). 
Withdrawal of PTH treatment for 3 years reduced these 
differences in the vertebra, but less so in the femur. 
Bone neoplasia was not detected in any groups. 
Biomechanical testing, histology and radiography. 
(Vahle et al., 2008) 
Sheep  
PTH (1-34) 
Sheep, femoral 
and humeral 
cylindrical defects 
- 8 x 13mm  
 5 and 8 weeks 
Transglutaminase / PTH 
fusion protein incorporated 
fibrin gels, implant 
50, 100, 400, or 
1,000 μg/mL 
PTH fusion protein increased percentage bone 2.2 fold 
(100 μg/mL), 2.1 fold (400 μg/mL), and 3.4 fold (1,000 
μg/mL) compared to fibrin only gels. Histology and 
micro CT.  
(Arrighi et al., 2009) 
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1.2. Small Animal Models 
Mouse 
PTH (1-84), PTH 
(1-34), PTH (28-
48) or PTH (53-
84) 
ICR Neonatal 
Mouse  17 d Subcutaneous injection 
0.05 or 0.2 
μg/g/d 
Tibial DNA content was increased with low dose PTH 
(1-84) and (1-34) (approx. 5.9 and 6.3 fold), low and 
high dose PTH (28-48) (approx. 6.3 fold), and was not 
affected by PT13.1H (53-84). Mandibular condyle 
DNA content was dose-dependently increased with 
PTH (1-84), (1-34) and (28-48) but was unaffected by 
PTH (53-84). Low dose PTH (28-48) increased cellular 
proliferation 3 fold, and IGF expression 1.3 fold. 
Biochemistry, in situ hybridisation and radiography 
(auto). 
(Rihani-Bisharat et al., 1998) 
Teriparatide  
C57BL/6 Mouse, 
femoral 
diaphyseal defect 
- 4mm  
 2, 4 and 9 weeks Subcutaneous injection 
0.4, 4, or 40 
μg/kg/d 
Significant effects were only observed with 40 μg PTH 
and with either immediate or 1 week post-op treatment. 
PTH treatment increased percentage union ratio 
(approx. 2 fold), osteoclast number (between 3 and 4 
fold) and markers of bone formation (collagen type I, 
osteocalcin). Biomechanical testing, histology, 
histomorphometry, micro CT and RT-PCR. 
(Takahata et al., 2012) 
PTH (1-34) CD1 Mouse, tibial defect - 0.5mm   4 weeks 
Calcium phosphate coated 
titanium implants 10 or 100 μg 
The highest dose of PTH improved osseointegration of 
implants, increasing bone-implant contact by 1.6 fold 
compared to controls. Histology, histomorphometry, 
micro CT, radiography and SEM.  
(Yu et al., 2012b) 
PTH (1-34) 
C57BL/6 Mouse, 
closed femoral 
fracture 
 2 to 28 d Subcutaneous injection 30 μg/kg/d 
PTH increased callus formation, with a 3 fold increase 
in chondrogenesis over osteogenesis, and increased 
expression of Wnts 4, 5a, 5b, and 10b. Histology, 
histomorphometry, PCR, radiography and western blot. 
(Kakar et al., 2007) 
Teriparatide  
C57BL/6 Mouse, 
femoral segmental 
defect - 2 x 4mm  
 6 and 9 weeks 
PLA or PLA/β-TCP 
scaffold, implant 
Subcutaneous injection 
40 μg/kg/d 
Teriparatide increased new bone volume in PLA and 
PLA/β-TCP scaffolds at 6 weeks (3 fold and 2.1 fold) 
and in PLA/β-TCP scaffolds at 9 weeks (1.8 fold). 30% 
of teriparatide-treated defects demonstrated a bridging 
union. No union was observed in control animals. 
Biomechanical testing, histology and micro CT. 
(Jacobson et al., 2011) 
Teriparatide  
C57BL/6 Mouse, 
femoral defect - 
4mm 
 4 and 6 weeks 
Devitalised femoral 
allograft, implant 
Subcutaneous injection,  
40 μg/kg/d 
Teriparatide induced prolonged cartilage formation at 4 
weeks, leading to enhanced trabeculated bone callus 
formation and graft-host integration at 6 weeks. 
Teriparatide increased normalized callus volume (2 
fold), union ratio (2 fold), torsional rigidity (3.8 fold), 
and yield torque (1.5 fold). Biomechanical testing, 
histology and micro CT. 
(Reynolds et al., 2011) 
Teriparatide C57BL/6 Mouse, femoral fracture  7 to 21 d Subcutaneous injection 40 μg/kg/d 
Teriparatide treatment significantly increased the 
fracture callus volume at 7, 10 and 14 d (approx. 1.4 
fold, 4 fold, and 2.1 fold, respectively), with enhanced 
cartilage formation at day 10 and bone formation at day 
14 and upregulation of Osterix expression. Histology, 
histomorphometry, immunohistochemistry and 
radiography. 
(Kaback et al., 2008) 
PTH (1-34), PTH 
(2-34) or, PTH 
(1-31) 
Swiss/Webster 
Mouse  15 d Subcutaneous injection 
40 to 800 
μg/kg/d 
PTH (1-34) significantly increased serum OCN, bone 
ALP and bone TRAP (maximum 1.7 fold, 1.8 fold, and 
1.7 fold increase after 10 days respectively) as well as 
bone density (1.2 fold). PTH (2-34) and PTH (1-31) 
were less potent. Biochemistry, biomechanical testing 
and QCT. 
(Mohan et al., 2000) 
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PTH (1-34) 
C57BL/6x129/Sv 
OVX Ampka1+/+ 
and Ampka1-/- 
Mouse 
 6 weeks Subcutaneous injection 80 μg/kg/d 
PTH treatment increased BV/TV (as well as other 
trabecular and cortical bone indexes) by approx. 4 fold 
in OVX Ampkα1+/+ mice, but only by approx. 2.2 fold 
in OVX Ampkα1−/− mice. By contrast, non-OVX 
Ampkα1−/− mice responded better to PTH treatment than 
non-OVX Ampkα1+/+ mice (approx. 2.2 fold compared 
to 1.3 fold increase in BV/TV respectively). Histology, 
hitomorphometry, micro CT, RT-PCR and western blot. 
(Jeyabalan et al., 2012) 
PTH (1-34) 
Wild-type and 
Pth-/- Mouse, mid-
diaphyseal 
femoral fracture 
 2 and 4 weeks Subcutaneous injection 80 μg/kg/d 
Bone healing was impaired in Pth-/- sham mice. 
Addition of PTH enhanced fracture healing at 4 weeks 
in wild-type and Pth-/- mice, increasing calcified callus 
formation (approx. 1.3 and 1.8 fold), maximum load 
(approx. 1.4 and 1.3 fold), maximum stress (1.5 fold), 
and energy to failure (approx. 2.5 and 2 fold), although 
healing was better in wild-type compared to Pth-/- mice. 
Biomechanical testing, histology, 
immunohistochemistry, micro CT, radiography, RT-
PCR and western blot. 
(Ren et al., 2011) 
PTH (1-34) 
Mouse, femoral 
fracture non-union 
- 1.7mm 
 6 weeks Subcutaneous injection 30 μg/kg 
6.3 fold increase in rate of bony union and 3.9 fold 
reduction in mean gap size in PTH groups compared to 
controls. Histology and radiography. 
(Lin et al., 2012b) 
Black bear PTH 
(1-84) 
C57BL/10ScSn/D
MD-mdx Mouse   10 weeks Subcutaneous injection 28 nmol/kg 
Black bear PTH increased bone volume fraction, with a 
greater response in mdx mice than wild type (7 fold and 
2 fold increase, respectively). Black bear PTH also 
increased trabecular number and osteoblast area, and 
decreased osteoclast area, in mdx mice only. 
Biomechanical testing, histology and micro CT. 
(Gray et al., 2012) 
Rabbit 
Teriparatide 
New Zealand 
White Rabbit, 
posterolateral 
arthrodesis 
 8 weeks 
Autologous iliac crest, 
implant 
Subcutaneous injection 
10 μg/kg/d 
PTH treatment increased fusion rates1.7 fold and 
improved fusion quality by Emery grading. 
Biomechanical testing, histology, manual palpation and 
radiography. 
(Lehman et al., 2010) 
PTH (1-34) 
New Zealand 
White Rabbit, 
posterolateral 
spinal fusion 
 6 weeks Subcutaneous injection 10 μg/kg/d 
PTH increased fusion (2.7 fold), percentage bone (2.1 
fold), percentage cartilage (9.9 fold), osteoblast 
numbers (2.1 fold) and osteoclast numbers (2.5 fold). 
Biomechanical testing, faxitron radiography, histology, 
histomorphometry and micro CT. 
(O'Loughlin et al., 2009) 
PTH (1-34)  
New Zealand 
White Rabbit, 
tibial wedge 
osteotomy - 4 x 
10mm 
 4 weeks 
β-TCP / CMC scaffold, 
implant 
Subcutaneous injection 
10 or 40 
μg/kg/d PTH 
Low dose PTH increased BMC 1.3 fold. Biomechanical 
testing, histology, QCT and radiography. (Tsiridis et al., 2007b) 
PTH (1-34) 
New Zealand 
White Rabbit, 
tibial mid-
diaphyseal 
osteotomy and 
distraction 
osteogenesis 
 5, 14 and 28 d Subcutaneous injection 25 μg/kg/d 
PTH increased BMC (1.5 fold), BMD (1.3 fold), 
ultimate load (1.3 fold) and work to failure (2 fold). 
Biomechanical testing, DXA and micro CT.  
(Aleksyniene et al., 2009) 
PTH (1-34) Rabbit, calvarial defect  8 weeks 
Titanium implants filled 
with PEG matrix and 
HA/TCP granules, implant 
20 or 100 
μg/mL matrix 
PTH increased new bone formation; 1.7 fold (20 μg) 
and 1.9 fold (100 μg) increase in percentage mineralised 
bone, and 2.2 fold (20 μg) and 2.3 fold (100 μg) 
increase in regenerated bone area, both compared to 
empty defects. Histology and histomorphometry.  
(Jung et al., 2007b) 
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Rat 
PTH (1-38) 
PX Sprague-
Dawley Rat, 
calcium-free diet 
 1 to 24 h Subcutaneous infusion 0.4 to 800 µg/kg/d 
Continuous PTH infusion stimulated bone resorption, 
resulting in a dose response increase in serum-ionized 
calcium and osteoclast numbers (2.1 fold and 3 fold 
increase over vehicle control at 24 h respectively), as 
well as a dose-dependent decrease in OPG mRNA (3-
fold decrease after 6 h, 7.5 fold decrease after 24 h) and 
reciprocal increase in RANKL mRNA (27-fold increase 
after 6 h, 5.5 fold increase after 24 h). Markers of bone 
formation were significantly reduced. Biochemistry, 
histology, immunohistochemistry and northern blot. 
(Ma et al., 2001) 
PTH (1-34) 
OVX Sprague-
Dawley Rat, 
femoral fracture 
 35 d Subcutaneous injection 3, 10 or 30 
μg/kg/d 
PTH dose-dependently increased BMD (approx.1.1 
fold, 1.2 fold and 1.5 fold) as well as BMC, cortical 
area and cortical thickness. Woven bone was 
established within the defects and intramedullary 
spaces, but not the periosteum. Systemic effects of PTH 
were seen at vertebral non-fracture sites. Biochemistry, 
biomechanical testing, histology, histomorphometry, 
and QCT. 
(Komatsu et al., 2009) 
PTH (1-34) Fischer 344 Rat, bone neoplasms  24 months Subcutaneous injection 
5, 30 or 75 
μg/kg/d 
Incidence of bone tumour increased exponentially, but 
only in the 30 and 75 μg PTH doses, and only after 500 
to 600 d of treatment. Bone mass increased with all 
PTH treatments, but reduced after treatment 
withdrawal. Histology and QCT.  
(Vahle et al., 2004) 
Rat PTH (1-34) 
or bovine PTH 
(1-34) 
OVX Sprague-
Dawley Rat  
4 and 8 
weeks Subcutaneous injection 
5, 25 or 50 
μg/kg/d 
All doses of  rat and bovine PTH improved bone in 
OVX rats, increasing BMC (1 to 2.6 fold - rat PTH, 1.3 
to 2.7 fold - bovine PTH), BMD (1.2 to 2.1 fold - rat 
PTH, 1.3 to 2.5 fold - bovine PTH) and BV/TV (5.4 
to10 fold - rat PTH, 7.3 to 13.1 fold - bovine PTH). 
Bovine PTH was 4 to 6 fold more potent than rat PTH. 
Histology, histomorphometry and radiography. 
(Li et al., 2001) 
PTH (1-34) 
Sprague-Dawley 
Rat, unilateral 
mandibular 
fracture  
 7 and 21 d Subcutaneous injection 10 μg/kg/d 
PTH increased callus formation and bone density at 7 
days, and new bone formation at 21 d. Histology and 
radiography. 
(Rowshan et al., 2010) 
PTH (1-34) 
Sprague-Dawley 
Rat, mid-
diaphyseal 
femoral fracture 
 42 d Subcutaneous injection 10 μg/kg/d 
PTH induced callus formation and remodelling, 
increasing ultimate load 2.2 fold, BMC 1.5 fold and 
BMD 1.3 fold, as well as proliferation, osteoclast 
number and bone markers (collagen I, osteonectin, 
osteocalcin and serum calcium). Biochemistry, 
biomechanical testing, DXA, histology, in situ 
hybridisation and northern blot.  
(Nakajima et al., 2002) 
PTH (1-34) 
OVX Wistar Rat, 
proximal tibial 
cancellous bone 
osteotomy 
 4 weeks Subcutaneous injection 14.3 μg/kg/d 
PTH increased cancellous bone volume 1.8 fold and 
osteoid surface 1.8 fold and 1.6 fold, in both sham and 
OVX animals respectively, and repressed bone 
resorption parameters including eroded surface (1.8 
fold), osteoclast surface (1.4 fold) and osteoclast 
number (5.3 fold), within OVX animals only. PTH also 
increased cellular proliferation and percentage bone 
union (1.5 fold in sham and 1.6 fold in OVX animals). 
Histology and histomorphometry. 
(Nozaka et al., 2008) 
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Rat PTH (1-34) 
Sprague-Dawley 
Rat, calvarial 
defect - 8mm 
 4 and 8 weeks 
β-TCP scaffold, implant 
Subcutaneous injection,  15 μg/kg/d 
At 4 weeks PTH increased percentage bone fill 2 fold, 
which was further increased with β-TCP (3.1 fold). At 8 
weeks PTH increased percentage bone fill 1.3 fold, and 
1.6 fold with β-TCP. Histology, histomorphometry and 
radiography. 
(Yun et al., 2010) 
Rat PTH (1-34) 
Sprague-Dawley 
Rat, mechanical 
vertebral loading  
 1, 2 and 4 weeks Subcutaneous injection 15 μg/kg/d 
PTH and mechanical treatment alone increased 
trabecular bone formation and mineralisation. 
Combination of treatments enhanced the effect. 
Histology, histomorphometry and micro CT. 
(Kim et al., 2003) 
PTH (1-84) 
OVX Sprague-
Dawley Rat, 
bilateral tibial 
fracture 
 30 d Subcutaneous injection 15 or 150 
μg/kg/d 
Low and high dose increased callus formation, with 1.3 
and 1.5 fold increases in percenatge trabecular bone, 
and improved mechanical strength with 1.6 and 2 fold 
increases in ultimate load, 1.5 and 1.8 fold increases in 
ultimate stiffness, and 1.2 and 1.9 fold increases in 
ultimate stress. Biomechanical testing, histology and 
histomorphometry. 
(Kim and Jahng, 1999) 
PTH (1-34) 
OVX Sprague-
Dawley Rat, 
posterolateral 
spinal fusion 
 4 and 6 weeks Subcutaneous injection 30 μg/kg/d 
PTH induced 2.5 fold (4 weeks) and 1.6 fold change (6 
weeks) in fusion rate, approx. 2 fold increase in OCN 
and 1.2 fold increase in collagen type I, and increased 
micro CT assessed bone parameters with increased 
trabecular bone formation. Biochemistry, histology, 
manual palpation, micro CT and radiography. 
(Qiu et al., 2013) 
PTH (1-34) 
Sprague-Dawley 
Rat, posterolateral 
spinal fusion 
 6 weeks Subcutaneous injection 30 μg/kg/d 
PTH increased fusion rate 1.5 fold and serum 
osteocalcin 1.5 fold. Biochemistry, histology and 
manual palpation, 
(Lawrence et al., 2006) 
PTH (1-34) 
Sprague-Dawley 
Rat, ulna stress 
fracture 
 2, 4 and 8 weeks Subcutaneous injection 40 μg/kg/d 
After 8 weeks PTH treatment increased BMD (1.1 
fold), BMC (1.1 fold) percentage crack repair (2.5 fold), 
ultimate force (1.2 fold) and stiffness (1.1 fold).  
Biomechanical testing, DXA, histology and 
histomorphometry.  
(Sloan et al., 2010) 
PTH (1-34) 
Fisher 344 Rat, 
mid-shaft femoral 
bone marrow 
ablation 
 3 months Dorsal neck subcutaneous injection 40 μg/kg/d 
Treatment with PTH for 3 months enhanced endosteal 
and periosteal bone formation, with a 1.3 fold increase 
in cortical thickness. Biomechanical testing, CT, 
histology and radiography.  
(Zhang et al., 2010b) 
PTH (1-34) 
Fisher 344 Rat, 
femoral bone 
marrow ablation 
 21 d Dorsal neck subcutaneous injection 40 μg/kg/d 
PTH promoted formation of lamellar bone after marrow 
ablation, increasing osteocalcin serum levels approx. 
1.7 fold and reducing serum TRAP levels approx. 1.2 
fold, as well as increasing the maximum load 1.3 fold 
and stiffness 1.2 fold. Biochemsitry, biomechanical 
testing, histology, micro CT, QCT and radiography. 
(Zhang et al., 2008) 
PTH (1-34) 
Sprague-Dawley 
Rat, spinal 
arthrodesis 
 2 to 42 d Autologous iliac bone graft Subcutaneous injection 40 μg/kg/d 
100 % of PTH-treated animals showed spinal fusion at 
day 28 and 42, a 1.2 fold increase compared to controls. 
BV/TV increased 1.4 fold after 42 d of PTH treatment, 
as well as trabecular thickness (1.1 fold) and number 
(1.2 fold). PTH also increased a number of osteoclast 
and osteoclast-related genes. Biochemistry, histology, 
manual palpation, micro CT, PCR and radiography. 
(Abe et al., 2007) 
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PTH (1-34) 
Wistar Rat, 
femoral open or 
closed fracture 
 6 weeks Subcutaneous injection 50 μg/kg/d 
100 % of closed fractures healed regardless of 
treatment, while only 52 % of open fractures healed in 
control groups with no significant increase after PTH 
treatment (58%). However PTH did increase other 
parameters in closed and open fractures; callus volume 
(1.5 fold / 1.7 fold), BMC (1.3 fold / 1.4 fold), stiffness 
(1.4 fold / 1.5 fold) and callus trabecular BV/TV (1.6 
fold/ 1.3 fold).  Biomechanical testing, histology, QCT 
and radiography. 
(Tagil et al., 2010) 
PTH (1-34) 
Wistar Rat, 
calvarial defect - 
5mm  
 35 d 
Subcutaneous injection, 
PTFE membrane covering 
defect site 
60 μg/kg/d 
PTH increased dry weight (1.5 fold), ash weight (1.5 
fold) and ultimate stiffness (1.9 fold). Biomechanical 
testing. 
(Andreassen and Cacciafesta, 
2004) 
PTH (1-34) Wistar Rat, tibial closed fracture  20 and 40 d Subcutaneous injection 
60 and 200 
μg/kg/d 
High dose PTH increased ultimate load (1.8 fold) and 
callus volume (2 fold) after 20 d. 60 and 200 μg PTH 
increased ultimate load (2.3 and 2.8 fold), ultimate 
stiffness (3.1 and 3.5 fold) and callus volume (1.4 and 
1.7) after 40 d. Biomechanical testing, DXA and 
histology.  
(Andreassen et al., 1999) 
PTH (1-34) Sprague-Dawley Rat  1 to 24 h Subcutaneous injection 80 μg/kg/d 
PTH induced rapid and transient induction of c-fos (8.4 
fold increase at 1 h, returning to basal levels by 6 h), c-
jun (2.8 fold increase at 1 hour, returning to basal levels 
by 3 h) and c-myc (2.1 fold increase at 1 h, returning to 
basal levels by 3 h) mRNA. PTH reduced proliferation 
within 12-24 h, and induced IL-6 mRNA at 1 h only. 
Northern blot and radiolabelling. 
(Onyia et al., 1995) 
PTH (1-34) 
Sprague-Dawley 
Rat, femoral 
transverse 
osteotomy 
 3, 6 and 12 weeks Subcutaneous injection 10 or 30 μg/kg 
High dose PTH pre-treatment and 10 and 30 μg PTH 
post-treatment increased BMD 1.1 fold 12 weeks after 
fracture. Ultimate load was significantly increased (1.5 
fold) after 30 μg PTH post-treatment 12 weeks after 
fracture, as well as percentage bone area. 
Biomechanical testing, histology, histomorphometry 
and QCT. 
(Komatsubara et al., 2005) 
PTH (1-34) 
OVX Sprague-
Dawley Rat, 
proximal tibial 
osteotomy 
 1 to 4 weeks Subcutaneous injection 30 μg/kg 
PTH treatment induced a 1.2 fold increase in tibial 
BMD at 4 weeks compared to control, as well as 
increases in bone volume and osteoid surface. Enhanced 
bone union was observed at 2 weeks (but not at 4 
weeks). Histology, histomorphometry and 
immunohistochemistry. 
(Tsuchie et al., 2013) 
PTH (1-34) 
ORX Sprague-
Dawley Rat, 
bilateral 
metaphyseal tibial 
osteotomy 
 12 weeks Subcutaneous injection 40 μg/kg  
PTH increased OCN serum levels in both sham and 
ORX animals (3.1 fold). Osseous bridging was 
increased 1.5 fold in sham animals and 1.1 fold in ORX 
animals treated with PTH. Biochemistry, histology and 
CT.  
(Komrakova et al., 2011) 
PTH (1-34) 
OVX Wistar Rat, 
periodontal 
disease model 
 4 weeks Subcutaneous injection 40 μg/kg 
PTH reduced periodontal bone loss by 2.3 fold, and 
increased optical density by 1.1 fold. Histology, 
histomorphometry, radiography and SEM. 
(Marques et al., 2005) 
PTH (1-34) 
OVX Female 
Sprague Dawley 
Rat, severe 
osteopenia model 
 120 d Subcutaneous injection 40 μg/kg 
Treatment with PTH (1-34) increased trabecular bone 
volume 2.9 (micro CT) and 1.9 fold (histology) 
compared to OVX controls. Biomechanical testing, 
biochemistry, histology, histomorphometry and micro 
CT. 
(Lane et al., 2003b) 
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7 
 
PTH (1-34) 
Sprague-Dawley 
Rat, mechanical 
tibial loading (4-
point bending)  
 4 weeks Subcutaneous injection 50 μg/kg 
PTH treatment and mechanical bending induced bone 
formation. Combination increased this anabolic effect. 
Finite element analysis and histology.  
(Roberts et al., 2009) 
PTH (1-34) 
Wistar Rat, 
mandibular 
distraction 
osteogenesis 
 10 d, 1 and 3 weeks Subcutaneous injection 60 μg/kg 
PTH increased bone volume at 10 days (1.6 fold), 1 
week (1.7 fold) and 3 weeks (1.7 fold). Histology, 
immunohistochemistry and micro CT. 
(Ali et al., 2012) 
PTH (1-34) OVX Wistar Rat  14 weeks Subcutaneous injection 60 μg/kg 
PTH restored metaphyseal bone loss following OVX 
after 2 weeks of treatment, with maximum increases 
after 6 weeks; BV/TV increased approx. 2.5 fold, 
trabecular number approx. 2.1 fold, and trabecular 
thickness approx. 1.6 fold. PTH also increased 
epiphyseal bone parameters but to a lesser degree. 
Biomechanical testing and micro CT. 
(Brouwers et al., 2009) 
PTH (1-34), PTH 
(1-31) or 
monocyclic PTH 
(1-31) 
Wistar Rat, tibial 
closed fracture  
8 and 16 
weeks Subcutaneous injection 15 nmol/kg 
PTH increased ultimate load 1.6 fold (PTH (1-34)) and 
1.7 fold (PTH(1-31), monocyclic PTH(1-31)), ultimate 
stiffness 1.6 fold (PTH (1-34), PTH (1-31)) and 1.5 fold 
(monocyclic PTH (1-31)), and diaphyseal BMC 1.2 fold 
(PTH (1-34)), 1.3 fold (PTH (1-31)), and 1.2 fold 
(monocyclic PTH (1-31)), after 8 weeks of treatment. 
No differences observed between groups after removal 
of PTH treatment, although mechanical quality and 
strength continued to increase. Biomechanical testing 
and DXA. 
(Andreassen et al., 2004) 
 
2. Animal Models for combinational direct and indirect PTH delivery 
2.1 Large Animal Models 
Sheep 
PTH (1-34) and 
tiludronate 
Romanov-
Limousin Sheep  3 months Subcutaneous injection 
500 IU/d PTH 
1 mg/kg/d 
tiludronate 
Bone turnover was increased with PTH treatment and 
reduced with tiludronate or combined PTH/tiludronate 
treatment. PTH alone increased serum OCN 2 to 4 fold, 
whereas tiludronate or combined therapy did not alter 
OCN levels. PTH alone increased osteoclast number 
(approx. 4.3 fold) which was reduced with tiludronate 
or combined therapy (approx. 6.3 fold). Biochemistry, 
histology and histomorphometry.  
(Delmas et al., 1995) 
2.2 Small Animal Models 
Mouse 
PTH (1-34) and 
rapamycin C57BL/6J Mouse  44 d 
Rapamycin pellet, implant 
Subcutaneous injection 
10, 30, or 90 
μg/kg/d PTH 
3 mg/kg/d 
rapamycin 
PTH alone increased BMD 1.2 fold (10 μg) and 2 fold 
(30 and 90 μg), BMC 1.4 fold (10 μg), 2.2 fold (30 μg) 
and 2.9 fold (90 μg), as well as bone / mineral CT 
parameters. Addition of rapamycin decreased BMC and 
bone / mineral CT parameters, especially at higher PTH 
doses. Biochemistry, DXA, histomorphometry, micro 
CT and QCT. 
(Niziolek et al., 2009) 
PTH (1-34) and 
human PDL cells 
CD-1 Nude 
Mouse, 
subcutaneous 
implantation - 
3.5mm 
 4 weeks Gelatin sponge, implant Subcutaneous injection  
40 μg/kg/d 
3 x 106 cells 
PTH increased expression of bone markers ALP (1.7 
fold), OPN (1.2 fold) and OCN (1.3 fold), 
mineralisation (1.9 fold), and blood serum OCN levels 
(3 fold). Biochemistry, histology and 
immunohistochemistry. 
(Wolf et al., 2012) 
Supplementary Table 5. Bone tissue engineering in vivo utilising PTH within animal models and human trials. 
 
8 
 
PTH (1-34) and 
BMSCs 
NIH III Nude 
Mouse, 
subcutaneous 
implantation - 3.5 
x 5mm  
 15 weeks Gelatin sponge, implant Subcutaneous injection 
40 μg/kg/d 
2 to 3 x 106 
cells 
PTH increased the number of BMSC-derived ossicles 
1.9 fold, percentage bone volume 2.5 fold, BMD 2.3 
fold, and calcium content 1.9 fold when administered 
for 3 weeks. Biochemistry, histology, 
histomorphometry, micro CT, northern blot, 
radiography and raman spectroscopy. 
(Pettway et al., 2005) 
PTH (1-34), 
BMSCs and 
zoledronic acid 
NIH III Nude 
Mouse, 
subcutaneous 
implantation 
 3 weeks 
Gelatin sponges, implant 
Intraperitoneal injection 
(zoledronic acid) 
Subcutaneous injection 
(PTH) 
40 μg/kg/d PTH 
3 μg/mouse/d 
zoledronic acid 
PTH alone administered 1 d or 1, 2, or 3 weeks after 
BMSC implantation increased bone formation approx. 3 
fold, 4.3 fold, 2 fold and 2 fold, respectively. PTH alone 
increased osteoblast numbers (administered 1 d, 1 week 
or 2 weeks after BMSC implantation) or osteoclast 
numbers (administered 3 weeks after BMSC 
implantation). Combined PTH and zoledronic acid 
reduced cell proliferation and marker expression but did 
not reduce PTH-induced bone formation. Biochemistry, 
histology, histomorphometry, micro CT and RT-PCR. 
(Pettway et al., 2008) 
PTH (1-34) and 
GFP-labelled 
MSCs 
C57BL/6J Mouse, 
and 
C57BL/6J/Rag2-/- 
Mouse, 
intramedullary 
injection 
 1 week Subcutaneous injection 40 μg/kg 5 x 105 cells 
1.5 to 2 fold increase in osteoblast Smad 
phosphorylation in C57BL/6J mice treated with PTH, 
and a 6 fold increase in Smad phosphorylation in bone 
marrow transplanted GFP-labelled MSCs in 
C57BL/6J/Rag2-/- mice treated with PTH. 1.8 fold 
increase in bone marrow transplanted Osterix+ GFP-
labelled MSCs in C57BL/6J/Rag2-/- mice after PTH 
treatment, indicating stimulation of osteoblast 
differentiation. FACS and immunocytochemistry. 
(Yu et al., 2012a) 
PTH and PTHrP 
(1-84) peptide 
Wildtype and 
PTHrP knockout 
Mouse 
 1 month Subcutaneous injection 0.2 µg/d 
Increased endochondral long bone formation was 
observed in both trabecular (approx. 3 fold) and cortical 
bone (approx. 2 fold). Augmented growth plate 
chondrocyte proliferation, differentiation and cartilage 
matrix mineralisation. Faxitron analysis, histology, 
immunohistochemistry, micro CT, radiography, RT-
PCR and western blot analysis. 
(Xue et al., 2005) 
Rabbit 
PTH (1-34) and 
rhBMP-7 
New Zealand 
White Rabbit, 
tibial wedge 
osteotomy - 4 x 
10mm 
 4 weeks 
β-TCP particles and CMC, 
implant (rhBMP-7) 
Subcutaneous injection 
(PTH (1-34)) 
10 μg/kg/d PTH 
200 μg rhBMP-
7 
Micro CT analysis revealed approx. 1.6 and 1.4 fold 
increased bone volume and BMC compared to controls. 
Histological analysis revealed approx. 1.3 fold 
increased bone area compared to controls. Torsional 
rigidity and compressive strength increased approx. 1.4 
and 1.2 fold compared to controls. Biomechanical 
testing, histology, immunohistochemistry and micro 
CT. 
(Morgan et al., 2008) 
Rat 
PTH (1-34), PTH 
(28-48) with IL-6 
and IL-6 soluble 
receptor 
Wistar Rat, tibial 
fracture  
1 to 6 
weeks Subcutaneous injection 
1 μg PTH 
40 ng IL-6 
100ng IL-6 
soluble receptor  
At 14 days PTH (1-34) alone increased tibia volume 
compared to non-fractured bones. Combination of PTH 
and IL-6/IL-6 soluble receptor significantly increased 
tibia volume approx. 2.4 fold (PTH (1-34)) and 3 fold 
(PTH (28-48)), compared to fractured vehicle-treated 
control tibia. At 5 weeks PTH treatment enlarged callus 
formation, whereas PTH with IL-6/IL-6 soluble 
receptor led to full healing, and increased the power to 
failure approx. 3.1 fold (PTH (1-34)) and 2.3 fold (PTH 
(28-48)). Biomechanical testing, histology and 
radiography.  
(Rozen et al., 2007) 
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PTH (1-34) and 
ibandronate 
OVX Sprague-
Dawley Rat  
8 and 12 
weeks Subcutaneous injection 
10 μg/kg PTH 
7 μg/kg 
ibandronate  
PTH and ibandronate alone or combined reversed 
ovariectomy induced deteriorations in trabecular and 
cortical bone. Combined PTH/ibandronate restored 
bone microarchitectural indices earlier than that PTH 
alone, preserving mean BMD. Micro CT, 
nanoindentation testing, QCT and SEM.  
(Yang et al., 2013) 
PTH (1-34) and 
BMP-2 
Harlan Sprague-
Dawley Rat, mid-
diaphyseal 
femoral defect - 
5mm 
 8 weeks 
BMP2-incorporated PLGA 
microspheres in gelatin 
hydrogel, implant 
Subcutaneous injection 
10 μg/kg PTH 
6.5 μg BMP-2 
PTH did not induce bone formation in empty control 
defects. BMP-2 scaffolds with PTH treatment increased 
bone volume by approx. 4.1 and 1.7 fold compared to 
control defects and BMP-2 scaffold only, respectively. 
DXA, histology and micro CT.  
(Kempen et al., 2010) 
PTH (1-34) and 
alendronate OVX Wistar Rat  14 weeks Subcutaneous injection 
40 μg/kg PTH 
15 μg/kg 
alendronate 
PTH alone and combined with alendronate increased 
BV/TV (approx. 2.4 and 2.9 fold increase respectively 
at 14 weeks), cortical thickness (approx. 1.3 and 1.4 
fold increase respectively at 14 weeks) trabecular 
thickness (approx. 1.5 fold increase at 14 weeks) and 
stiffness (approx. 1.3 and 1.5 fold increase at 14 weeks) 
over the treatment period. Micro CT.  
(Campbell et al., 2011) 
PTH (1-34) and 
zoledronic acid 
OVX Sprague-
Dawley Rat, 
proximal tibial 
defect -1mm 
 12 weeks 
HA-coated titanium, 
implant 
Subcutaneous injection 
60 μg/kg PTH 
1 mg/mL 
zoledronic acid 
Combination treatment increased BV/TV by 2.2 fold, 
trabecular number by 1.3 fold, percentage 
osseointegration by 1.6 fold, bone to implant contact by 
1.8 fold and percent bone area by 2.1 fold, compared to 
controls. Monotherapy with PTH or zoledronic acid 
showed no difference when compared to each other. 
Biomechanical testing, histology and micro CT.  
(Li et al., 2013) 
PTH (1-34) and 
bFGF 
OVX Female 
Sprague Dawley 
Rat, severe 
osteopenia model 
 60 to 100 d 
 
Subcutaneous injection 
 
 
 
 
 
Intravenous injection 
 
80 μg/kg/5x per 
week PTH (1-
34) 
(starting on day 
82) 
 
200 μg/kg/d for 
15 d bFGF 
(starting on day 
60) 
Percentage bone volume and connectivity were 
increased 1.6 and 2.5 fold when treated with PTH and 
bFGF compared to OVX controls after 110 days. 
Biochemistry and XTM. 
(Lane et al., 2003a) 
PTH (1-34), 
pamidronate and 
ibandronate 
Sprague-Dawley 
Rat, tibial defect - 
1.7 x 3mm 
 2 weeks 
Bisphosphonates bound to 
stainless steel screws, 
implant 
Subcutaneous injection 
Unknown 
(PTH) 
300 ng/cm2 
pamidronate 
340 ng/cm2 
ibandronate 
 
PTH alone, and bisphosphonate alone increased pull-
out force (1.9 fold and 1.5 fold) and pull-out energy 
(2.3 fold and 1.7 fold), compared to controls. 
Combining PTH with bisphosphonate further increased 
the pull-out force (2.1 fold) and pull-out energy (3 
fold), compared to both controls and individual 
treatment. Biomechanical testing.  
(Aspenberg et al., 2008) 
3. Human Trials for PTH delivery 
Healthy Adults 
PTH (1-34)  Human, healthy young adults 7 d Continuous infusion pump 
2 to 4 
pmol/kg/h 
PTH treatment increased bone resorption markers and 
decreased bone formation markers. Higher doses 
induced hypercalcemia. Biochemistry.  
(Horwitz et al., 2011) 
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Low Bone Mineral Density 
Teriparatide  
Human, 
institutionalized 
with low BMD 
1 year Subcutaneous injection 20 μg/d 
No adverse effects were observed with teriparatide 
treatment, and calcium levels remained unchanged. 
Teriparatide rapidly increased the P1NP marker of bone 
formation and the C-telopeptide marker of bone 
resorption, which remained elevated at 12 months (2.1 
and 2.7 fold increase respectively). Biochemistry.  
(Ryder et al., 2010) 
Mandibular Repair 
Teriparatide  
Human, 
bisphosphonate-
related 
osteonecrosis of 
the mandible 
2 and 3 
months Subcutaneous injection 20 μg/d 
PTH increased osteocalcin 5.4 to 5.7 fold, and C-
telopeptide 2.4 to 3.2 fold. Biochemistry. (Kwon et al., 2012) 
Teriparatide  
Human, 
edentulous lower 
jaw with titanium 
mandibular 
implant 
9 weeks Subcutaneous injection 20 μg/d 
Teriparatide increased new bone volume in the 
periosteal, cortical and medullary compartments (1.1, 
1.5 and 1.6 fold respectively), and new bone to implant 
contact in the periosteal and medullary compartments 
(1.2 and 4.7 fold respectively) but reduced bone to 
implant contact in the cortical compartment. Histology 
and histomorphometry. 
(Kuchler et al., 2011) 
Teriparatide  
Human, 
periodontal 
osseous defect  
12 months Subcutaneous injection 20 μg/d 
Teriparatide resulted in significant linear resolution of 
periodontal defects, with increased bone gain (11.6 
fold) and attachment (3.7 fold), and reduction in 
probing depth (1.8 fold) at 12 months. Biochemistry, 
clinical assessment and radiography. 
(Bashutski et al., 2010) 
Postmenopausal Women 
Teriparatide  
Human, 
postmenopausal 
women 
6 and 18 
months Subcutaneous injection 20 μg/d 
Teriparatide increased trabecular volumetric BMD by 
1.8 % and 4.6 % at 6 and 18 months respectively. At 18 
months teriparatide also increased strength-density ratio 
by 4 %, hip area BMD by 2.8 %, and femoral neck area 
BMD by 3.7 %. DXA and QCT.  
(Keaveny et al., 2012) 
Teriparatide  
Human, 
postmenopausal 
women with distal 
radial fracture 
 Subcutaneous injection 20 or 40 μg/d 
Low dose teriparatide decreased time to complete 
cortical bridging from 9.1 weeks to 7.4 weeks (1.3 fold) 
while high dose teriparatide did not significantly reduce 
healing time (8.8 weeks). Clinical assessment, CT and 
radiography. 
(Aspenberg et al., 2010) 
PTH (1-34)  
Human, 
postmenopausal 
women with 
atraumatic 
vertebral fracture 
24 months Subcutaneous injection 20 or 40 μg/d 
PTH reduced the risk of one or more new vertebral 
fracture by 7 fold, reduced the number of fractures by 
2.8 fold (20 μg) and 4.5 fold (40 μg) and increased 
BMD dose-dependently. Biochemistry and radiography. 
(Neer et al., 2001) 
PTH (1-84) with 
ibandronate  
Human, 
postmenopausal 
women with low 
bone mass 
24 months 
Oral tablet (ibandronate) 
Subcutaneous abdominal 
injection (PTH) 
100 μg/d PTH 
150 mg/month 
ibandronate 
Trabecular BMD increased at both radius (2.26 %) and 
tibia (3.22 %). Cortical thickness and BMD decreased 
at the radius (1.9 % and 0.76 %). Cortical porosity 
increased at the tibia (9.43 %). Biochemistry, DXA and 
QCT.  
(Schafer et al., 2013) 
PTH (1-34)  
Human, 
postmenopausal 
women with 
pelvic fracture 
 Subcutaneous injection 100 μg/d 
PTH treatment reduced fracture healing time (1.6 fold) 
and increased healing rate (11 fold). CT and 
radiography.  
(Peichl et al., 2011) 
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PTH (1-84)  
Human, 
postmenopausal 
women with 
osteoporosis 
4 to 24 
weeks Subcutaneous injection 100 μg/d 
PTH treatment increased bone formation markers P1NP 
(446.1 %) and bone specific ALP (129.6 %) compared 
to baseline and improved quality of life parameters. 
Biochemistry and quality of life analysis.  
(Quesada-Gomez et al., 2011) 
PTH (1-84) with 
alendronate  
Human, 
postmenopausal 
women with low 
BMD 
1 and 2 
years 
Oral tablet (alendronate) 
Subcutaneous injection 
(PTH) 
Patients received different 
treatment regimes in year 1 
and year 2 
100 μg/d PTH 
10 mg/d 
alendronate 
All treatment groups apart from PTH (year 1) / placebo 
(year 2) increased femoral strength after 2 years (PTH 
(year 1) / alendronate (year 2) 7.7 fold, PTH and 
alendronate (year 1) / alendronate (year 2) 4.2 fold, 
alendronate (year 1) / alendronate (year 2) 4.8 fold), 
with corresponding increases in trabecular density. 
DXA and QCT.  
(Keaveny et al., 2008) 
PTH (1-34)  
Human, 
postmenopausal 
women with 
osteoporosis 
36 months Subcutaneous injection 400 U/d 
PTH increased Haversian system area by 1.1 fold, 
lamellar thickness by 1.2 fold, and percentage osteons 
by 2 to 4 fold. Birefringence, radiography, SEM and 
TEM.  
(Ascenzi et al., 2012) 
Vertebral Fracture 
Teriparatide  Human, prevalent vertebral fracture 72 weeks Subcutaneous injection 56.5 μg/week 
Teriparatide treatment reduced the occurrence of new 
vertebral fracture by 4.7 fold and significantly increased 
BMD (by 6.4, 3 and 2.3 fold at the lumbar spine, hip, 
and femoral neck respectively). Biochemistry, DXA 
and radiography. 
(Nakamura et al., 2012) 
 
Abbreviations: ALP (alkaline phosphatase), BMC (bone mineral content), BMD (bone mineral density), BMSC (bone marrow stromal cell), BV/TV (bone volume/tissue volume), CMC (carboxymethyl cellulose), CT 
(computerised tomography), DXA (dual-energy X-ray absorptiometry), FACS (fluorescence-activated cell sorting), GFP (green fluorescent protein), HA (hydroxyapatite), IGF (insulin-like growth factor), IL-6 
(interleukin-6), OCN (osteocalcin), OPG (osteoprotegrin), ORX (orchiectomised), OVX (ovariectomised), P1NP (procollagen type 1 N propeptide), PDL (periodontal ligament cells), PEG (polyethylene glycol), PLA 
(poly lactic acid), PLGA (poly(lactic-co-glycolic) acid), PTFE (polytetrafluoroethylene), PX (parathyroidectomized), QCT (quantitative CT), RANKL (receptor activator of nuclear factor kappa-B ligand), RGD 
(arginylglycylaspartic acid), RT-PCR (real time polymerase chain reaction), SEM (scanning electron microscopy), TCP (tricalcium phosphate), TEM (transmission electron microscopy), TRAP (tartrate resistant acid 
phosphatase) and XTM (X-ray tomographic microscopy). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct PTHrP delivery 
Small Animal Models 
Mouse 
C-terminal 
PTHrP (107-139) 
peptide 
Male ARC Swiss-
Webster Mouse  12 d 
Periosteal calvarial 
injection 
0.00035 to 13.8 
µg daily 
Substantial anti-osteoclastic effects were observed, with 
a 70 % decrease in osteoclast number. Mineralised bone 
area increased 1.1 fold at the highest dose. Histology 
and histomorphometry. 
(Cornish et al., 1997) 
C-terminal 
PTHrP (107-139) 
peptide 
Male CD-1 
Diabetic Mouse    14 d Subcutaneous injection  
100 µg/kg every 
other day 
PTHrP was highly osteogenic reversing diabetic-
induced decreases in bone mass, structure, and gene 
expression. PTHrP also exhibited angiogenic effects 
(via VEGF stimulation). Histology, 
immunohistochemistry, micro CT, RT-PCR and 
western blot analysis. 
(Lozano et al., 2010) 
N-terminal 
PTHrP (1-36) 
peptide 
Male CD-1 
Diabetic Mouse  13 d Subcutaneous injection 
100 µg/kg every 
other day 
PTHrP reversed deleterious diabetic effects on bone cell 
number and function. DXA, histology and micro CT. (Lozano et al., 2009) 
Rabbit 
PTHrP analogue 
(RS-66271) 
New Zealand 
White Rabbit, 
Modified 
segmental ulnar 
defect – 1 mm  
 6 to 10 weeks 
Subcutaneous daily 
injection 10 µg/kg/d 
PTHrP enhanced healing, union, and biomechanical 
strength. Radiographic intensity was increased 1.2 to 
1.4 fold, and callus area increased 2.1 fold 
anteroposteriorly and 4.2 fold laterally. Torque and 
stiffness were increased 1.9 and 1.6 fold, respectively. 
Biomechanical testing and radiography. 
(Bostrom et al., 2000) 
C-terminal 
PTHrP epiptope 
(107-111) - 
osteostatin 
Female New 
Zealand Rabbit, 
lateral and medial 
femoral 
epiphyseal defect 
– 5 x 4/5mm 
 4 to 8 weeks 
Osteostatin-loaded silica-
based mesoporous SBA15 
material scaffold, implant 
100 nM 
PTHrP (osteostatin) favoured bone regeneration, 
induced revascularisation via VEGF, and decreased 
bone resorption. Bone volume was increased approx. 2 
to 10 fold dependent on conditions. Histology, 
immunohistochemistry and micro CT. 
(Trejo et al., 2010) 
Rat 
N-terminal 
PTHrP (1-36) 
peptide 
Female Sprague-
Dawley Rat, 
osteopenia model 
following 
ovariectomy 
 6 months Subcutaneous injection 40 µg/kg/d 
PTHrP increased bone formation rate, mass, and 
biomechanical properties. Ultimate load was increased 
up to 3 fold. Biochemical and biomechanical testing, 
DXA and histomorphometry. 
(Stewart et al., 2000) 
C-terminally 
substituted 
PTHrP analogue 
(RS-66271) 
Rat, osteopenia 
model following 
ovariectomy 
 unknown Subcutaneous injection 80 µg/kg/d 
PTHrP analogue reversed trabecular and cortical bone 
loss, and increased surface area covered by osteoblasts. 
Electron microscopy and histomorphometry. 
(Vickery et al., 1996) 
C-terminal 
PTHrP (1-34) 
peptide. 
Male Sprague-
Dawley Rat  12 or 26 d Subcutaneous injection  
10 to 320 
µg/kg/d 
Increased cortical bone mass was observed, alongside 
an increase of 1.3 to 1.4 fold in trabecular bone (higher 
dose only). Biochemical testing and histomorphometry. 
(Hock et al., 1989) 
Synthetic PTHrP 
(1-74) 
Male Sprague-
Dawley Rat   12 days Subcutaneous injection 
0.01 or 0.02 
µmol/kg/d 
Synthetic PTHrP increased bone weight and calcium / 
hydroxyproline content at low-dosage levels for 
prolonged periods. Biochemical testing. 
(Weir et al., 1992) 
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2. Animal Models for combinational direct and indirect PTHrP delivery 
Small Animal Models 
Mouse 
PTHrP (1-86) 
peptide and PTH 
Wildtype and 
PTHrP knockout 
Mouse  
 1 month Subcutaneous injection 0.2 µg/d 
Increased endochondral long bone formation was 
observed in both trabecular (approx. 3 fold) and cortical 
bone (approx. 2 fold). Augmented growth plate 
chondrocyte proliferation, differentiation and cartilage 
matrix mineralisation. Faxitron analysis, histology, 
immunohistochemistry, micro CT, radiography, RT-
PCR and western blot analysis. 
(Xue et al., 2005) 
N-terminal 
PTHrP (1-36) 
peptide and C-
terminal PTHrP 
(107-139) peptide 
OVX Female 
Charles River 
C57BL/6J Mouse, 
osteopenia model  
 4 or 8 weeks 
Sub-cutaneous daily 
injection 
80 µg/kg/d 
(5 days/week) 
PTHrP (1-36) exerted anabolic bone effects. PTHrP 
(107-139) exerted anabolic bone effects and 
significantly reduced bone resorption. Mineral density 
(1.7 to 2.2 fold) and total volume (1.5 fold) were 
significantly increased. Biochemical testing, histology, 
immunohistochemistry, micro CT and RT-PCR. 
(de Castro et al., 2011) 
N-terminal 
PTHrP (1-36) 
peptide and C-
terminal PTHrP 
(107-139) peptide 
Male CD1 type I 
Diabetic Mouse,   4 weeks Subcutaneous injection 
100 µg/kg every 
other day 
PTHrP reversed diabetes-induced loss of bone mineral 
density (approx. 1.1 fold) and content (approx. 1.4 
fold). Biochemical testing, DXA, 
immunohistochemistry and RT-PCR. 
(Portal-Nunez et al., 2010) 
3. Human Trials for PTHrP delivery 
Healthy Adults 
N-terminal 
PTHrP (1-36) 
peptide 
 
Human, healthy 
postmenopausal 
estrogen deficient 
females 
2 weeks Subcutaneous abdominal injection 
1.36 to 6.56 
µg/kg/d 
Activated bone formation with increased alkaline 
phosphatase and osteocalcin expression observed 
alongside reduced bone resorption (approx. 1.3 to 1.45 
fold decrease in resorption markers). Biochemical 
testing. 
(Plotkin et al., 1998) 
N-terminal 
PTHrP (1-36)  
Human, healthy 
adult - systemic 
infusion 
7 d Continuous intravenous infusion  
2 followed by 4 
pmol/kg/h 
Bone resorption increased rapidly, but was reversed 
following cessation of PTHrP infusions. Bone 
formation was suppressed by 1.3 to 1.4 fold, but 
recovered after PTHrP withdrawal. Biochemical testing. 
(Horwitz et al., 2011) 
N-terminal 
PTHrP (1-36) 
peptide 
 
Human, healthy 
adult - systemic 
infusion 
2 or 4 d Continuous intravenous infusion  
8 to 28 
pmol/kg/h 
Profoundly suppressed bone formation following 
multiple doses over time. Biochemical testing. (Horwitz et al., 2005) 
N-terminal 
PTHrP (1-34) 
peptide 
 
Human, healthy 
adult - systemic 
infusion 
3 x 12 h 
infusions 
Intermittent intravenous 
infusion 
8 or 80 
pmol/kg/h 
Significantly increased serum total ionized calcium, 
urinary phosphate and serum VitD3. Biochemical 
testing. 
(Fraher et al., 1992) 
 
Abbreviations: PTHrP (parathyroid hormone-related peptide), CT (computerised tomography), DXA (dual energy X-ray absorptiometry), VEGF (vascular endothelial growth factor), RT-PCR (real time polymerase 
chain reaction) and VitD3 (1,25-dihydroxyvitamin D3). 
 
Supplementary Table 7. Bone tissue engineering in vivo utilising TGF-β3 singularly and combination. 
 
1 
 
Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human 
clinical trial 
and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct TGFβ-3 delivery 
1.1. Large Animal Models 
Baboon 
TGF-β3 
Adult Chacma 
Baboon, maxillary 
and mandibular 
furcation – 10 to 
12 mm 
 60 d Matrigel,  implant 75 µg 
Significantly increased periodontal tissue regeneration 
was observed (approx. 75 %) which could be further 
enhanced with the addition of inducible minced muscle 
tissue. Histology and histomorphometry. 
(Teare et al., 2008) 
TGF-β3 
Adult Chacma 
Baboon, maxillary 
and mandibular 
furcation – 10 to 
12 mm 
 60 d Matrigel, implant 75 and 125 µg 
Enhanced alveolar bone regeneration (approx. 3 fold), 
coronal extension and cementogenesis (approx. 1.6 
fold) was observed at lower dose TGF-β3 in Matrigel 
with the addition of minced muscle tissue. Histology 
and histomorphometry. 
(Ripamonti et al., 2009b) 
TGF-β3 
Adult Chacma 
Baboon, ectopic 
intramuscular 
injection  
Calvarial defect – 
25 mm 
 30 and 90 d Collagenous matrix, implant 5, 25, 125 and 250 µg/mg 
Significant ectopic endochondral bone formation with 
large mineralized and corticalized ossicles was 
observed with minced autogenous fragments of the 
rectus abdominis muscle which may have provided 
inducible stem cells (approx. 1.9 fold increase). 
Histology, histomorphometry, PCR and western 
blotting. 
(Ripamonti et al., 2008) 
1.2. Small Animal Models 
Mouse 
TGF-β3 
Male Sprague 
Dawley Rat, 
acute transection 
of the rotator cuff 
 2 and 4 weeks 
Calcium phosphate matrix, 
implant 2.75 µg 
Newly formed bone exhibiting. After 2 weeks approx. 
5.4 % more bone and 23.3 % more cartilage was 
observed exhibiting significantly greater ultimate stress 
at  4 weeks. Biomechanical testing, histomorphometry, 
immunohistochemistry and micro CT. 
(Kovacevic et al., 2011) 
Rat 
TGF-β3 
Sprague Dawley 
Rat, postnatal day 
9 posterior 
interfrontal suture 
 14 d Collagen gel, implant 0.003 and 0.03 µg 
High dose maintained the suture site in an unossified 
state. Immunohistochemistry. (Opperman et al., 2002) 
2. Animal Models for combinational direct and indirect TGFβ-3 delivery 
Small Animal Model 
Mouse 
TGF-β3 
(recombinant 
adeno-associated 
virus) 
Nude mouse, 
ectopic 
subcutaneous 
implant 
 30 d PLA/PEG scaffold, implant 1 x 106 cells 
Sizeable 3D cartilage constructs were observed 
exhibiting 18.8 and 30.3 fold increase in collagen type 
II and Sox9 expression. Histology, 
immunohistochemistry and western blot. 
(Rizk and Rabie, 2013) 
3. Animal Models for combinational direct and indirect TGFβ-3 delivery 
3.1. Large Animal Models 
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Baboon 
TGF-β3 and OP-1 
Adult Chacma 
Baboon, ectopic 
intramuscular 
implant 
 90 d 
HA/calcium carbonate 
macroporous scaffold, 
implant 
125 µg 
Co-expression induced enhanced bone formation 
substantially greater than individual expression (max. 
1.7 fold) and controls (max. 5.3 fold). Formation of 
large mineralized and corticalized ossicles provides a 
therapeutic strategy for human osteoinduction. 
Histology, histomorphometry and rt-PCR. 
(Ripamonti et al., 2010) 
Sheep 
TGF-β3 and 
ovine MSCs 
(sheep) 
Adult Sheep, 
patella punch 
defect – 4 mm 
 9 weeks Chitosan/fibrin clot, implant 0.05 µg TGF-β3 1 x 107 MSCs 
Partial thickness defect was filled with chondrocyte-like 
cells and hyaline-like cartilaginous extracellular matrix 
demonstrating neocartilage repair. Chondrogenesis was 
observed after 3 weeks. TGF-β3 enhanced cell 
proliferation and favoured  integration of the neotissue 
within the host cartilage. Histology, 
immunohistochemistry and RT-PCR. 
(Mrugala et al., 2008) 
3.2. Small Animal Models 
Mouse 
TGF-β3, BMP-2 
and MSCs 
CB-17 SCID 
Mouse, ectopic 
subcutaneous 
implant 
 3 to 22 weeks Alginate gel, implant 
0.02 µg TGF-β3 
0.2 µg BMP-2 
1 x 106 cells 
Combinational treatment induced significant implanted 
MSC-mediated bone formation. After 3 weeks 
cartilaginous tissue was observed with interspersed 
bone. By 15 weeks extensive bone was observed 
(approx. 13 fold increase in bone area). Histology and 
histomorphometry. 
(Simmons et al., 2004) 
TGF-β3 and 
Chondrocytes 
(rabbit) 
Female BALB/c 
Mouse, ectopic 
subcutaneous 
injection 
 1 to 8 weeks 
pNIPAm-co-AAc hydrogel 
scaffold, injection 
0.1 µg/mL 
TGF-β3 
5 x 106 cells 
Enhanced chonrogenesis with significant cartilage 
specific extracellular matrix production including 
collagen (approx. 1.6 fold) and GAG (approx. 4 fold) 
after 8 weeks. Histology and immunohistochemistry. 
(Park et al., 2009) 
TGF-β3 and 
Chondrocytes 
(rabbit) 
NOD Mouse, 
ectopic 
subcutaneous 
implant 
 6 weeks 
Chondroitin sulphate bound 
TGF-β3 within PEG-PCL 
hydrogel, implant 
0.1 µg/mL 
TGF-β3 
5 x 106 cells 
Significant chondrogenesis was observed within 
constructs demonstrating suitability for cell-based 
cartilage tissue engineering approaches. GAG and 
collagen were increased approx. 3 and 1.7 fold, 
respectively. Histology and immunohistochemistry. 
(Park et al., 2010b) 
TGF-β3 and 
hMSCs 
Female BALB/c 
Nude Mouse, 
ectopic 
subcutaneous 
injection 
 
New Zealand 
White Rabbit, full 
thickness condyle 
defect – 3 mm 
 
1 and 7 
weeks 
(Mouse) 
 
1 and 6 
weeks 
(Rabbit) 
hMSC loaded pNIPAm-co-
AAc hydrogel scaffold, 
injection 
0.1 µg/mL 
TGF-β3 
1 x 106 hMSCs 
Significant chondrogenesis at ectopic sites, and 
enhanced hyaline cartilage tissue regeneration of 
condyle defects was observed with 2 fold increase in 
GAG content. Biochemical testing, histology, 
immunohistochemistry and rt-PCR. 
(Park et al., 2010a) 
TGF-β3 and 
hMSCs 
Female BALB/c 
Nude Mouse, 
ectopic 
subcutaneous 
injection 
 
New Zealand 
White Rabbit, full 
thickness condyle 
defect – 3 mm 
 
1 to 4 
weeks 
(Mouse) 
 
1 to 6 
weeks 
(Rabbit) 
hMSC and heparinized PLL 
nanoparticle loaded hydrogel 
scaffold, injection 
0.1 µg/mL 
TGF-β3 
1 x 106 hMSCs 
TGF-β3 enhanced hMSC survival and proliferation 
within ectopic implants, inducing expression of 
chondrocyte-specific extracellualr matrix genes and 
their proteins. TGF-β3 and hMSCs exhibited enhanced 
regeneration of hyaline articular cartilage within defect 
sites. Histology and immunohistochemistry. 
(Park et al., 2011) 
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TGF-β3, hMSCs 
and polyplexed 
Sox9 protein 
Female BALB/c 
Mouse, ectopic 
subcutaneous 
injection 
 1 to 8 weeks 
hMSCs with 
Sox9/heparinized TGF-β3 
coated dexamethasone 
loaded-PLGA microparticles, 
injection 
0.1 µg/mL 
TGF-β3 
2 x 106 hMSCs 
1,000 µg/mL 
Sox9 
Enhanced chondrogenesis with increased cartilage 
extracellular matrix GAG production (2.5 fold). 
Provides a tool for simultaneous delivery of genes and 
growth factors preventing dedifferentiation of 
transfected cells. Histology, immunohistochemistry and 
rt-PCR. 
(Park et al., 2012) 
Rabbit 
TGF-β3 and 
Chondrogenic 
MSCs 
New Zealand 
White Rabbit, 
femoral condyle 
defect 
 12 weeks PLGA scaffold and fibrin glue, implant 
0.01 µg/mL 
TGF-β3 
unknown,  MSC 
number  
Good cartilage formation was observed with improved 
mechanical strength compared to controls (30-60 % in 
mechanical stiffness). Biomechanical testing and 
histology. 
(Lee et al., 2004) 
TGF-β3 and 
Chondrocytes 
(rabbit) 
Nude Mouse, 
ectopic 
subcutaneous 
injection 
 8 weeks Hydrogel scaffold, injection 
0.1 µg/mL 
TGF-β3 
5 x 106 cells 
Organised chondrogenesis and increased extracellular 
matrix production within implanted cell loaded 
scaffolds. Collagen  and GAG were observed within 
lacunae structures. Type II collagen production was 
increased 22 fold. Biochemical testing, histology, 
immunohistochemistry and rt-PCR. 
(Na et al., 2006) 
TGF-β3 and 
Chondrocytes 
(rabbit) 
Nude Mouse, 
ectopic 
subcutaneous 
injection 
 1 to 8 weeks Hydrogel scaffold,  injection 
0.1 µg/mL 
TGF-β3 
1 x 106 cells 
Enhanced cartilage and related extracellular matrix 
production containing collagen (3.8 fold) and sulfated 
GAG (2.8 fold). May provide a rapid and clinically 
effective approach to cartilage regeneration. 
Biochemical testing, histology and 
immunohistochemistry. 
(Choi et al., 2007) 
TGF-β3 and 
MSCs (rabbit) 
New Zealand 
White Rabbit, 
femoral condyle 
defect – 6 x 3 mm 
 12 weeks PLGA scaffold, implant 
0.01 µg/mL 
TGF-β3 
2 x 106 cells 
Cartilage regeneration similar to native tissues, showing 
good integration and void filling. Demonstrated approx. 
80 % Young’s modulus of native cartilage. Collagen 
and GAG content increased approx. 10 and 8 fold, 
respectively. Biomechanical testing, histology and 
immunohistochemistry. 
(Han et al., 2008) 
Rat 
TGF-β3 and 
BMP-2 
Female Sasco 
Sprague Dawley 
Rat - femoral 
segmental defect – 
8 mm  
 4 to 16 weeks PLDL scaffolds,  implant 
0.02 µg TGF-β3 
0.2 µg BMP2    
Increased mineralization with a higher but not 
consistent rate of bone bridging across the defect. A 
non-significant torsional strength improvement was 
achieved. 12.8 fold increased bone formation was 
observed compared to empty defects. Biomechanical 
testing, histology and micro CT. 
(Oest et al., 2007) 
TGF-β3 and 
TGF-β1 
Male Sprague 
Dawley Rat, 
proximal humerus 
defect – 0.5 mm 
drill defect 
 1 to 4 weeks 
Osmotic pump, continuous 
infusion 0.005µg/d 
TGF-β isoforms did not improve supraspinatus tendon-
to-bone healing. This may have been due to a 
suboptimal delivery method or suboptimal 
timing/duration of growth factor administration. Defect 
sites were predominantly filled with scar tissue. 
Biomechanical testing, histology and 
immunohistochemistry. 
(Kim et al., 2010a) 
 
Abbreviations: BMP-2 (bone morphogenetic protein 2), CT (computer tomography), GAG (Glycos-Amino Glycan), HA (hydroxyapatite), MSC (mesenchymal stem cell), OP-1 (osteogenic protein 1), PCL (poly-
caprolactone), PCR (polymerase chain reaction), PEG (poly-ethylene glycol), PLDL (poly(L-lactide-co-D,L-lactide)), PLA (poly-lactic acid), PLGA (poly(lactic co-glycolic acid)), PLL (poly-L-lysine), pNIPAm-co-AAc 
(poly(N-isopropylacrylamide-co-acrylic acid)), RT-PCR (real time PCR), rt-PCR (reverse transciption PCR) and TGF-β3 (transforming growth factor beta 3). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human clinical 
trial and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct VEGF delivery 
Small Animal Models 
Mouse 
rhVEGF165 
Male MF1 nu/nu 
Mouse, femur 
segmental defect – 
5 mm 
 4 weeks PLA scaffold and hBMSCs, implant 1.7 µg 
Significant osteogenic growth and repair was observed. 
VEGF/hBMSCs increased blood vessel formation 
compared to control. Bone volume was increased 
approx.  1.65 fold. Histology, immunohistochemistry, 
micro CT and radiography. 
(Kanczler et al., 2008) 
rhVEGF 
Male BALB/c 
Mouse, calvarial 
defect – 4 mm 
 4 weeks 
Biphasic calcium 
phosphate ceramics, 
implant 
5 µg/mL 
Promoted biomaterial vascularization but had no 
distinct impact on bone formation. Histology, 
histomorphometry and intravital microscopy. 
(Wernike et al., 2010) 
2. Animal Models for indirect VEGF delivery 
Small Animal Models 
Mouse  
VEGF165 (plasmid 
vector) 
Male C57BL/6 
Mouse, ectopic 
subcutaneous 
implant and intra-
femoral defect – 1 
x 8 mm 
 30 d 
Collagen/calcium 
phosphate scaffold, 
implant 
0.35 µg/mm3 
(plasmid DNA 
to scaffold 
approx. 20 µg) 
Increased bone formation (2 fold) was observed, 
however blood vessel formation was not significantly 
different to controls. Histology, histomorphometry and 
rt-PCR. 
(Keeney et al., 2010) 
Rabbit 
VEGF165 (plasmid 
vector) 
New Zealand 
White Rabbit, 
radial segmental 
defect – 15 mm 
 16 weeks 
Transfected cells on 
Biocoral (calcium 
carbonate) scaffold, 
implant 
5 x 106 cells 
Significantly enhanced vascularization and increased 
bone formation by 1.6 fold compared to controls. 
Histology, histomorphometry, micro CT and 
radiography. 
(Geiger et al., 2007) 
VEGF (plasmid 
vector) 
Adult Rabbit, 
tibial segmental 
defect – 10 mm 
 12 weeks 
Transfected cells delivered 
via impregnated gelfoam, 
implant 
5 x 106 cells 
Newly formed trabecular bone, callus formation and 
ossification across the entire defect were observed. 
Bone volume doubled. Histology, 
immunohistochemistry, micro CT and radiography. 
(Li et al., 2009b) 
3. Animal Models for combinational direct and indirect VEGF delivery 
3.1. Large Animal Models 
Dog 
VEGF and BMP-
2 
Beagle Dog, 
ectopic paraspinal 
muscle implant, 
ulna critical size 
defect 
 9 weeks 
Gelatin (fast release) or 
PLGA microparticle 
(sustained release) loaded 
biphasic calcium phosphate 
scaffold, implant 
0.4 µg VEGF 
12 µg BMP-2 
(ectopic site) 
 
4 µg VEGF 
120 µg BMP-2 
(ulna defect) 
Ectopic BMP-2 fast release showed significantly more 
bone compared to sustained release, independent of the 
VEGF profile. Significant enhancement of bone 
formation was observed within all orthotopic groups 
compared to controls independent of growth factor 
release profile or combination. Histology, 
histomorphometry and immunohistochemistry. 
(Geuze et al., 2012) 
Pig 
VEGF and 
rhBMP-2  
Female Domestic 
Pig, cranial drill 
defect – 4.2mm 
 1 to 4 weeks 
Titanium plugs with 
adsorbed octacalcium 
phosphate, implant 
1.32 µg VEGF 
5.26 µg BMP-2,  
Implants revealed enhanced bone volume density 
(approx. 1.6 fold increase), but not osseointegration. 
Histology, histomorphometry and micro-radiography. 
(Ramazanoglu et al., 2011) 
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3.2. Small Animal Models 
Mouse 
VEGF-A , FGF-2 
and rhBMP-2 
CD-1 Mouse, 
calvarial defect – 
2 mm 
 12 weeks Collagen sponge, implant 0.2 µg 
VEGF-A and BMP-2 showed enhanced healing 
capacities compared to FGF-2, however no significant 
differences between VEGF-A and BMP-2 were 
observed. Immunohistochemistry and micro CT. 
(Behr et al., 2012) 
VEGF and BMP-
7 
Black C57/B16 
Mouse, ectopic 
subcutaneous 
implant 
 12 weeks 
Injection within biphasic 
calcium phosphate 
ceramics, implant 
2 µg VEGF 
5 µg BMP-7 
Woven bone formation was observed on scaffold 
surface and within pores. However, combination of 
VEGF and BMP-7 did not enhance bone formation 
significantly. Histology and SEM. 
(Roldan et al., 2010) 
VEGF and 
rhBMP-2  
Male MF1 nu/nu 
Mouse, femur 
segmental defect – 
5mm 
 4 weeks Alginate and PLA, implant 20 µg 
Significantly increased new endochondral bone matrix 
formation (approx. 3.2 fold). Histology, 
immunohistochemistry and micro CT. 
(Kanczler et al., 2010) 
VEGF and BMP-
4 (retrovirus) 
SCID Mouse, 
ectopic 
intramuscular 
implant 
 7 to 35 d Transduced cells on gelatin sponge, implant 2 x 10
5 cells 
Co-expression of BMP-4 and VEGF impaired ectopic 
endochondral bone formation at high VEGF ratio. 
When VEGF release was low and sustained, any 
negative effects were no longer observed. Biochemical 
testing, histology and radiography. 
(Li et al., 2009a) 
VEGF/BMP-2 
(recombinant 
adeno-associated 
virus 6) 
Athymic Nude 
Mouse, tibiae 
segmental defect – 
2/3mm 
 5 weeks 
Transduced male mouse 
MSCs, intravenous 
injection 
1 x 106 cells: 
5 x (2 x 105 
cells) – 1 per 
day 
Enhanced bone formation was observed within defect 
sites compared to control groups. Bone volume, peak 
load and stiffness increased approx. 6, 4.5 and 4 fold 
respectively, compared to control group. DXA, 
histology, immunohistochemistry and micro CT 
(Kumar et al., 2010b) 
VEGF and BMP-
2 (plasmid 
vector) 
BALB/c nu/ nu 
Nude Mouse, 
ectopic 
intramuscular 
implant 
 4 and 8 weeks 
Transfected cells on β-TCP 
scaffold, implant 
2.5 x 106 
cells/mL 
Co-expression showed significant bone formation 
compared to BMP-2 alone at 4 weeks. Bone area 
increased 10 fold by 8 weeks. VEGF may enhance 
BMP-2 induced bone formation through angiogenesis 
modulation. Histology, histomorphometry, 
immunohistochemistry and in situ hybridization  
(Samee et al., 2008) 
Rabbit 
VEGF and BMP-
2 
Male New 
Zealand Rabbit, 
intramedullary 
femur defect. 
 2 to 12 weeks 
Growth factor loaded-
PLGA microspheres within 
porous PLGA scaffolds, 
implant 
0.35 or 1.75 µg 
VEGF 
3.5 or 17.5 µg 
BMP-2 
Co-expression exhibited a temporal dose-dependent 
positive synergistic effect on bone formation, with new 
bone after 2 weeks and neovascularisation after 4 
weeks. Histology, histomorphometry and 
immunohistochemistry. 
(Hernandez et al., 2012) 
VEGF, PDGF 
and TGF-β1  
Male New 
Zealand Rabbit, 
intramedullary 
femur defect - 6 
mm (1.5 to 2 cm 
depth) 
 4 weeks Brushite cement, implant 
0.35 µg VEGF 
(PLGA 
encapsulated 
microspheres) 
0.25 µg PDGF 
0.1 µg TGF-β1 
(liquid phase) 
Triple combination increased new bone formation 
approx. 10 fold compared to controls where individual 
factor treatment increased new bone formation 
maximum 5 fold. Histology and histomorphometry. 
(Reyes et al., 2012) 
rhVEGF165  
and BMP-2 
New Zealand 
Rabbit, sinus floor 
elevation 
 4 and 12 weeks 
Sonication-induced silk 
hydrogel, implant 
20 µg VEGF165 
30 µg BMP-2 
VEGF promoted higher tissue infiltration and 
accelerated gel degradation. Co-expression induced 
significantly larger bone area than single factor groups 
and the silk control (1.4 to 4.9 fold more bone). 
Histology, histomorphometry, micro CT and 
radiography 
(Zhang et al., 2011a) 
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VEGF and BMP-
2 (adenovirus) 
Female New 
Zealand White 
Rabbit, bilateral 
orbital defect – 
12mm 
 4 to 16 weeks 
Transduced BMSCs on 
biocoral composite, 
implant 
1.2 x 106 cells 
VEGF 
6 x 106 cells 
BMP-2 
New bone deposition and formation was observed, 
mimicking natural bone development. Bone volume 
increased approx. 20 fold after 4 weeks, 3 fold after 8 
weeks and 2 fold after 16 weeks, compared to controls. 
Histology, histomorphometry, immunocytochemistry, 
micro CT and radiology. 
(Xiao et al., 2011) 
VEGF165 and 
BMP-7 
(recombinant 
adeno-associated 
virus) 
Male New 
Zealand Rabbit, 
ectopic 
intramuscular 
injection 
(hindlimb 
ischemia model) 
 2 to 8 weeks 
Direct intramuscular 
injection 
5.5 x 1011 
particles 
Co-expression stimulated angiogenesis and bone 
regeneration. Capillary density and mean blood flow 
were both increased approx. 2 fold. Biochemical 
testing, histology and radiography. 
(Zhang et al., 2010a) 
VEGF and BMP-
2 (baculovirus) 
New Zealand 
White Rabbit, 
femoral segmental 
defect – 10mm 
 8 weeks Transduced rabbit MSCs in PLGA scaffold, implant 3 x 10
6 cells 
Increased bone formation of improved quality was 
observed. Torsional stiffness and maximum torque were 
increased 208 and 26.5 fold respectively, compared to 
scaffold alone. Biomechanical testing, histology, 
immunohistochemistry, micro CT, micro-PET and 
radiography. 
(Lin et al., 2010) 
VEGF, BMP-2 
and FLP 
(baculovirus) 
Female New 
Zealand White 
Rabbit, calvarial 
defect – 8mm 
 4 and 12 weeks 
Transduced rabbit MSCs in 
PLGA scaffold, implant 3 x 10
6 cells 
FLP episome formation prolonged BMP-2/VEGF 
expression and augmented bone repair from rabbit 
MSCs. Bone regeneration area increased 3.4 fold 
compared to scaffold alone. Histology, micro CT, 
micro-PET and radiography. 
(Lin et al., 2012a) 
VEGF, PDGF-
BB and MSCs 
Rabbit, segmental 
bone defect  
Mouse, ectopic 
implantation 
 unknown PRP membrane, implant unknown 
In an ectopic mouse model as well a rabbit segmental 
bone defect model the platelet-rich plasma-based 
membrane & PDGF was able to biomimic a periosteal 
response in vivo enhancing bone regeneration. 
(El Backly et al., 2013) 
Rat 
VEGF and 
rhBMP-2  
Harlan Sprague-
Dawley Rat, 
femoral defect – 
5mm 
 4 and 6 weeks 
PLGA in PPF (rhBMP-2) 
within gelatin hydrogel 
(VEGF), implant 
2 µg VEGF 
6.5 µg rhBMP-2 
Microangiography showed sufficient vascularization. 
Implants demonstrated bone formation within 
orthotopic defects. Vessel volume doubled, and bone 
volume increased approx. 3 fold, compared to control 
scaffolds. Histology, histomorphometry, 
microangiography, micro CT and radio-labelling. 
(Kempen et al., 2009) 
VEGF and BMP-
2 
Male Fischer Rat, 
cranial defect – 
8mm 
 12 weeks 
Loaded PPF/gelatin 
microparticle composite, 
implant 
6 to 12µg 
VEGF 
0.5 to 2µg 
BMP-2 
Dose-dependent increase in bone formation was 
observed with increased BMP-2 (approx. 5.3 fold). 
VEGF showed no further augmentation, however 
increased defect bridging was observed. Histology and 
micro CT. 
(Young et al., 2009) 
VEGF and BMP-
2 
Syngeneic 
Fischer-344 Rat, 
calvarial defect – 
8 mm 
 4 and 12 weeks 
Gelatin microparticles 
entrapped within PPF 
scaffolds, implant 
12 µg VEGF 
2 µg BMP-2 
VEGF increased blood vessel formation and acted 
synergistically with BMP-2 to enhance bone formation. 
Bone volume was increased approx. 5 fold. Histology 
and micro CT. 
(Patel et al., 2008) 
 
Abbreviations: BMP-2 (bone morphogenetic protein 2), CT (computer tomography), DXA (dual energy X-ray absorptiometry), FGF-2 (fibroblast growth factor 2), hBMSC (human bone marrow stromal cell), PET 
(positron emission tomography), PLGA (poly(lactic co-glycolic acid)), PPF (poly-propylene fumarate), rhVEGF (recombinant human VEGF), rt-PCR (reverse transcription polymerase chain reaction) and VEGF 
(vascular endothelial growth factor). 
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Growth factor  
(single or 
combination) 
Animal model 
(species/strain, 
location and 
defect) 
Human 
clinical trial 
and defect 
Time Delivery system Dose/ Conc. Analysis (read outs, efficacy and methodology) Reference 
1. Animal Models for direct Wnt delivery 
Small Animal Models 
Mouse 
Wnt 3A 
Col2.3-11βHSD2 
transgenic mice 
(Subcutaneous 
calvarial 
injection) – 
disrupted 
glucocorticoid 
signalling 
(delayed skeletal 
development) 
 3 d Direct defect injection 100 ng 
Parietal bone volume and mineralisation were 
significantly increased. Suture areas were significantly 
reduced after 3 d (approx. 1.4 fold). Biochemical 
testing, histology, immunohistochemistry, in situ 
hybridisation, micro CT and RT-PCR. 
(Zhou et al., 2009) 
Wnt 3A 
Axin2 LacZ/LacZ 
Mouse, tibial 
defect – 1 mm 
 28 d  Liposomal vesicles, injection 0.5 µg/mL 
Increased osteogenesis resulting in accelerated 
mineralisation and osteoid deposition. Stimulated 
skeletal progenitor cell proliferation and osteoblastic 
differentiation. Histology. 
(Minear et al., 2010) 
 
2. Animal Models for indirect Wnt delivery 
Small Animal Models 
Chick 
Wnt 6 (plasmid 
vector) 
Chick embryo, 
forelimb bud 
injection 
 4 d Transfected CHO cells, injection unknown 
Inhibition of chondrogenesis was observed within 
central limb mesenchyme, and promotion of 
myogenesis within peripheral limb mesenchyme. In situ 
hybridisation. 
(Geetha-Loganathan et al., 
2010) 
Mouse  
Wnt 1 (lentivirus) 
Female Immuno-
deficient Mouse, 
subcutaneous 
injection 
 12 weeks  Transduced cells on HA/TCP, implant 1 x 10
6 cells 
Enhanced bone formation up to 1.3 fold at injection site 
(dependant on cell dose). Histology and 
immunohistochemistry. 
(Liu et al., 2009) 
Wnt 3A (plasmid 
vector) 
SCID Mouse, 
 
1. direct injection 
into implanted 
human bone 
 
2. subcutaneous 
injection 
 
3. subcutaneous 
injection with 
implanted human 
multiple myeloma 
cells 
 
1. 11 weeks 
 
2. 9 weeks 
 
3. 4 weeks 
Transfected H929 cells, 
injection (1 and 2) 
Recombinant Wnt 3A, 
injection (3) 
1. 5 x 105 cells 
 
2. 5 x 106 cells 
 
3. 16 µg 
No effect was observed outside of implanted human 
bone. Within implanted human bone, tumour growth 
was attenuated and mineral density elevated through 
activation of osteogenesis leading to the increased 
presence of osteocalcin-expressing cells. 1. Bone 
preservation was observed with only 18 % loss 
compared to 56 % loss in untreated hosts. 2. BMD 
increased by 1.12 fold. 3.  Inhibited multiple myeloma 
cell progression. Histology, immunohistochemistry and 
radiography. 
(Qiang et al., 2008) 
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Wnt 4 (retrovirus)  
Beige nu/nu 
Mouse, 
subcutaneous 
implant 
 
1. Nude Rat, 
alveolar defect – 2 
x 3 mm 
 
2. SCID Mouse – 
calvarial defect – 
5 mm 
 
1. 8 weeks 
(Mouse) 
 
2. 5 weeks  
(Nude Rat 
and SCID 
Mouse)  
Transduced MSCs in 
HA/TCP or PLGA 
scaffolds, implant 
4 x 106 cells 
(Mouse) 
 
2.5 x 105 cells  
(Nude Rat) 
 
5 x 105 cells 
(SCID Mouse) 
Enhanced and integrated new mineralised bone tissue 
was observed in greater abundance compared to 
controls. Alveolar bone observed within the rat model 
was increased 3 to 5 fold. Histology and micro CT. 
(Chang et al., 2007) 
Wnt 3A (plasmid 
vector) 
Female CD-1 
nu/nu Mouse, 
intramuscular 
injection 
 2 weeks 
Transfected L-cells co-
injected with porcine 
articular chondrocytes 
5 x 106 cells 
(12 injections) 
Wnt-3A induced proliferation and de-differentiation of 
articular chondrocytes when co-injected in vivo. After 2 
weeks a 1.5 fold increase in cartilage was observed. 
Histology. 
(Nalesso et al., 2011) 
Wnt 5A (plasmid 
vector) 
FVB/N Mouse, 
transfected 
embryo  
 New-born mouse 
Plasmid injection directly 
into mouse embryo 
N/A (transgenic 
animal) 
Ectopic Wnt 5A expression results in a variety of 
developmental defects including reduced endochondral 
and intramembranous bone formation. However, 
controlled spatiotemporal expression did exhibit 
increased calvarial ossification. Histology, 
histomorphometry and immunohistochemistry. 
(van Amerongen et al., 2012) 
Wnt 10B 
(plasmid vector) 
C57BL/6 Mouse, 
transfected 
embryo 
 
4 weeks 
(ovariectomy 
study) 
 
23 months 
(ageing 
study) 
Plasmid injection directly 
into mouse embryo 
N/A (transgenic 
animal) 
Transfected mice exhibited increased bone volume 
(approx. 3 fold). Wnt 10B maintained femoral 
architecture including bone volume, mineral density 
and trabeculae number, following either ovariectomy 
(bone loss model) or ageing. Bone volume increased 12 
fold by 23 months. Biomechanical testing, micro CT 
and radiography. 
(Bennett et al., 2005) 
Wnt 10B 
(plasmid vector) 
C57BL/6 Mouse, 
transfected 
embryo 
 3 months Plasmid injection directly into mouse embryo 
N/A (transgenic 
animal) 
Increased osteoblastogenesis was observed leading to 
increased bone formation through elevated mineral 
density and higher trabeculae number. Overall, 1.8 fold 
increase in bone formation was observed. 
Histomorphometry, micro CT and radiography. 
(Bennett et al., 2007) 
 
Abbreviations: CT (computer tomography), HA (hydroxyapatite), MSC (mesenchymal stem cell), PLGA (poly(lactic co-glycolic acid)), RT-PCR (real time polymerase chain reaction), SCID (severe combined immuno-
deficient), TCP (tri-calcium phosphate) and Wnt (wingless-type MMTV integration site family). 
 
